






The Role of SAMSN1 
 in Multiple Myeloma 
 
Natasha Lauren Friend 
 
Myeloma Research Laboratory 
Adelaide Medical School 
Faculty of Health and Medical Sciences 
The University of Adelaide 
&  
Cancer Theme 




A thesis submitted to the University of Adelaide  




TABLE OF CONTENTS 
 
TABLE OF CONTENTS ................................................................................ ii 
ABSTRACT ..................................................................................................... v 
DECLARATION ........................................................................................... vii 
ACKNOWLEDGEMENTS ......................................................................... viii 
ABBREVIATIONS ......................................................................................... x 
PUBLICATIONS ......................................................................................... xiii 
1 INTRODUCTION .................................................................................... 1 
1.1 Multiple myeloma: Clinical description .............................................................. 2 
1.1.1 Epidemiology ............................................................................................................. 2 
1.1.2 Clinical manifestations ............................................................................................... 2 
1.1.3 Disease stages............................................................................................................. 3 
1.1.4 Treatment ................................................................................................................... 8 
1.2 Genetic aetiology of MM ...................................................................................... 9 
1.2.1 Normal PC development ............................................................................................ 9 
1.2.2 Inherited genetic variation ........................................................................................ 10 
1.2.3 Primary genetic events ............................................................................................. 10 
1.2.4 Secondary genetic events ......................................................................................... 13 
1.2.5 Gene expression changes ......................................................................................... 19 
1.2.6 Epigenetic aberrations .............................................................................................. 20 
1.2.7 Clonal heterogeneity and evolution.......................................................................... 22 
1.2.8 Oncogene dependencies ........................................................................................... 23 
1.2.9 Progression from MGUS/SMM to MM ................................................................... 25 
1.2.10 Transgenic mouse models of MM ............................................................................ 26 
1.3 SAMSN1 ............................................................................................................... 27 
1.3.1 Gene, mRNA and protein ......................................................................................... 27 
1.3.2 Functions in normal cells ......................................................................................... 29 
1.3.3 Role in cancer ........................................................................................................... 31 
1.4 Summary and aims ............................................................................................. 34 
2 MATERIALS AND METHODS .......................................................... 36 
2.1 Molecular biology ................................................................................................ 37 
2.1.1 RNA techniques ....................................................................................................... 37 
2.1.2 DNA techniques ....................................................................................................... 39 
2.1.3 Protein techniques .................................................................................................... 42 
2.2 Cell culture techniques ....................................................................................... 44 
2.2.1 Maintenance of cells in culture ................................................................................ 44 
2.2.2 Generating primary KaLwRij BMSC-conditioned medium .................................... 46 
2.2.3 Generating genetically modified cell lines ............................................................... 46 
 
iii 
2.2.4 In vitro assays ........................................................................................................... 47 
2.3 Animal techniques ............................................................................................... 50 
2.3.1 Generating knockout mice ....................................................................................... 50 
2.3.2 Peripheral blood counts ............................................................................................ 52 
2.3.3 Multi-colour flow cytometry analyses of primary mouse cells ................................ 50 
2.3.4 Isolation of primary murine PC ................................................................................ 54 
2.3.5 In vivo models of MM tumour growth ..................................................................... 54 
2.3.6 In vivo bioluminescence imaging ............................................................................. 55 
2.3.7 Serum protein electrophoresis .................................................................................. 55 
2.3.8 Detection of GFP+ tumour cells in mouse tissues by flow cytometry ...................... 56 
2.3.9 Immunohistochemistry ............................................................................................. 56 
2.3.10 In vivo BM homing assay ......................................................................................... 57 
2.3.11 Ex vivo CD8+ T cell cytotoxicity assay .................................................................... 57 
2.3.12 Detection of anti-Samsn1 antibodies in serum ......................................................... 58 
2.4 In silico analyses and statistics ........................................................................... 58 
2.4.1 Publicly available microarray data ........................................................................... 58 
2.4.2 Statistics ................................................................................................................... 59 
3 INVESTIGATION OF THE POTENTIAL CO-OPERATIVE 
TUMOUR SUPPRESSOR EFFECTS OF SAMSN1 AND GLIPR1 IN 
MULTIPLE MYELOMA ............................................................................. 60 
3.1 Introduction ......................................................................................................... 61 
3.2 Results .................................................................................................................. 63 
3.2.1 Reduced GLIPR1 expression is associated with reduced SAMSN1 expression in the 
PCs of MM patients ................................................................................................. 63 
3.2.2 Re-expression of Glipr1 in 5TGM1 cells reduces MM disease development in vivo .. 
  .................................................................................................................................. 65 
3.2.3 Samsn1 expression in the BM microenvironment does not affect MM tumour growth 
in vivo ....................................................................................................................... 68 
3.2.4 Generation of Glipr1 knockout mice using CRIPSR-Cas9 genome editing ............ 71 
3.2.5 Analysis of B cell development in Glipr1 and/or Samsn1 knockout mice ............... 75 
3.2.6 Glipr1 and/or Samsn1 knockout does not result in MM disease development in vivo 
  .................................................................................................................................. 81 
3.3 Discussion ............................................................................................................. 87 
4 INVESTIGATING THE TUMOUR SUPPRESSOR MECHANISM 
OF SAMSN1 IN MURINE MULTIPLE MYELOMA .............................. 95 
4.1 Introduction ......................................................................................................... 96 
4.2 Results .................................................................................................................. 98 
4.2.1 Identifying novel binding partners of Samsn1 in 5TGM1 cells ............................... 98 
4.2.2 Samsn1 does not bind to, but reduces the phosphorylation of, Hs1 in 5TGM1 cells
 102 
4.2.3 Samsn1 does not affect the migration, or adhesion to endothelium, of 5TGM1 cells in 
vitro ........................................................................................................................ 102 
 
iv 
4.2.4 Samsn1 expression does not have a significant impact on the transcriptome of 5TGM1 
cells ........................................................................................................................ 105 
4.2.5 Samsn1 inhibits the metastasis of 5TGM1 cells in vivo ......................................... 110 
4.2.6 Samsn1 expression in 5TGM1 cells does not affect homing to, but inhibits expansion 
within, the BM in vivo ............................................................................................ 110 
4.3 Discussion ........................................................................................................... 113 
5 INVESTIGATING THE POTENTIAL TUMOUR SUPPRESSOR 
ROLE OF SAMSN1 IN HUMAN MULTIPLE MYELOMA ................ 120 
5.1 Introduction ....................................................................................................... 121 
5.2 Results ................................................................................................................ 123 
5.2.1 Generation of HMCLs with stable knockdown of SAMSN1 using CRISPR-Cas9 123 
5.2.2 Reduced SAMSN1 does not affect the proliferation or migration of HMCLs in vitro 
  ................................................................................................................................ 126 
5.2.3 Reduced SAMSN1 does not affect the growth or metastasis of HMCLs in vivo... 126 
5.2.4 Overexpression of SAMSN1 does not affect the proliferation of HMCLs in vitro 129 
5.2.5 Overexpression of SAMSN1 does not affect the growth of HMCLs in vivo ......... 129 
5.2.6 Samsn1 expression does not affect 5TGM1 tumour growth in NSG mice ............ 132 
5.2.7 Samsn1 expression in 5TGM1 cells may enhance cytotoxic T lymphocyte activity ... 
  ................................................................................................................................ 132 
5.2.8 Samsn1 does not affect the expression of MHC class I molecules on the surface of 
5TGM1 cells........................................................................................................... 135 
5.2.9 Samsn1 expression in 5TGM1 cells does not affect tumour growth in C57BL/6 mice 
  ................................................................................................................................ 140 
5.2.10 Samsn1 expression in 5TGM1 cells inhibits tumour growth in C57BL/Samsn1-/- mice
  ................................................................................................................................ 140 
5.2.11 Samsn1-/- mice may generate a humoral immune response against 5TGM1-derived 
Samsn1 ................................................................................................................... 145 
5.3 Discussion ........................................................................................................... 145 
6 FINAL DISCUSSION .......................................................................... 152 






Multiple myeloma (MM) is a haematological malignancy characterised by the uncontrolled 
clonal proliferation of neoplastic plasma cells (PCs) within the bone marrow (BM). Our 
group previously identified a homozygous deletion of Samsn1, a gene encoding a putative 
adaptor protein, in the genome of the MM-prone C57BL/KaLwRij mouse strain. In addition, 
the re-expression of Samsn1 in the C57BL/KaLwRij-derived 5TGM1 MM PC line was 
shown to inhibit tumour growth in vivo. Furthermore, SAMSN1 expression was found to be 
down-regulated in the PCs of MM patients compared to healthy controls. Collectively, these 
data suggested that SAMSN1 may be a novel tumour suppressor gene in MM. 
 
The fact that Samsn1-/- C57BL/KaLwRij mice develop MM with late onset and incomplete 
penetrance suggested that Samsn1 loss may co-operate with another lesion to drive disease 
development. In this thesis, bioinformatic analysis revealed that the down-regulation of the 
tumour suppressor GLIPR1 was significantly associated with reduced SAMSN1 expression 
in the PCs of MM patients. Glipr1 expression was found to be absent in 5TGM1 cells and 
its re-introduction reduced tumour growth in vivo, although this did not reach statistical 
significance. In addition, Samsn1 and Glipr1 double knockout mice were generated and 
monitored for clonal PC expansions for one year. These mice were not found to display 
enhanced PC abnormalities compared to wildtype mice, suggesting that the concomitant loss 
of Samsn1 and Glipr1 is insufficient to promote MM development within this timeframe. 
 
Although Samsn1 was previously shown to negatively regulate the proliferation and 
cytoskeletal remodelling of activated B cells, the mechanism(s) by which it inhibited 
5TGM1 tumour formation was yet to be determined. In this thesis, Samsn1 was found to 
inhibit the growth of metastatic, but not primary, 5TGM1 tumours following intratibial 
injection into C57BL/KaLwRij mice but had no effect on the BM homing of 5TGM1 cells 
in vivo. These data suggest that Samsn1 may promote the action of anti-tumour factors from 
within the BM microenvironment. In addition, Samsn1 was found to not inhibit 5TGM1 
tumour growth in immunodeficient mice and to promote the cytotoxicity of 
C57BL/KaLwRij-derived CD8+ T cells towards 5TGM1 cells. These findings suggest that 
Samsn1 may enhance immune system-mediated targeting of MM PCs. Notably, Samsn1 was 
found to inhibit 5TGM1 tumour growth in immunocompetent C57BL/Samsn1-/- mice, but 
not wildtype C57BL/6 mice, and anti-Samsn1 antibodies were detected in the serum of a 
Samsn1-/- mouse. These data suggest that the increased immunogenicity of Samsn1-
 
vi 
expressing 5TGM1 cells in C57BL/KaLwRij mice may be due to the presence of adaptive 
immune cells that recognise Samsn1 as a foreign antigen in this Samsn1-/- mouse strain. As 
SAMSN1-specific immune cells will be deleted by tolerance processes in patients, the 
findings from the 5TGM1/KaLwRij model no longer support a potential tumour suppressor 
role for SAMSN1 in human MM. Given that SAMSN1 levels were found to have no effect 
on the growth of human MM cell lines in vitro or in vivo, the current weight of evidence 
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1.1 Multiple myeloma: Clinical description 
Multiple myeloma (MM) is a haematological malignancy of plasma cells (PCs), the 
terminally-differentiated and antibody-producing cells of the B cell lineage. This cancer is 
characterised by the clonal expansion of neoplastic PCs within the bone marrow (BM), 
which produce large amounts of a non-functional monoclonal immunoglobulin, also known 
as a paraprotein/M protein, that can be detected in blood serum and urine (light chain only)1. 
MM displays a high degree of heterogeneity both biologically (underlying genetic 
abnormalities) and clinically (response to treatment and outcome)2. There are premalignant 
PC proliferative disorders associated with MM and the disease can also progress to more 
advanced stages with inferior prognosis. Although recent treatment advances have improved 
the outcomes for MM patients, the majority of patients relapse with refractory disease and 
thus MM remains largely incurable3. 
 
1.1.1 Epidemiology 
MM accounts for ~10% of haematological malignancies and ~1% of all cancers1,4. In 
Australia, 1,885 new cases of MM were diagnosed in 2015, with an age standardised 
incidence rate of 6.9 cases per 100,0005. The incidence of MM is higher in developed 
countries, such as Australia, the United States of America (USA) and the United Kingdom, 
which is likely due to increased awareness and better diagnostic capabilities1. MM is 
primarily a disease of older adults, with a median age at diagnosis of 71.5 years in Australia5. 
The adjusted prevalence rates of MM among males are ~50% higher than those among 
females5,6. There are also disparities in the incidence of MM according to ethnicity, with 
MM found to occur twice as frequently in people with African heritage compared to 
Caucasians6. The median overall survival (OS) for MM is ~6 years7, which is consistent with 
the most recently reported Australian five-year relative survival rate of 50.7% (2011-2015)5.  
 
1.1.2 Clinical manifestations 
The major clinical manifestations of MM are due to either the direct effects of expanded 
clonal PCs within the BM or indirect effects of their by-products on other organs. The major 
cause of morbidity for MM is bone disease, which causes pain and pathologic fractures in 
~60% of cases8. The bone disease results from lytic lesions, which are generated due to the 
increased number and activity of bone-resorptive osteoclasts and the decreased number and 





to the altered production of key signalling molecules involved in bone homeostasis, 
including receptor activator of nuclear factor-κB ligand (RANKL)9-11, osteoprotegerin 
(OPG)10,11, stromal-derived factor-1α (SDF-1α/CXCL12)12 and dickkopf-related protein 1 
(DKK1)13, by MM PCs and/or BM stromal cells (BMSCs). A related clinical feature of MM 
is high levels of calcium in the blood (hypercalcemia), which occurs as a result of 
osteolysis14. This complication arises in approximately one third of MM cases and can cause 
a range of symptoms, including nausea and confusion14. Hypercalcemia and the large 
amount of MM PC-derived free monoclonal immunoglobulin light chains (FLC) in the blood 
promotes the development of renal insufficiency, which occurs in ~20-40% of MM 
patients15. In addition, anaemia occurs in almost all MM patients, which can cause 
debilitating fatigue16. The reduction in red blood cell number has been attributed to a number 
of factors, including marrow replacement by tumour cells, decreased erythropoietin 
production from impaired kidneys and/or cytokine-mediated marrow suppression16. 
Together hypercalcemia, renal insufficiency, anaemia and bone lesions constitute the 
common set of clinical manifestations of MM known as the CRAB features17. Furthermore, 
another major cause of morbidity and mortality in MM is infection, which is attributable to 
the immune suppression present in almost all MM patients due to underlying disease biology 
and/or therapy18. 
 
1.1.3 Disease stages 
1.1.3.1 Monoclonal gammopathy of undetermined significance 
All cases of malignant MM are preceded by the premalignant, asymptomatic condition 
monoclonal gammopathy of undetermined significance (MGUS), characterised by a clonal 
proliferation of PCs in the BM19,20. For a diagnosis of MGUS three criteria must be met: (1) 
serum monoclonal protein < 3 g/dL, (2) clonal BM PCs < 10% and (3) absence of end-organ 
damage, such as the CRAB features, that is related to the PC dyscrasia (Table 1.1)21. MGUS 
is a common disorder in older individuals, with an estimated prevalence of 3-4% in people 
over 50 years of age22,23. The risk of progression from MGUS to overt MM is a persistent 
1% per year, but the time to progression (TTP) is highly variable, with the majority of MGUS 
cases never progressing to symptomatic disease24,25. Currently, it is not possible to accurately 
predict if, or when, MGUS will progress on an individual level, but markers of increased 
abnormal PC bulk (M protein ≥ 1.5g/dL and serum FLC ratio > 1.65) have been associated 
with an increased risk of progression25,26. A recent study found that the lifetime risk of 








Table 1.1: International Myeloma Working Group diagnostic criteria for MM and 







All 3 criteria must be met: 
 Serum monoclonal protein (non-IgM type) < 3 g/dL 
 Clonal BM PCs < 10% 
 Absence of end-organ damage such as hypercalcemia, renal 
insufficiency, anaemia, and bone lesions (CRAB) that can be 





Both criteria must be met: 
 Serum monoclonal protein ≥ 3 g/dL, or urinary monoclonal 
protein > 500 mg per 24 hours and/or clonal BM PCs 10%-60% 
 Absence of myeloma defining events (MDEs) or amyloidosis 
Multiple 
myeloma (MM) 
Both criteria must be met: 
 Clonal BM PCs ≥ 10% or biopsy-proven bony or 
extramedullary plasmacytoma 
 Any one or more of the following MDEs: 
o Evidence of end organ damage that can be attributed to 
the underlying PC proliferative disorder, specifically: 
 Hypercalcemia: serum calcium > 0.25 mM                
(> 1 mg/dL) higher than the upper limit of normal or        
> 2.75 mM (>11 mg/dL) 
 Renal insufficiency: creatinine clearance < 40 mL 
per minute or serum creatinine > 2 mg/dL 
 Anaemia: haemoglobin value of > 2 g/dL below the 
lower limit of normal or a haemoglobin value  
< 10 g/dL 
 Bone lesions: one or more osteolytic lesions on 
skeletal radiography, computed tomography, or 
positron emission tomography-CT 
o Clonal BM PCs ≥ 60% 
o Involved:uninvolved serum FLC ratio ≥ 100 (involved 
FLC level must be ≥ 100 mg/L) 
o ≥ 2 focal lesions on magnetic resonance imaging (MRI) 





Both criteria must be met: 
 Meet the criteria for a diagnosis of MM 
 Peripheral blood PC count of 2 × 109/L or > 20% of the 







abnormal FLC ratio, 20% for those who have one of these factors and only 7% for those who 
have neither risk factor25. The recommended management of MGUS patients is ongoing 
monitoring for disease progression, the frequency of which depends on their risk 
stratification28,29. 
 
1.1.3.2 Smouldering MM 
Smouldering MM (SMM) is an intermediate disease stage between MGUS and MM that is 
still an asymptomatic PC proliferative disorder but is more advanced than MGUS (Table 
1.1)21,30. SMM is a clinically-defined entity that includes patients with asymptomatic, early 
MM, who rapidly progress to end organ damage, and more indolent MGUS-like cases, who 
have a much lower rate of disease progression31. Consistent with this, the risk of progression 
for SMM patients is 10% per year for the first five years post-diagnosis but decreases to 3% 
per year over the next five years and 1.5% per year thereafter30. This means that 50% of 
SMM cases, probably those with asymptomatic malignancy, progress to MM in the first five 
years post-diagnosis, while one third of SMM cases, most likely those with biological 
premalignancy, do not progress within the first 10 years30. Several factors have been found 
to predict for a high risk of progression in SMM patients, including BM PCs > 20%30, 
evolving M protein levels32,33, an abnormal PC immunophenotype34, serum FLC ratio ≥ 835 
and suppression of ≥ 2 uninvolved immunoglobulins (immunoparesis)30,34.  
 
Studies showed that SMM patients with ≥ 60% clonal BM PCs36,37, a serum FLC ratio             
≥ 10037,38 and ≥ 2 focal lesions on MRI39,40 had an ~80% risk of progressing to symptomatic 
MM within two years. In addition, the first randomised trial in which early treatment was 
assessed in high-risk SMM patients found that it increased the TTP and OS of these 
patients41,42. Consequently, the 10-15% of SMM patients that had one or more of these 
biomarkers, and thus an ultra-high-risk of progression, were reclassified as having MM 
requiring treatment in 201421. For the remaining SMM patients, a recent study found that 
BM PCs > 20%, M protein > 2 g/dL and a serum FLC ratio > 20 were independent predictors 
of progression to MM, which led to the development of the Mayo “20-2-20” risk 
stratification system43. SMM patients with two or more of the “20-2-20” risk factors (~36%) 
were found to have an ~50% risk of progressing to MM within two years and thus were 
classified as high-risk43. The current standard of care for SMM involves the close monitoring 





for the finding that the OS of MM patients with a prior diagnosis of SMM was higher 
compared to those with a prior diagnosis of MGUS44. 
 
1.1.3.3 Multiple myeloma 
The updated diagnostic criteria for MM stipulate that patients must have ≥ 10% clonal BM 
PCs and at least one myeloma-defining event (MDE), which consist of characteristic end-
organ damage (CRAB features, section 1.1.2) and the three new biomarkers of progressive 
asymptomatic disease (section 1.1.3.2; Table 1.1)21. Notably, the current description of MM 
does not include a measure of M protein, as 15-20% of MM cases only produce 
immunoglobulin light chains and 3% of MM patients have non-secretory disease16,45. The 
risk stratification of newly diagnosed MM patients was previously based on the International 
Staging System (ISS), which used two measures of tumour burden, β2-microglobulin and 
serum albumin levels, to generate three risk groups (Table 1.2)46. A Revised ISS (RISS) was 
subsequently proposed that had improved prognostic power due to the addition of two factors 
related to disease biology, serum lactate dehydrogenase levels and high-risk cytogenetic 
abnormalities (sections 1.2.3 and 1.2.4.3; Table 1.2)47. In addition, there is the Mayo 
Stratification of Myeloma and Risk-Adapted Therapy (mSMART) staging system, which 
takes into account additional cytogenetic/genetic factors and gene expression profiling 
(GEP, section 1.2.5; Table 1.2)48,49.  
 
1.1.3.4 Plasma cell leukaemia and extramedullary disease 
MM continues to progress post diagnosis, as is evidenced by the inevitable relapse of 
symptomatic and refractory disease following treatment1. In the later stages of MM, the 
malignant PCs can lose their dependence on the BM microenvironment and can be found 
growing at other sites in the body50. MM PCs can undergo a leukemic progression, resulting 
in many tumour cells being present in the peripheral circulation, which is known as plasma 
cell leukaemia (PCL)51,52. The current diagnostic criteria for PCL are ≥ 20% circulating PCs 
and/or > 2 x 109 PC/L in the peripheral blood, which occurs in 1-2% of MM patients (Table 
1.1)27. The median TTP from a diagnosis of MM to PCL is 31 months53 and PCL is 
associated with a very inferior prognosis54,55. Recent studies have found that cases with 
circulating PCs ≥ 5% have a similarly poor prognosis compared to cases with circulating 
PCs ≥ 20%, suggesting that the diagnostic criteria for PCL should be revised55-57. MM PCs 
can also infiltrate other anatomical sites distant to the BM and adjacent soft tissue, which is 














Table 1.2: Common risk stratification systems for MM patients. 
System Variables Stages 
International 
Staging 
System (ISS)46  
Serum albumin and β2m 
levels 
 I: serum albumin ≥ 3.5 g/dL and β2m   
< 3.5 mg/dL 
 II: neither stage I nor III 





Serum albumin, β2m, 
LDH levels and high-risk 
cytogenetics (del(17p), 
t(4;14) or t(14;16)) 
 I: ISS stage I, LDH normal, and no 
high-risk cytogenetics 
 II: neither stage I nor stage III 




RISS, high-risk genetic 
abnormalities, GEP 
 Standard risk: no high-risk factors 
 High risk: RISS III, t(4;14), t(14;16), 
t(14;20), del(17p), TP53 mutation, gain 
1q, GEP high-risk signature 
 
β2m = β2-microglobulin, del = deletion, LDH = lactate dehydrogenase, GEP = gene expression profiling, 







is 6-16% and the most common extramedullary sites of MM PC growth include the lung, 
pleura, liver and central nervous system59-63. Relapsed patients with EMD also have a 
significantly poorer prognosis compared to other relapsed patients, with a median survival 
of 5-16 months from EMD diagnosis61-63. Notably, most human myeloma cell lines 
(HMCLs) are derived from relapsed MM patients with PCL or EMD and thus grow 
independently of BM-derived factors in vitro64.  
 
1.1.4 Treatment 
The outcomes for MM patients have improved significantly over the past 15 years and can 
largely be attributed to the increased use of autologous stem cell transplants (ASCT) and the 
introduction of new classes of drugs, particularly proteasome inhibitors and 
immunomodulatory imide drugs (IMiDs)65,66. Proteasome inhibitors, including first-
generation bortezomib (Velcade), directly target MM PCs through enhancing the existing 
high levels of endoplasmic reticulum stress in these secretory cells, which induces a terminal 
unfolded protein response and apoptosis67. Conversely, IMiDs, including first generation 
thalidomide and second generation lenalidomide (Revlimid), primarily act indirectly by 
promoting anti-myeloma activity of T cells and natural killer (NK) cells68,69. This is achieved 
through the binding of IMiDs to the E3 ligase Cereblon in immune cells, which causes rapid 
ubiquitination and degradation of the transcription factors Ikaros and Aiolos70,71.  
 
The initial induction phase of treatment for newly diagnosed MM patients involves 4-6 
rounds of therapy, which is typically a triplet regimen consisting of Velcade, Revlimid and 
the corticosteroid dexamethasone (VRD) in the USA4. However, the most commonly used 
induction regimen in Australia contains Velcade, cyclophosphamide (chemotherapy) and 
dexamethasone (VCD), as the Australian Pharmaceutical Benefits Scheme does not allow 
the concurrent use of a proteasome inhibitor and an IMiD72. Eligible patients are then 
recommended to receive high dose therapy (HDT) coupled with ASCT, which has been 
shown to significantly improve OS73-75. Finally, following HDT-ASCT, or additional cycles 
of therapy for transplant-ineligible patients, maintenance therapy with an IMiD is 
recommended, as it has been shown to improve progression-free survival (PFS) and OS76,77. 
Lenalidomide is the standard of care for maintenance therapy in the USA, whereas 






Although the TTP greatly varies, MM patients almost invariably relapse and the salvage 
treatment employed is dependent upon factors related to treatment (prior response, 
resistance), disease (risk group stratification) and the patient (age, co-morbidities and 
performance status)78. Several new drugs have recently been approved by the Food and Drug 
Administration (FDA) for the treatment of relapsed MM and promise to further improve 
patient outcomes78. These include the next-generation proteasome inhibitors carfilzomib79,80 
and ixazomib81,82, the third generation IMiD pomalidomide83,84, the histone deacetylase 
(HDAC) inhibitor panobinostat85,86, and the monoclonal antibodies daratumumab87,88 and 
elotuzumab89. Furthermore, there are many emerging options for the treatment of MM 
currently in clinical trials, including chimeric antigen receptor (CAR) T cell therapies 
targeting B cell maturation antigen (BCMA)90 and the B cell lymphoma 2 (Bcl-2) inhibitor 
venetoclax91,92. 
 
1.2 Genetic aetiology of MM 
1.2.1 Normal PC development 
Early B cells are derived from haematopoietic stem cells in the BM and undergo 
rearrangement of their immunoglobulin genes to produce a functional B cell receptor 
(BCR)93. Mature B cells expressing a BCR on their surface then migrate to secondary 
lymphoid organs, including lymph nodes and spleen94. Upon encountering their cognate 
antigen in the periphery, mature B cells are activated and proliferate rapidly within a 
germinal centre95. Here activated B cells undergo several processes, including affinity 
maturation and class-switch recombination, that produce B cells expressing a high affinity 
BCR with different effector functions. These processes involve the generation of DNA 
double-stranded breaks at the immunoglobulin heavy chain (IgH) locus, which are generated 
by activation-induced cytidine deaminase (AID)96. The resultant B cells can then 
differentiate into either memory B cells or antibody-secreting PCs, which is mediated by the 
altered expression of a few key transcription factors, including interferon regulatory factor 
4 (IRF4) and PR domain zinc finger protein 1 (PRDM1)97. Following differentiation, PCs 
migrate to the BM and establish themselves in specific niches that support their long-term 






1.2.2 Inherited genetic variation 
Familial aggregation of PC disorders, including MM and MGUS, has been reported over 
several decades98-100. In addition, large scale case-control studies found that there was a two 
to three-fold increased risk of PC disorders in first degree relatives of MGUS/MM 
patients101-103. Furthermore, the increased risk of MGUS/MM in people with African 
heritage compared to Caucasians was maintained when socioeconomic status was 
considered6. Together, these data suggested that there was inheritable susceptibility to 
developing MGUS and MM. Large-scale genome-wide association studies (GWAS) 
provided the first unambiguous evidence that this was the case by identifying common 
genetic variants that were enriched in MM patients compared with healthy controls104-108. To 
date 23 single nucleotide polymorphisms (SNPs) have been identified that are independent 
risk loci for MM104-108. Most of these SNPs are in non-coding regions of the genome, which 
suggests that they affect the regulation of gene expression107. Investigations of the candidate 
causal genes associated with these SNPs found that most were linked to four functions: 
chromatin remodelling (SP3, ABCF2, CBX7), regulation of cell cycle and genomic stability 
(CEP120, POT1, CDKN2A), B cell development (ELL2, PRDM1, TNFRSF13B) and 
apoptosis/autophagy (CDCA7L, WAC, RFWD3, KLF2)107. Hence, dysregulation of these 
processes may be involved in the pathogenesis of PC proliferative disorders, however, 
functional validation is required. Notably, a recent study identified lysine-specific 
demethylase 1 (KDM1A) as an autosomal dominant MM germline predisposition gene, 
suggesting that rare inherited variants also contribute to the development of MGUS/MM109.  
 
1.2.3 Primary genetic events 
The development of MM is a multi-step process that involves the accumulation of acquired 
genetic lesions within PCs (Figure 1.1)110. The majority of MM patients have one of two 
types of cytogenetic abnormality that, in most cases, are mutually exclusive and present in 
the entire population of clonal PCs: hyperdiploidy (≥ 48 chromosomes) and translocations 
involving the IgH locus on chromosome 14 (14q32)111,112. The fact that these genomic 
lesions are found at a similar frequency in MGUS patients compared to MM patients 
suggests that they are primary genetic events that initiate PC immortalisation113-115. 
However, as hyperdiploidy and IgH translocations are present in MGUS patients that never 
progress to MM, these lesions are likely to be necessary, but not sufficient, for the 
development of overt malignancy116. Despite this, primary genetic events were found to have 











Figure 1.1: Initiation and progression of MM. The initiation of MM development is 
caused by a primary genetic event in a post-germinal centre B cell, which differentiates into 
a PC that resides in the BM. The benign clonal proliferation of this abnormal PC within the 
BM results in MGUS. The subsequent progression of disease to malignant MM is due to the 
acquisition of secondary genetic lesions and changes to the tumour microenvironment. As 
the disease progresses further, the neoplastic PCs can become independent of the BM, 
leading to PCL or EMD. Adapted from Kumar et al., 20171. MGUS = monoclonal 
gammopathy of undetermined significance, PCL = plasma cell leukaemia, EMD = 






The primary cytogenetic event in ~40% of MM patients is a translocation between the IgH 
locus and one of five recurrent partner chromosomes (4, 6, 11, 14 and 20)120-122. The 
breakpoints of these translocations indicate that most are caused by an error in chromosomal 
reassembly following the AID-mediated generation of DNA double stranded breaks at the 
IgH locus during class switch recombination123,124. The translocations juxtapose a proto-
oncogene(s) on the partner chromosome to the powerful IgH enhancer, resulting in its 
overexpression93. The most common IgH translocation is t(11;14) (q13;q32), which is found 
in ~18%125-127 of MM patients at diagnosis and is considered to be of standard risk49. This 
chromosomal rearrangement results in the overexpression of the cyclin D1 (CCND1) gene, 
which, along with other D-group cyclins, is required for progression through G1 phase of 
the cell cycle123,124. 
 
The second most prevalent translocation is t(4;14) (p15;q32), which is detected in ~13% of 
newly diagnosed MM cases125-127. This rearrangement results in the overexpression of the 
nuclear receptor binding SET domain protein 2 (NSD2) gene, which encodes a histone 
methyltransferase, in all cases and the fibroblast growth factor receptor 3 (FGFR3) gene, 
which encodes a tyrosine kinase, in ~70% of cases118,128. The up-regulation of NSD2 causes 
epigenetic reprogramming and thus gene expression changes that alter the adhesion, increase 
the proliferation and enhance the survival of PCs, including increasing the expression of the 
cyclin D2 (CCND2) gene129,130. While t(4;14) was initially considered to be a high-risk 
feature117-119, the emergence of clinical trial results showing that bortezomib treatment 
negated/attenuated the poor patient outcomes associated with t(4;14)131-134 led to its re-
classification as an intermediate-risk factor48,135. However, in the latest version (v3.0) of the 
mSMART risk stratification guidelines, t(4;14) was reinstated as a high-risk abnormality49. 
This may be due to the fact that t(4;14) was found to be an independent predictor of poor 
prognosis in recent large clinical trials in which MM patients were treated with novel 
therapies121,127. 
 
Another two recurrent primary IgH translocations are t(14;16) (q32;q23) and t(14;20) 
(q32;q11), which are found in ~4% and ~1% of MM patients, respectively125-127. Both 
t(14;16) and t(14;20) result in the overexpression of an oncogenic MAF transcription factor 
(MAF or MAFB, respectively), which causes up-regulation of a range of genes, including 
CCND2129,136-139. The MAFs were also found to increase the expression of cytidine 





resulting in an increased mutational burden that may contribute to the poor prognosis 
associated these translocations in MM121,125. Finally, the standard risk translocation t(6;14) 
(p21;q32) is present in ~1%125-127 of MM cases and causes direct overexpression of the cyclin 
D3 (CCND3) gene129,140.  
 
The primary genetic event in ~55% of MM patients is hyperdiploidy120-122, which is caused 
by multiple trisomies of the odd-numbered chromosomes 3, 5, 7, 9, 11, 15, 19 and/or 
21111,115,141-143. The mechanism by which these trisomies occur remains to be elucidated, but 
it has been suggested that they are gained in a single catastrophic event involving the mis-
segregation of chromosomes at mitosis144. In the absence of high-risk secondary genetic 
events, patients with hyperdiploidy are of standard risk49,121. Similar to the recurrent IgH 
translocations, hyperdiploidy also results in increased expression of D group cyclins, 
specifically cyclin D1 and cyclin D2121,129. Notably, hyperdiploidy and recurrent IgH 
translocations converge to directly, or indirectly, upregulate D-group cyclins (Figure 1.2). 
Therefore, deregulation of the G1-S cell cycle transition appears to be an early and unifying 
pathogenic event that drives the development of MGUS129. 
 
1.2.4 Secondary genetic events 
Secondary genetic events are thought to promote the transition from MGUS/SMM to MM 
and the progression from newly diagnosed MM to refractory MM/EMD/PCL110. Genetic 
lesions that have a higher frequency in MM patients compared to MGUS patients are 
generally considered to be secondary events2. Several different types of secondary genetic 
events are thought to contribute to malignant transformation in MM, including DNA 
mutations, translocations and copy number alterations (CNAs)145.  
 
1.2.4.1 DNA mutations 
The advent of massively parallel next-generation sequencing (NGS) of DNA has enabled 
the mutational spectrum of MM PCs to be assessed in large cohorts of patients146. Genes that 
are found to be affected by non-synonymous mutations more frequently than predicted from 
the background mutation rate are classified as being recurrently mutated, suggesting that 
they are drivers of MM development147,148. The NGS studies of newly diagnosed MM have 
revealed the absence of a universal driver mutation and instead demonstrated a high degree 
of interpatient heterogeneity120,122,147-149. Only a few recurrently mutated genes were found 










Figure 1.2: Primary cytogenetic events converge to dysregulate the G1/S cell cycle 
checkpoint. MM initiating events, translocations involving the IgH locus and hyperdiploidy 
(HRD), either directly (indicated by solid lines) or indirectly (indicated by dashed lines) lead 
to the up-regulation of cyclin D1, cyclin D2 or cyclin D3. These D-group cyclins can all 
form complexes with cyclin-dependent kinase 4 (CDK4) and CDK6, which phosphorylate 
the retinoblastoma protein (RB), leading to its dissociation from the transcription factor E2F. 
This enables E2F to drive the transcription of genes required for progression through the 






were recurrently mutated at a frequency below 5%120,122,147-149. Up until recently, 16 genes 
had been identified as recurrently mutated in at least one whole exome sequencing (WES) 
study of MM patients (Figure 1.3)120,148,149. However, in the largest WES study of newly 
diagnosed MM patients to date (n = 1,273)122, a combination of frequency and function-
based approaches led to the identification of an additional 47 mutated driver genes122.  
 
The MM mutated driver genes cluster in particular pathways, suggesting that the 
dysregulation of these functions promotes disease progression120,122,150. Approximately 50% 
of MM patients have an oncogenic mutation in a gene involved in the pro-proliferative 
MEK/ERK signalling pathway, including KRAS (~20%), NRAS (~20%) and BRAF 
(~7%)120,122,148-150. Two MM driver genes with a relatively high mutation frequency are the 
RNA exonuclease DIS3 (~10%) and the non-canonical poly(A) polymerase FAM46C (~9%), 
which are both involved in RNA processing120,148,149. FAM46C was demonstrated to be a 
tumour suppressor that inhibits the proliferation and survival of MM PCs151,152, but the role 
of DIS3 in MM PCs remains to be determined122. In addition, negative regulators of the 
nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) signalling pathway are 
affected by inactivating mutations in ~11% of MM patients, including TRAF3 (~5%) and 
CYLD (~3%)120,122,148-150. This leads to aberrant activation of the NF-κB pathway, which 
promotes the survival of MM PCs153,154. Furthermore, ~24% of MM cases harbour a 
mutation in an epigenetic regulator, including HIST1H1E (~4%), ARID1A (~2%) and 
KMT2B (~2%), and ~5% have a mutation in a gene involved in B cell development, 
including IRF4 (~3%) and PRDM1 (~2%)122. DNA mutations were found to be of little 
prognostic value in MM127,150 with the notable exception of mutations in the crucial tumour 
suppressor gene TP53 (~5%), which have consistently been associated with poor patient 
outcomes120,150,155. However, several studies have shown that having an increased number 
of driver mutations, irrespective of the genes involved, is associated with reduced survival 
in newly diagnosed MM patients127,150.  
 
1.2.4.2 Secondary translocations: MYC abnormalities 
Chromosomal translocations that are not associated with class switch recombination are 
another type of secondary genetic event that is present in the PCs of MM patients. Most 
secondary translocations involve the MYC oncogene at 8q24 and are found in ~20% of newly 
diagnosed MM patients125,156-159. The immunoglobulin genes constitute ~40% of MYC 















Figure 1.3: Recurrently mutated genes in patients with newly diagnosed MM. The 
frequency of DNA mutations in the 16 genes that were found to be significantly mutated in 
at least two of the four WES studies of newly diagnosed MM (NDMM) patients to date are 
listed120,122,148,149. The function of each gene is also shown and the average mutation 






 (6%) and BMP6 (3.5%)125. These translocations invariably juxtapose the MYC locus to a 
superenhancer associated with the partner gene, resulting in significant overexpression of 
MYC156-158. Other chromosomal rearrangements, including gains and inversions, have been 
identified at the MYC locus, such that MYC rearrangements are found in ~50% of MM 
patients158. In addition, two thirds of MM patients were found to have a MYC activation 
gene expression signature, suggesting that there are alternative mechanisms by which MYC 
is aberrantly activated in MM160. Regarding prognostic significance, translocation/gain of 
MYC was found to be associated with significantly reduced PFS and OS of MM 
patients125,127,150,157. While some studies also found MYC rearrangements to be an 
independent negative prognostic factor in MM125,157, the most recent studies have not 
confirmed this in multivariate analyses127,150. Interestingly, a recent study showed that 1.5% 
of MM patients have a non-MYC secondary translocation that generates a fusion gene 
predicted to cause activation of oncogenic kinases involved in the MEK/ERK or NF-κB 
signalling pathways161. 
 
1.2.4.3 Copy number alterations 
CNAs, which are gains or losses of genomic regions ranging from a few kilobases up to 
whole chromosome arms, are common secondary genetic events in MM145. Recurrent CNAs 
most likely constitute driver events and thus one or more of the genes in the minimally 
affected region may be important for the pathogenesis of MM145. Deletions are thought to 
aid in MM development by disrupting an allele of one or more tumour suppressor genes in 
the lost region, leading to their inactivation by haploinsufficiency or in combination with a 
mutation/deletion of the second allele145. A recent study found that loss of heterozygosity    
> 4.6% across the genome was found to be associated with a significantly poorer prognosis 
in MM patients, suggesting that increased CNA-mediated tumour suppressor disruption 
promotes disease progression127. Conversely, recurrent copy number gains are thought to 
contribute to the pathogenesis of MM by increasing the expression of important oncogenes 
that promote PC growth and survival145.  
 
Deletion of all or part of the long arm of chromosome 13, del(13q), is present in the PCs of 
~45% of newly diagnosed MM patients119-122,162,163. It is likely that del(13q) disrupts multiple 
tumour suppressor genes, but there are several pieces of evidence to suggest that RB1 is a 
key target: (1) it is located in a minimally deleted region at 13q14.2122,162, (2) it is 





of patients120,122,148. Other putative tumour suppressor genes affected by del(13q) include 
DIS3 and metabolism-associated TGDS, which were also found to be recurrently mutated in 
MM122. While del(13q) was originally found to confer a poor prognosis117,119, subsequent 
studies found that this adverse impact on MM patient outcome was nullified when the 
association of del(13q) with high-risk cytogenetic lesions, such as t(4;14), were taken into 
account120,127,162. 
 
Other recurrent chromosomal deletions in MM involve the long arm of chromosomes 14 and 
16, which are present in ~14% and ~19% of patients, respectively120-122. The negative 
regulators of the NF-κB pathway TRAF3 and CYLD are likely to be the critical tumour 
suppressor genes targeted by del(14q) and del(16q), respectively, as they are affected by 
recurrent mutations and homozygous deletions120,122,148,162. Biallelic inactivation of TRAF3 
and CYLD has been found to occur in 5.2% and 2.6% of MM cases, respectively122, but was 
not found to impact the prognosis of MM patients120,127,162. Another commonly deleted 
region in MM is the short arm of chromosome 1, some portion of which is lost in ~25% of 
patients120,122,162. Commonly deleted regions of 1p include 1p32.3 and 1p12, which are lost 
in ~9% and ~15% of newly diagnosed MM cases, respectively120,122,162,164. Pro-apoptotic 
FAF1 (1p32.3), negative cell cycle regulator CDKN2C (1p32.3) and recurrently mutated 
FAM46C (1p12) were found to be affected by homozygous deletions, suggesting that these 
are at least some of the target tumour suppressor genes on 1p162. Deletions of 1p32 and 1p12 
have been associated with impaired OS120,121,162,164,165 but were not found to be independent 
negative prognostic factors49,127.  
 
There are two recurrent CNAs that have been identified as robust independent negative 
prognostic factors for OS in newly diagnosed MM145. One is the gain of the long arm of 
chromosome 1, which is present in ~35% of MM patients120-122,162 and was shown to be an 
independent predictor of inferior outcome120,127,162,166. However, recent studies found that 
only amplification of 1q21 (≥ 4 copies) was significantly associated with inferior OS, 
suggesting that quantifying the copy number of 1q21 is key for identifying a very high-risk 
group of MM patients120,127. The minimally gained region at 1q21 contains several candidate 
oncogenes162, including the cyclin dependent kinase activator CKS1B that has been shown 
to promote the growth and survival of human MM cell lines in vitro166-168. In a recent study, 
an RNA interference screen of 78 genes at 1q21 showed that the down-regulation of known 





ILF2) impaired HMCL proliferation and survival in vitro169. Of these genes, 1q21 
amplification-driven overexpression of ILF2 (interleukin enhancer binding factor 2) was 
found to promote HMCL survival in vivo by enhancing DNA damage repair and thus 
tolerance of genomic instability, suggesting that ILF2 overexpression may also be involved 
in the pathogenesis of 1q21 gains169.  
 
The second recurrent CNA that is consistently found to be an independent adverse prognostic 
factor for MM patients is deletion of the short arm of chromosome 17, del(17p)117,119-121,162. 
This deletion is present in ~9% of MM patients and the main target is thought to be 
TP53120,122,162. A significant negative correlation between the percentage of PCs harbouring 
del(17p) and the OS of MM patients has been shown, but there is a lack of consensus on the 
optimum percentage cut-off that should be used to identify high-risk patients170-173. 
Importantly, recent studies have found that the inferior prognosis associated with del(17p) 
is attributable to those patients that have biallelic inactivation of TP53, which occurs in 
~40% of cases with del(17p)127,170. Hence, it has been suggested that the mutational, as well 
as the copy number, status of TP53 must be determined in order to accurately identify MM 
patients with truly high-risk disease127.  
 
1.2.5 Gene expression changes 
Global gene expression profiling (GEP), initially using microarray and later RNA 
sequencing technology, revealed that the transcriptome of MM PCs is significantly different 
to normal and MGUS PCs174-177. Interestingly, the difference in the transcriptome between 
normal and MGUS PCs was found to be greater than the difference between MGUS and 
MM PCs, suggesting that primary genetic events have a greater impact on gene expression 
than secondary events175,177. Genes differentially expressed in MM PCs were found to cluster 
in pathways relevant to disease, including cell cycle, apoptosis and MYC activation160,174,178. 
Hierarchical clustering of MM cases based on their transcriptome identified up to 11 
different subgroups, which reflects the molecular heterogeneity evident in MM179,180. Most 
of the subgroups are strongly correlated with primary cytogenetic abnormalities but some 
are also associated with clinical features179,180. For example, the low bone lesion subgroup 
is characterised by low or no incidence of bone lesions, which is likely due to reduced 
expression of DKK1179,180. Notably, a number of these subgroups were found to be associated 
with high-risk disease, including the t(4;14)-associated NSD2 subgroup and the t(14;16) and 





identify certain gene expression signatures, consisting of between 4 and 92 genes, which are 
independent prognostic factors in MM182-189. While there is minimal overlap between the 
genes included in these signatures, a recent study found that simply averaging two of the 
existing signatures could reliably predict MM patient outcome190. Despite the predictive 
power of these signatures, GEP is not currently performed in general clinical practice due to 
issues with standardisation and unknown relevance to different therapeutic regimens191.     
 
1.2.6 Epigenetic aberrations 
Although the aberrant gene expression pattern in MM has been well characterised, the 
dysregulation of epigenetic mechanisms, including DNA methylation, histone modifications 
and microRNA expression, that contribute to these changes remains poorly understood. The 
fact that approximately a quarter of newly diagnosed MM patients have a driver mutation in 
an epigenetic gene that functions in histone acetylation (CREBBP, EP300), histone 
methylation (KDM6A, KMT2B, KMT2C, SETD2), DNA methylation (DNMT3A, IDH1, 
IDH2, TET2), or chromatin remodelling (ARID1A, ARID2) highlights the importance of 
epigenetic aberrations to the pathogenesis of MM122,192. Regarding DNA methylation, 
studies comparing the DNA methylome of normal or MGUS PCs to MM PCs have 
consistently shown that MM is characterised by widespread hypomethylation193-196, which 
is associated with genomic instability in cancer197. In addition, MM cases were found to have 
focal regions of gene-specific DNA hypermethylation embedded within the 
hypomethylation pattern194-196. Hypermethylation of CpG sites was found in the promoters 
of tumour suppressor genes, leading to their decreased expression, and was associated with 
adverse outcomes for some genes194,198. Another study found that hypermethylation of 
intronic enhancer regions was a feature of MM, resulting in reduced expression of the 
cognate genes196. Notably, the levels and patterns of DNA methylation in MM were found 
to be highly heterogeneous, which may be associated with the different primary cytogenetic 
lesions194,196.  
 
Another layer of epigenetic regulation of gene expression is the post-translational 
modification of histones, which modulates the structure of chromatin. The relevance of 
aberrant histone modification in the development of MM is highlighted by the pathogenic 
nature of up-regulating the H3K36 methyltransferase NSD2 in t(4;14) cases, which has been 
shown to significantly alter the histone methylation pattern and transcriptome of MM PCs130. 





another histone methyltransferase, enhancer of zeste homologue 2 (EZH2), was also found 
to be associated with worse outcomes for MM patients199,200. EZH2 inhibitors were shown 
to cause cell cycle arrest and apoptosis of MM PCs in vitro, indicating that the maintenance 
of epigenetic deregulation is crucial for the growth and survival of tumour cells200. In 
addition, the expression of class I HDACs has been found to be increased in MM PCs 
compared to normal PCs and higher expression of HDAC1 in MM was shown to be 
associated with significantly shorter PFS and OS201. The HDAC inhibitor panobinostat was 
demonstrated to have anti-MM activity in vitro202 and significantly prolong the PFS of 
relapsed/refractory patients in combination with bortezomib and dexamethasone203, 
suggesting that aberrant HDAC activity is a key contributor to the growth and survival of 
MM PCs. Furthermore, a recent study found that there is widespread conversion of normally 
heterochromatic regions to active euchromatin in MM PCs, suggesting that chromatin 
decondensation contributes to the development of MM204. 
 
MicroRNAs (miRNAs) are small (18–22 nucleotides) endogenous non-coding RNAs that 
post-transcriptionally regulate gene expression in a sequence-specific manner. An important 
role for miRNA-mediated regulation of gene expression in the development of MM is 
suggested by the finding that MM PCs have a miRNA signature that is distinct from MGUS 
PCs and normal PCs205-208. For example, the oncogenic miR17-92 cluster was found to be 
significantly up-regulated and the tumour suppressor miRNAs mir-15a and mir-16 were 
found to be significantly down-regulated in MM PCs205-208. The oncogenic/tumour 
suppressor role of these miRNAs was confirmed by the finding that miR-19a/b antagonists 
and mir15-a or mir-16 mimics inhibit the growth of HMCLs in vivo205,206. In addition, the 
tumour suppressor let-7 family of miRNAs, the targets of which include MYC, KRAS and 
CCND1, was found to be down-regulated in MM, and a let-7b mimic reduced MM tumour 
growth in vivo209. The activity of the key tumour suppressor TP53 may also be regulated by 
miRNAs, as the expression of miR-192, -194, and -215 were found to be reduced in MM 
compared to MGUS, leading to increased levels of the TP53 inhibitor MDM2210. Notably, 
the miRNA expression profile in circulating exosomes was shown to be significantly 
different in MM patients compared to healthy controls211. For example, let-7b levels were 
significantly reduced in the MM exosomes, and low let-7b was associated with an adverse 
outcome in MM patients211. Hence, profiling circulating exosomal miRNAs may be a novel 






1.2.7 Clonal heterogeneity and evolution 
In addition to the considerable interpatient heterogeneity of genetic driver events in MM, 
NGS studies have revealed that there is also significant intrapatient heterogeneity148,149,212-
216. MM tumours were shown to be composed of multiple genetically heterogeneous 
subpopulations of cells called subclones, with a median of six subclones present at diagnosis 
per patient217. These subclones share a common pool of clonal mutations, which likely 
represent lesions that occurred early in disease development, but also harbour distinct 
subclonal mutations, which likely occurred later in MM progression148,149,212-216. Many 
secondary genetic events that are considered key drivers of MM development can be clonal 
or subclonal, including KRAS and NRAS mutations, suggesting that they can occur at various 
stages of disease148,149. In addition, NGS analysis of MM tumour samples collected from 
separate sites within a patient at the same timepoint has revealed that 75% of patients display 
spatial heterogeneity218. Some MM patients were found to have subclones harbouring high-
risk genetic drivers, such as biallelic inactivation of TP53, in some BM sites but not others218. 
Hence, the current practice of performing genetic analyses on BM samples from a single site 
may lead to inaccurate risk classification, and thus sub-optimal clinical management, of MM 
patients.  
 
The subclonal architecture of a tumour can evolve over time and this is thought to occur in 
a Darwinian manner in which subclones compete with one another for growth and survival 
under selective pressures, such as immune surveillance and treatment219. Analyses of the 
subclonal structure of paired tumour samples collected from the same MM patient prior to 
treatment and at relapse has revealed several patterns of clonal evolution149,214,217,220,221. 
Approximately two thirds of MM patients exhibit branching evolution, which is 
characterised by both the loss of some subclones and the gain of other subclones with novel 
mutations217. A pattern of linear evolution is observed in ~20% of cases in which genetic 
lesions are gained but there is no apparent loss of clones217. Both of these patterns of 
evolution are most commonly seen in patients who achieve a deep response to treatment and 
result from the emergence of minor, pre-existing resistant subclones217. In the remaining 
~15% of patients there is no change in the subclones at relapse, which is termed a stable 
evolutionary pattern217. In a recent study, stable evolution was only observed in cases that 
did not achieve a complete response to therapy, suggesting that a dominant, innately-
resistant clone was present at diagnosis217. In those patients with branching or linear 





novel clones that had additional acquired lesions, including gain of 1q, biallelic inactivation 
of TP53 and MYC translocations217,220,221. Notably, studies in which MM patients were 
treated uniformly showed that there was no unifying mutation that emerged, suggesting that 
resistance/relapse occurs through multiple mechanisms217,220. Hence, in order to effectively 
achieve long-term control of MM and prevent relapse, therapies will need to target clonal 
drivers or be used in combination. 
 
1.2.8 Oncogene dependencies 
The increasing numbers of newly diagnosed MM patients undergoing in-depth genetic 
analysis has enabled the relationships, or oncogenic dependencies, between driver events to 
be comprehensively assessed120,122,150. Recent studies have revealed patterns of co-occurring 
and mutually exclusive cytogenetic events, CNAs and mutations in MM patients, with 
primary IgH translocations and hyperdiploidy events found to have positive and negative 
associations with distinct secondary genetic hits (Table 1.3)120,122,150. These data suggest that 
the selective advantage of emergent genetic hits is predetermined by existing lesions in 
clonal PCs122. In most MM tumours, KRAS and NRAS mutations were found to exhibit 
mutual exclusivity120,148,150 and, when they did co-occur in a patient, they were shown to be 
within separate subclones of the tumour216. This is consistent with mutations in either of 
these genes causing activation of the MAPK/ERK pathway and thus being functionally 
redundant148,216. 
 
Some of the most significant positive associations were found to be between primary IgH 
translocations and mutations within the partner oncogene on derivative chromosome 
14120,122,125. While the mutational signature suggests that the partner genes were altered by 
AID, the mutations were non-randomly distributed in the genes, suggesting that they are 
likely to be co-operative driver, not passenger, events125. Another common type of positive 
association was the co-occurrence of a CNA and a mutation that collaborated to cause the 
biallelic inactivation of a tumour suppressor gene, including del(17p) and TP53 mutation, 
del(13q) and DIS3 mutation and del(16q) and CYLD mutation122,150. The potential 
mechanism of co-operativity between other significantly co-occurring lesions, such as 
hyperdiploidy and FAM46C mutations, are not immediately apparent and require further 
investigation122. Furthermore, specific mutations within a gene were shown to have a 














Table 1.3: Oncogenic dependencies between primary and secondary genetic events in 
MM. The secondary translocations, gene mutations (indicated by gene names) and CNAs 
that were found to significantly co-occur (positive association) or be mutually exclusive 
(negative association) with primary cytogenetic events in newly diagnosed MM patients. 




Positive association Negative association 
Hyperdiploidy t(MYC), FAM46C, +6p 
IRF4, PRKD2, CCND1, 
DIS3, MAX, -4p, -13q,  
-14q 
t(4;14) 
FGFR3, DIS3, PRKD2,  
-1p, -4p, -11q, -12p, -13q,  
-14q, +1q 
NRAS, t(MYC), -16q 
t(11;14) CCND1, IRF4 
t(MYC), -1p, -4p, -8p,  
-13q, -14q, -16q, +1q, +6p 
t(14;16) 
BRAF, DIS3, TRAF2,  
-13q, +1q 
- 
t(14;20) - - 







predominant in the t(14;16) subgroup, whereas BRAFV600E was the most common variant in 
the other subgroups122. This suggests that distinct mutations within the same gene may vary 
in their mechanism of action and thus the selective advantage they confer on different genetic 
backgrounds.  
 
1.2.9 Progression from MGUS/SMM to MM 
Understanding the mechanisms by which disease progresses from asymptomatic MGUS and 
SMM to overt MM is crucial for identifying key therapeutic targets that promote 
malignancy. With respect to primary cytogenetic events, both MGUS and SMM patients 
with t(4;14) or hyperdiploidy were found to have an increased risk of disease progression, 
despite the fact that hyperdiploid MM is considered to be of standard risk43,222-224. Notably, 
many of the recurrent mutations, CNAs and cytogenetic rearrangements in MM that are 
generally considered to be secondary events are also found at the MGUS/SMM stages, albeit 
at a lower frequency114,225-228. Such lesions, including gain 1q and del(13q)228, may further 
prime immortalised PCs for malignant transformation but are unlikely to drive disease 
progression to overt MM229. Conversely, there are some lesions that are absent or found at a 
very low frequency in MGUS patients, such as TP53 mutations/deletions and MYC 
rearrangements, which likely constitute genuine drivers of progression to overt MM226,228. 
A small number of NGS studies have examined paired MGUS/SMM and MM samples from 
the same patient, showing that the transition to overt malignancy is associated with an altered 
pattern, but not load, of mutations and CNAs215,230-232. There was no gene or pathway found 
to be universally disrupted during the progression from asymptomatic to symptomatic 
disease, suggesting that there are varied molecular mechanisms by which the transition from 
MGUS to MM occurs231,232. Mutations in several genes that are recurrently affected in MM 
were found to be associated with the MGUS/SMM to MM transition, including KRAS, DIS3, 
SP140, TRAF3, PRDM1 and IRF4, suggesting that these lesions may be key drivers of 
disease progression232. However, the potential role of KRAS mutations in driving malignant 
transformation is undermined by the fact that they were also found in MGUS patients232 and 
were not associated with reduced TTP228.  
 
NGS studies of PCs from MGUS/SMM patients have shown that there is a similar degree of 
clonal heterogeneity present compared to MM PCs, suggesting that disease evolution is 
already occurring at early stages of the disease215,230-232. Paired MGUS/SMM and MM 





during the transition from MGUS/SMM to MM231,232. The evidence of a stable evolutionary 
pattern in some patients indicates that the clones capable of causing symptomatic disease are 
already present at pre-symptomatic stages of disease231,232. This finding suggests that PC-
extrinsic factors, such as inhibition of microenvironment-mediated growth control, may play 
an important role in promoting malignant transformation. Consistent with this, primary 
MGUS PCs were shown to be capable of progressive expansion in the BM of a humanised 
mouse strain, with different minor subclones reproducibly emerging in the xenotransplant 
compared to the baseline tumour sample233. However, branching evolution was also 
observed in the MGUS/SMM to MM transition, which was associated with a longer TTP 
compared to stable evolution231. This suggests that the acquisition of additional genetic 
drivers is required to enable malignant transformation in some patients. Overall, it is likely 
that the progression from asymptomatic MGUS/SMM to overt MM requires the 
accumulation of specific PC-intrinsic driver lesions, as well as changes to PC-extrinsic 
factors in the BM microenvironment.  
 
1.2.10  Transgenic mouse models of MM 
Transgenic mouse models are important tools for demonstrating the driver status of recurrent 
genetic abnormalities in malignancy. However, many of the transgenic mice that were 
generated to model MM have been of limited relevance because the transgenes investigated 
were not observed to be mutated or dysregulated in the PCs of MM patients234,235, and/or the 
transgenes were expressed in early B cells, resulting in lymphomas and extra-medullary 
plasmacytomas rather than an MM-like disease236,237. For example, overexpression of Maf, 
in the B cell lineage resulted in the development of B cell lymphomas, not MM, in aged 
mice238. That said, a proportion of the Maf mice did display some clinical features of MM, 
such as increased M protein levels and a plasmablastic phenotype238. While the phenotype 
of these mice suggested that MAF overexpression promotes B cell tumorigenesis, its exact 
role in promoting the development of MM remains to be completely elucidated.  
 
A transgenic mouse model that faithfully recapitulates the key aspects of MM disease is the 
Vk*MYC model. In C57BL/6 mice harbouring the Vk*MYC transgene, MYC 
overexpression is sporadically activated by somatic hypermutation and thus only occurs in 
post-germinal centre B cells239. The resulting PC proliferative disorder has an indolent 
disease course and shares many of the biological and clinical features of human MM, 





and bone lesions239. The malignant nature of the expanded PCs was confirmed by their 
ability to be successfully transplanted into syngeneic mice239. Crucially, overexpression of 
MYC by the Vk*MYC transgene did not cause MM in the Balb/c mouse strain, which, unlike 
the C57BL/6 strain, are not prone to developing MGUS158. These data strongly suggest that 
the up-regulation of MYC can cause the progression from MGUS to MM, as was 
hypothesised from the prevalence of MYC activation in MM PCs but not MGUS PCs160. To 
continue improving the understanding of MM disease biology, further in vivo exploration of 
the role played by one, or a combination of co-occurring, putative driver mutations in the 
development of MM is warranted.  
 
1.3 SAMSN1 
1.3.1 Gene, mRNA and protein 
SAM domain, SH3 domain and nuclear localization signals 1 (SAMSN1), also known as 
SASH2/NASH1/HACS1/SLy2, was first identified in a study of genes expressed in MM and 
is localised on human chromosome 21 (q11.2)240. There are three verified transcript variants 
of SAMSN1 and the canonical sequence encodes a 373 amino acid protein isoform241. The 
SAMSN1 protein contains an N-terminal nuclear localisation sequence, a src homology 3 
(SH3) domain in the middle of the protein and a sterile alpha motif (SAM) domain toward 
the C-terminus of the protein240,242. Both SH3 and SAM domains are protein interaction 
modules, with SH3 binding to proline-rich regions and SAM binding to both SAM and non-
SAM domains240,242. The co-occurrence of SH3 and SAM domains in a protein like 
SAMSN1 often indicates that it has an adaptor or scaffolding function241. SAMSN1 is 
expressed highly in the haematopoietic compartment, including peripheral blood 
lymphocytes, immune tissues and the BM, and to a lesser extent in other tissues, including 
the heart, lung and brain240,242. Despite the presence of a nuclear localisation signal, 
SAMSN1 was found to primarily localise to the cytoplasm240. SAMSN1 belongs to the SH3 
domain protein expressed in the lymphocyte (SLy) family of proteins that also contains 
SASH3 (SLY/HACS2), which is highly homologous to SAMSN1, and SASH1, which 
contains an additional SAM domain (Figure 1.4)240,242. SASH3 is located on the X 
chromosome and is expressed exclusively in lymphocytes243, whereas SASH1 is ubiquitously 
expressed and found on the long arm of chromosome 6244. The genes encoding this family 
of proteins have orthologues in rodents, birds, reptiles and ray-finned fish, suggesting that 

















Figure 1.4: SLY family of proteins. A schematic representation of the SASH3, SASH1 and 
SAMSN1 mRNA transcripts and the SAMSN1 protein. The location of the conserved SH3 






1.3.2 Functions in normal cells 
SAMSN1 was shown to be significantly up-regulated in human and mouse splenic B cells 
following treatment with IL-4 and other B cell activators, including anti-IgM and anti-
CD40241. This induction of SAMSN1 was found to involve multiple signalling molecules, 
including signal transducer and activator of transcription 6 (STAT6), phosphoinositide 3-
kinase (PI3K), protein kinase C (PKC), and NF-κB241. In addition, in primary murine B cells, 
Samsn1 mRNA expression was found to be increased in activated germinal centre B cells in 
comparison to resting mature B cells247. Notably, the overexpression of Samsn1 in murine B 
cells was found to inhibit proliferation in response to activating stimuli241. Together, these 
data suggest that SAMSN1 is induced by BCR stimulation and negatively regulates the 
resultant activation of B cells. In keeping with this observation, Samsn1 was found to affect 
the function of B and T cells from Samsn1 knockout/transgenic mice compared to wildtype 
(WT) mice, despite the size of B and T cell populations in the BM and spleen not being 
affected245,248,249. Increased B cell and T cell proliferation in vitro and enhanced humoral 
immune responses in vivo were observed in Samsn1-/- mice compared to WT mice245. In 
contrast, Samsn1 transgenic mice were found to have reduced serum IgM levels at baseline, 
and following immunisation, compared to WT mice248. Together, these data suggest that 
SAMSN1 is an immunoinhibitory adaptor in normal B and T lymphocytes. Interestingly, 
functional deletion of homologous Sash3 in mice resulted in decreased lymphocyte function, 
suggesting that, in contrast to SAMSN1, SASH3 promotes activation of adaptive immunity.  
 
In relation to the mechanism by which SAMSN1 attenuates B cell responses, SAMSN1 was 
found to associate with tyrosine phosphorylated proteins in the BJAB B cell lymphoma cell 
line following BCR stimulation241. In addition, a yeast two-hybrid screen identified paired 
immunoglobulin-like receptor B (PIR-B), a negative regulator of B cell activation that is 
phosphorylated following BCR engagement250, as a putative interaction partner of 
SAMSN1241. This was supported by the finding that the overexpressed cytoplasmic tail of 
PIR-B bound to endogenous SAMSN1 in BJAB cells, although an association between 
endogenous PIR-B and Samsn1 in primary murine B cells was not detected241. These data 
suggest that SAMSN1’s inhibition of B cell activation may be mediated by binding to PIR-
B and enhancing negative regulation of BCR signalling. In addition, SAMSN1 has been 
implicated in the epigenetic control of gene expression251. When overexpressed in Jurkat 
acute T cell lymphoma cells and human embryonic kidney (HEK) 293T cells, SAMSN1, 





subcellular localisation shown to be controlled by interactions with 14-3-3 proteins251. In the 
nuclei of these cells, overexpressed SAMSN1 co-immunoprecipitated with overexpressed 
Sin3-associated polypeptide 30 (SAP30) and HDAC1251, which are both members of the 
Sin3 transcriptional co-repressor complex252. In addition, the presence of overexpressed 
SAMSN1 in lysates from HEK293T cells increased the deacetylase activity of overexpressed 
HDAC1 in vitro251. Although there are no reports of these findings being replicated with 
endogenously expressed proteins in normal B cells, these data suggest that SAMSN1 may 
be capable of directly modulating gene expression in B cells, resulting in the inhibition of 
adaptive immune responses.  
 
Another mechanism by which SAMSN1 may mediate its immunoinhibitory effects has also 
been proposed. Overexpression of SAMSN1 in HeLa cervical adenocarcinoma cells was 
found to cause morphological changes, including increased formation of actin-rich 
membrane ruffles in which SAMSN1 co-localised with polymerised F-actin249. This 
SAMSN1-mediated remodelling of the actin cytoskeleton was demonstrated to be dependent 
on the SH3 domain of SAMSN1 and the activity of the small Rho GTPase Rac1249, which is 
known to control the formation of branched actin structures in membrane ruffles253,254. In 
addition, SAMSN1 was found to interact in an SH3-dependent manner with cortactin, an 
activator of Arp2/3 complex-mediated actin polymerization255, suggesting that SAMSN1 
may affect cytoskeletal remodelling by modulating the activity of cortactin249. Furthermore, 
SAMSN1 was shown to enhance the spreading of HeLa cells on a gelatin-coated surface249. 
In contrast, B cells from Samsn1 transgenic mice exhibited significantly reduced cell 
spreading on an anti-IgM-coated surface compared to B cells from WT mice249. In the 
primary B cells from the transgenic mice, Samsn1 was demonstrated to bind endogenous 
Hs1, the lymphocyte-specific homologue of cortactin256. The difference in the effect of 
Samsn1 on cell spreading between HeLa and murine B cells may relate to the contrasting 
properties of normal motile B lymphocytes and transformed epithelial HeLa cells, including 
the cell type-specific differences in the proteins that interact with SAMSN1/Samsn1. 
Notably, cell spreading is crucial for maximising the interaction of lymphocytes with 
antigen, which promotes immune cell activation257. Hence, these data suggest that SAMSN1 
may negatively regulate adaptive immune responses by inhibiting cytoskeletal remodelling-
dependent immune synapse formation. Notably, fellow SLY family member SASH1 has 
also been found to interact with cortactin and modulate actin cytoskeletal remodelling, 





1.3.3 Role in cancer 
1.3.3.1 Identification as a putative tumour suppressor in MM 
SAMSN1 has recently been implicated as having a tumour suppressor role in MM. The first 
piece of evidence suggesting this came from a comparative study of the closely-related 
C57BL/KaLwRij (KaLwRij) and C57BL/6 mouse strains260,261. Both the C57BL/6 and 
KaLwRij strains develop an MGUS-like benign clonal PC proliferative disorder at the same 
rate of ~60-70% by two years old262, but KaLwRij mice are unique in their ability to 
spontaneously develop MM, albeit at a low frequency of ~0.5% in mice over two years 
old263,264. Hence, any genetic differences between the two strains of mice may contribute to 
the predisposition of KaLwRij mice to develop MM, which may also be relevant to the 
pathogenesis of human MM. Transcriptomic analysis of the BM from both mouse strains 
revealed that one of the most differentially expressed genes was Samsn1, which was found 
to be 52-fold down-regulated in the BM of KaLwRij mice compared to WT C57BL/6 
mice260. In fact, the expression of Samsn1 was shown to be completely lost in the BM of 
KaLwRij mice, including normal PCs, and in all the other cells/tissues tested260. This loss of 
Samsn1 expression was found to be caused by a 180 kb homozygous deletion on 
chromosome 16 in the KaLwRij genome, which entirely encompasses Samsn1 but not any 
other genes260. This finding was confirmed in a subsequent study, which through SNP array 
profiling found that the Samsn1 deletion was the most striking structural variant in the 
genome of KaLwRij mice compared to WT mice261. These findings suggested that the loss 
of Samsn1 may contribute to the capability of KaLwRij mice to progress from MGUS to 
MM.  
 
The potential role of Samsn1 as a tumour suppressor gene in murine MM was assessed using 
an immunocompetent 5T murine model of MM (5TMM). The 5TMM model is based on the 
finding that the transplantation of diseased BM from aged KaLwRij mice intravenously (i.v.) 
into young syngeneic recipients resulted in the development of MM, which recapitulated 
many features of human MM, including PC tumour growth in the BM, paraprotein 
production and lytic bone disease263,264. Subsequently, distinct MM cell lines were generated 
from different KaLwRij donor mice, including the 5T2263-266, 5T33vv264, 5T33vt267and 
5TGM1 (5T33 subclone)268 lines. The 5T2 and 5T33vv lines can only be passaged in vivo, 
while the 5T33vt and 5TGM1 cell lines are readily cultivated in vitro, enabling them to be 
genetically modified and maximising their utility for in vivo studies269,270. Using the 





found to significantly inhibit MM tumour development and associated bone disease 
compared to control 5TGM1 cells in vivo260. This suggested that the loss of Samsn1 promotes 
MM development in the KaLwRij model of murine MM. In relation to human MM, in silico 
analysis of microarray gene expression data from PCs revealed that the expression of 
SAMSN1 was significantly lower in MM patients compared to PCs from MGUS patients and 
normal controls260. In addition, reduced SAMSN1 expression was found to be significantly 
associated with adverse clinical parameters in MM patients, including increased tumour 
burden and lower OS260. Together, these data suggested that SAMSN1 may also be a tumour 
suppressor gene in human MM and a reduction in its expression may promote the transition 
from MGUS to MM.  
 
1.3.3.2 Role in other malignancies 
SAMSN1 was found to have reduced expression, and was thus implicated as a tumour 
suppressor gene, in several malignancies besides MM. The first description of reduced 
SAMSN1 expression was in lung cancer, in which loss of heterozygosity at 21q21 is a 
common abnormality271. SAMSN1 was one of eight genes located within a homozygously 
deleted region on 21q21 in a lung cancer cell line, but was the only gene with expression 
levels that were decreased in all the lung cancer cell lines tested compared to normal lung 
tissue271. This suggested that SAMSN1 may be a key target of the 21q21 deletion and thus a 
tumour suppressor gene in lung cancer271. In addition, ulcerative colitis patients with colon 
cancer were found to have significantly lower expression of SAMSN1 compared to those 
patients without cancer, suggesting that SAMSN1 may inhibit the transition from pre-
neoplastic lesions to overt malignancy in colorectal cancer272. Furthermore, SAMSN1 mRNA 
expression was found to be lower in cancerous tissues compared to normal adjacent tissue 
from gastric cancer and hepatocellular carcinoma patients273,274. Low SAMSN1 expression 
in these cancers was found to be associated with increased tumour size and decreased OS, 
suggesting that SAMSN1 may also be a tumour suppressor gene in gastric cancer and 
hepatocellular carcinoma273,274. In contrast, another study found that the expression of 
SAMSN1 was increased in glioma compared to normal brain tissue and high expression of 
SAMSN1 was associated with reduced survival for patients with glioblastoma multiforme275. 
This suggests that the role of SAMSN1 in malignancy may be cell-type specific. Notably, 
fellow SLY protein family member SASH1 was also shown to be down-regulated and 
associated with adverse clinical features in a range of cancers, including breast cancer244, 






1.3.3.3 Mechanism of disruption in cancer 
In relation to the mechanism by which the expression of SAMSN1 is reduced in cancers, 
~30% of human lung cancers have a 21q deletion, suggesting that deletion may be at least 
one way by which the expression of SAMSN1 is reduced in this malignancy 278. However, 
gain, not loss, of the long arm of chromosome 21 is a recurrent CNA in MM patients and 
thus the down-regulation of SAMSN1 expression is likely to occur by another mechanism162. 
In addition, DNA mutation is unlikely to be the cause of reduced SAMSN1 expression in 
MM PCs, as only one SAMSN1 mutation has been identified in NGS studies of cancers, 
which was a nonsense mutation in a patient with angioimmunoblastic T cell lymphoma279. 
However, DNA methylation at specific CpG sites in the SAMSN1 promoter were found to 
correspond with SAMSN1 expression levels in most human MM cell lines260. In addition, 
treatment with the DNA de-methylating agent 5-aza-2′-deoxycytidine was able to 
significantly increase SAMSN1 expression in many of the HMCLs with SAMSN1 promoter 
hypermethylation260. Hypermethylation of the SAMSN1 promoter and associated reduced 
expression of SAMSN1 was also observed in hepatocellular carcinoma cell lines273. This 
suggests that aberrant hypermethylation of the SAMSN1 promoter may be a key mechanism 
by which SAMSN1 expression is reduced in MM and other malignancies260,273. While a 
correlation between SAMSN1 methylation and expression is yet to be established in MM 
patient samples, the potential down-regulation of SAMSN1 by promoter hypermethylation is 
consistent with the known hypermethylation of tumour suppressor genes in MM PCs194,198.  
 
1.3.3.4 Mechanism of action in cancer 
To date there has been limited investigation of the potential mechanisms by which SAMSN1 
suppresses cancers, including MM. Given that SAMSN1 has been shown to inhibit the 
proliferation of normal B cells following BCR stimulation241,245 it is conceivable that 
SAMSN1 may limit the proliferation of MM PCs. While another group found that Samsn1 
significantly reduced the proliferation of 5TGM1 cells under basal conditions261, our group 
observed reduced proliferation of Samsn1-expressing 5TGM1 cells only when they were co-
cultured with KaLwRij-derived BMSCs in vitro260. Our group also showed that Samsn1-
expressing 5TGM1 cells and SAMSN1-expressing HMCLs display increased adhesion to 
BM stroma in vitro260. Interestingly, overexpression of SAMSN1 in human lung cancer cell 
lines was not found to affect cell proliferation in vitro271. Collectively, these data suggest 






limiting the proliferation of MM PCs, potentially in a BM microenvironment-dependent 
manner. Notably, SASH1 has been shown to have a range of tumour suppressor effects in 
epithelial cancer cells, including inhibiting the proliferation, viability and migration/invasion 
of malignant cells277,280,281. This suggests that there may be mechanisms beyond attenuating 
proliferation that contribute to the tumour suppressor effect of SAMSN1 in MM. 
Importantly, despite KaLwRij mice being Samsn1-/-, they only develop spontaneous MM 
with a long latency and low penetrance263,264. This suggests that Samsn1 loss is necessary, 
but not sufficient, to cause MM in KaLwRij mice. Hence, it is likely that SAMSN1 down-
regulation co-operates with other genetic/epigenetic “hits” to drive the development of 
malignant PCs.  
 
1.4 Summary and aims 
MM is the second most common haematological malignancy in adults, which is 
characterized by the clonal expansion of malignant PCs in the BM1. Recent genomic studies 
have revealed that MM is a genetically heterogenous disease and the genetic aberrations that 
drive MM development and progression are incompletely understood120,122,232. It was 
previously revealed that Samsn1 is homozygously deleted in the KaLwRij mouse strain260, 
which can develop an MM-like malignancy in old age263,264. In addition, the re-expression 
of Samsn1 in the KaLwRij-derived 5TGM1 MM PC line significantly inhibited tumour 
development following i.v. inoculation into syngeneic KaLwRij mice260. This suggests that 
Samsn1, a putative adaptor protein that has been shown to negatively regulate B cell 
responses241,245, is a tumour suppressor in the context of murine MM. However, the fact that 
MM only develops in Samsn1-/- KaLwRij mice with late onset and incomplete penetrance264 
suggests that Samsn1 loss must co-operate with other acquired genetic changes to promote 
the development of MM. In relation to human MM, SAMSN1 expression was found to be 
significantly reduced in the PCs from MM patients compared to healthy controls and 
SAMSN1 down-regulation was shown to be significantly associated with increased PC 
burden and reduced OS260,261. These data are consistent with SAMSN1 also potentially 
having a tumour suppressor role in the context of human MM. However, the functional role 
of SAMSN1 in human MM cells has not yet been empirically investigated. Furthermore, the 
underlying molecular mechanism(s) by which Samsn1/SAMSN1 suppresses MM remains 






The studies in this thesis were designed to address the following aims: 
1. Identify and investigate potential genetic aberrations that may co-operate with the down-
regulation of SAMSN1 to promote the development and/or progression of MM. 
2. Determine the mechanism(s) by which Samsn1 inhibits 5TGM1 tumour growth in vivo. 



















2.1 Molecular biology 
2.1.1 RNA techniques 
2.1.1.1 RNA-sequencing 
Total RNA was extracted from 5TGM1 cells using the RNeasy Mini Kit and the RNase-Free 
DNase Set (QIAGEN), according to the manufacturer’s instructions. RNA quantity was 
determined using the QubitTM RNA BR Assay Kit and QubitTM 2 Fluorometer (Thermo 
Fisher Scientific), according to the manufacturer’s instructions. RNA quality was 
determined using the RNA 6000 Nano kit on the Bioanalyzer 2200 (Agilent) and all samples 
had an RNA integrity number > 8. Library construction and RNA-sequencing with the 
NextSeq® 500 (Illumina) were performed by the David Gunn Genomics Facility (SAHMRI, 
Adelaide). RNA-seq libraries were prepared using NEXTflex™ Rapid Directional mRNA-
Seq Kit Bundle with RNA-Seq Barcodes and poly(A) beads (BIOO Scientific), according to 
the manufacturer’s instructions. Initial raw read processing was performed using an in-house 
pipeline developed at SAHMRI. Briefly, raw single-end FASTQ reads were aligned to the 
GRCh38/mm10 version of the mouse genome using the transcriptome algorithm STAR. 
After alignment, mapped sequence reads were summarised to the mm10 gene intervals using 
the tool featureCounts, available through the package RSubread. Quality control assessment 
was performed using FastQC, followed by data filtering for low counts. Differential gene 
expression analysis was then undertaken using limma-voom in R v3.5.1. Gene ontology 
analysis was performed using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID ) v6.8 available at <https://david.ncifcrf.gov/home.jsp>282. 
 
2.1.1.2 Total RNA isolation 
Total RNA was isolated from purified primary mouse CD138+ PCs using the All Prep 
DNA/RNA Micro Kit (QIAGEN). Total RNA from cell lines was extracted from 5-10 x 106 
cells using TRIzolTM Reagent (Invitrogen). Briefly, cells were lysed in 1 mL TRIzolTM and 
0.2 mL of chloroform was added. The TRIzolTM and chloroform were mixed by vigorous 
shaking and incubated for 3 minutes at room temperature. Samples were centrifuged at 
12,000 x g and 4°C for 5 minutes to separate phases, and the RNA-containing aqueous phase 
was collected. Total RNA was precipitated by the addition of 0.5 mL isopropanol and 2 μL 
(20µg) ribonuclease-free glycogen (Roche) and incubated at room temperature for 10 
minutes. The RNA was pelleted by centrifugation at 12,000 x g and 4°C for 15 minutes and 
then washed with 75% (v/v) ethanol. The RNA was resuspended in UltraPureTM 





60°C for 10 minutes to facilitate solubilisation. The concentration of RNA in solution was 
determined by measuring the absorption at 260 nm on a NanoDropTM 8000 
Spectrophotometer (Thermo Fisher Scientific). RNA was stored at -80°C. 
 
2.1.1.3 Reverse transcription polymerase chain reaction  
To qualitatively assess messenger RNA (mRNA) levels, reverse transcription polymerase 
chain reaction (RT-PCR) was performed. Firstly, total RNA (2 μg) was reverse transcribed 
into single-stranded complementary DNA (cDNA) using SuperScriptTM IV Reverse 
Transcriptase (Invitrogen). The RNA sample was resuspended in a total volume of 11 μL 
with NF water and 1 μL each of random hexamers (50μM), oligo(dT)20 (50μM) and 
deoxyribonucleotide triphosphate (dNTP) mix (10 mM) were added. The solution was 
incubated at 65°C for 5 minutes and immediately chilled on ice for at least 2 minutes. A mix 
containing 5 μL of 5x RT buffer, 1 μL of 0.1 M DTT and 1 μL of SuperScriptTM IV enzyme 
(200 U) was then added to the denatured RNA. This reaction mixture was incubated for 10 
minutes at 23°C, 10 minutes at 55°C and 10 minutes at 80°C. It was then diluted to a total 
volume of 0.1 mL with NF water and either used immediately for downstream applications 
or stored at –20°C. Negative control minus reverse transcriptase reactions were performed 
concurrently for all samples.  
 
PCR was then performed using AmpliTaq GoldTM DNA Polymerase (Thermo Fisher 
Scientific), with each 25 µL reaction containing 2 μL of cDNA, 0.2 mM dNTPs, 1.5 mM 
MgCl2, 0.5 µM forward primer, 0.5 µM reverse primer, 1x PCR Buffer II and 1.25 U DNA 
polymerase in NF water. No template control (NTC) reactions were performed for each 
target gene and primer sequences are listed in Table 2.1. Reactions were performed on a 
VeritiTM Thermal Cycler (Thermo Fisher Scientific) using the following cycling parameters: 
95°C for 10 minutes; 35 cycles of 95°C for 15 seconds, 55°C for 30 seconds and 72°C for 1 
minute; and 72°C for 5 minutes. The PCR products were then visualised by agarose gel 
electrophoresis. A gel was cast containing 2 % (w/v) agarose in TAE buffer (40 mM Tris 
base, 20 mM acetic acid and 1 mM ethylenediamine tetraacetic acid (EDTA)) and 1:10,000 
GelRed® (Biotium) for DNA visualisation. The PCR products (10 µL) were mixed with 6x 
Gel Loading Dye (New England BioLabs), loaded into the gel, resolved by electrophoresis 







2.1.1.4 Quantitative reverse transcription polymerase chain reaction  
To quantitatively assess mRNA levels, quantitative reverse transcription polymerase chain 
reaction (RT-qPCR) was performed. Firstly, RT of total RNA was performed as described 
in section 2.1.1.3. Secondly, qPCR was performed, with each 15 μL reaction containing          
2 μL of cDNA, 1x RT2 SYBR® Green qPCR Mastermix (QIAGEN), 0.5 μM forward primer, 
0.5 μM reverse primer in NF water in a 96-well clear PCR plate (Bio-Rad). Primer sequences 
are listed in Table 2.1. All cDNA samples were analysed in triplicate and minus reverse 
transcriptase and NTC reactions were included for each sample and target gene, respectively. 
Reactions were performed on the CFX ConnectTM Real-Time PCR Detection System (Bio-
Rad) using the following cycling parameters: 50°C for 2 minutes; 95°C for 15 minutes; 40 
cycles of 95°C for 15 seconds, 60°C for 25 seconds and 72°C for 10 seconds; and 72°C for 
3 minutes. A melt curve was then performed in which there was an incremental increase of 
0.5°C/5 seconds from 65°C to 95°C. Standard curves were generated to determine the 
reaction efficiency of each primer pair. Normalisation and relative expression analysis were 
performed, with the reaction efficiency taken into account, using Q-Gene software283.  
 
Table 2.1: RT-PCR and RT-qPCR primer sequences. 
Gene Species Forward/reverse primer sequences (5’ - 3’) 
Glipr1 ex1-2 Mouse 
TCACAACCAGCTTCGGTCAA/ 
GTGAATGCAGCTGTGGGTTG 






















2.1.2 DNA techniques 
2.1.2.1 Restriction enzyme digest 
Restriction digests of DNA were routinely performed by digesting 1 μg of DNA with 10 
units of restriction enzyme (New England BioLabs) in the supplied digestion buffer and in 





for 1 hour. The restriction enzyme was then inactivated by heat, where applicable, or the 
products were immediately resolved by agarose gel electrophoresis, as described in section 
2.1.1.3, and gel purified using the UltraClean® 15 DNA Purification Kit (MO BIO 
Laboratories), according to the manufacturer’s instructions. 
 
2.1.2.2 Ligation 
Ligations were routinely carried out in a total volume of 10 µL, containing insert and vector 
DNA at an insert:vector molar ratio of 3:1, 1x T4 DNA Ligase Reaction Buffer and 1 µL 
(400 U) of T4 DNA ligase (New England BioLabs). The ligation reaction mix was incubated 
at 4°C overnight. A negative control reaction containing no insert was also performed to 
assess the levels of vector re-ligation. 
 
2.1.2.3 Preparation of chemically competent E. coli JM109 cells 
Frozen Escherichia coli JM109 cells were streaked onto a LB agar plate, made using Difco 
LB Broth Lennox and BactoTM Agar (BD Biosciences), and incubated at 37°C overnight. A 
single colony was inoculated into 10 mL of LB broth and grown in a 37°C shaking incubator 
overnight. This starter culture was used to inoculate 200 mL of LB broth and was grown in 
a 37°C shaking incubator until the culture reached OD600 = 0.6. The bacteria were incubated 
on ice for 30 minutes, then pelleted at 3,000 x g and 4°C for 5 minutes. The cell pellet was 
then resuspended in 25 mL of ice-cold 0.1 M MgCl2 and pelleted again. The bacteria were 
resuspended in 8 mL of ice-cold 0.1 M CaCl2 and 15% (v/v) glycerol and incubated on ice 
for 1 hour. Aliquots were frozen and stored at -80°C until required. 
 
2.1.2.4 Transformation of competent cells 
A 100 µL frozen aliquot of chemically competent E. coli JM109 cells per ligation were 
incubated on ice for 5 minutes. The ligation reaction was added to a 100 µL aliquot of 
bacterial cells, mixed gently and incubated on ice for 30 minutes. The cells were then heat-
shocked at 42°C for 2 minutes and placed back on ice for 5 minutes. Following this, 200 μL 
of LB broth was added to the cells and incubated for 30 minutes in a 37°C shaking incubator. 
The cells were then spread onto a LB agar plate containing 100 μg/mL ampicillin (Sigma-
Aldrich) and incubated at 37°C overnight. Transformed colonies were picked and used to 







2.1.2.5 Purification of plasmid DNA from bacteria 
For small scale plasmid DNA extractions from bacteria, buffers P1, P2 and P3 (QIAGEN) 
were used to perform alkaline lysis-based mini-preps, according to the manufacturer’s 
instructions. For medium scale plasmid DNA extractions from bacteria, the PureLinkTM 
HiPure Plasmid Filter Midiprep Kit (Invitrogen) and PureLinkTM HiPure Precipitator 
Modules (Invitrogen) were used to perform midi-preps, according to the manufacturer’s 
instructions. 
 
2.1.2.6 Sanger sequencing 
Plasmids/linear DNA fragments and appropriate primers were provided to the Australian 
Genome Research Facility (AGRF), which undertook the Sanger sequencing reactions and 
generated sequencing chromatograms. Analysis of the sequencing data was performed using 
the publicly available chromatogram viewer Chromas v2.6.2 (Technelysium) and the 
multiple sequence alignment tool ClustalX v2.1 (Science Foundation Ireland).  
 
2.1.2.7 Generation of expression vectors 
HA-tagged Samsn1 overexpression vector 
A sequence encoding a HA-tag followed by a stop codon was inserted between the NdeI and 
XhoI restriction enzyme sites in the retroviral pRUFimCH2 vector260. The murine Samsn1 
coding sequence was then amplified from C57BL/6 splenocyte-derived cDNA by PCR such 
that the product contained the Samsn1 open reading frame with the start codon forming part 
of one NdeI site and the stop codon replaced by a second NdeI site. The NdeI-flanked Samsn1 
insert and the HA-tag-containing pRUFimCH2 vector were then NdeI digested and ligated 
to generate the pRUFimCH2.Samsn1-HA vector, which encodes Samsn1 with an in-frame 
C-terminal HA tag. 
 
Glipr1 overexpression vector 
To generate a Glipr1 overexpression vector, the Glipr1 coding sequence was amplified from 
C57BL/6 thymus-derived cDNA and subcloned into the pRUFimCH2 retroviral vector to 
generate pRUFimCH2.Glipr1, as previously described260. 
 
SAMSN1 overexpression vector 






SAMSN1 gRNA expression vectors 
The MIT CRISPR design tool (http://crispr.mit.edu) was used to select two guide RNAs 
(gRNAs) targeting exon 4 of SAMSN1. The sequences of gRNA #1 and #2 were                       
5’-GGTCACTGTTTCTATATGGG-3’ and 5’-GAGACTATCCATGGAGTCAC-3’, 
respectively. To clone the individual gRNAs, 24 bp complementary oligonucleotides 
containing the gRNA sequence and a 4-bp overhang (forward: TCCC and reverse: AAAC) 
were annealed and phosphorylated. The gRNA containing double-stranded DNA fragments 
were cloned into the BsmbI-digested pFH1tUTG lentiviral vector 284, which was kindly 
provided by Assoc Prof Marco Herold (WEHI, Australia). 
 
2.1.2.8 Heteroduplex mobility assay 
DNA was extracted and purified from CRISPR-targeted cells using a DNeasy® kit 
(QIAGEN). PCR was performed to amplify a 1.1 kb region encompassing exon 4 of 
SAMSN1 using primers F: 5’-CTAGGTGGCAAGCATGGTATTAGATTTG-3’ and            
R: 5’-AGAAAGAAAGAGACAGAGAATGGAGCAG-3’. The products were subjected to 
heteroduplex formation in which they were incubated at 95°C for 5 minutes and the 
temperature was then reduced to 85°C at a ramp rate of 51%, followed by a decrease to 25°C 
at a ramp rate of 2.6%. The products were resolved by gel electrophoresis within a 12% 
acrylamide gel in 1x TBE buffer (100 mM Tris base, 100 mM boric acid, 2 mM EDTA) and 
post-stained with GelRed® (Biotium) to enable DNA visualisation using a Gel DocTM XR+ 
Imager (Bio-Rad).  
 
2.1.3 Protein techniques 
2.1.3.1 Preparation of whole cell lysates 
Cells were washed in ice-cold 1x phosphate buffered saline (PBS, Sigma-Aldrich) and then 
resuspended in an appropriate volume of radioimmunoprecipitation assay (RIPA) buffer (1% 
NP-40 (v/v), 20 mM HEPES, 150 mM NaCl, 10% glycerol (v/v), 2 mM Na3VO4, 10 mM 
Na4P2O7, 2 mM NaF, and 1x cOmpleteTM EDTA-free Protease Inhibitor Cocktail (Roche)) 
by vortexing. Samples were incubated on ice for 30 minutes with occasional vortexing. The 
lysates were then centrifuged at 20,000 x g at 4°C for 20 minutes and the supernatant was 
collected. The protein concentration in the cleared whole cell lysate was determined using 
the RC DCTM Protein Assay Kit (Bio-Rad), according to manufacturer’s instructions. Protein 






2.1.3.2 Western blotting 
An appropriate amount of protein lysate was mixed with reducing buffer (50 mM Tris-HCl 
pH 7.4, 10% glycerol (v/v), 2% sodium dodecyl sulphate (SDS) (w/v), 0.02% bromophenol 
blue (w/v) and 5% β-mercaptoethanol (v/v)) and denatured by boiling for 4 minutes. Proteins 
were loaded into 10% SDS-polyacrylamide gel electrophoresis (PAGE) gels in Tris-
Glycine-SDS running buffer (0.3% (w/v) Tris-HCl, 1.44% (w/v) glycine and 0.1% (w/v) 
SDS). To resolve the proteins, gel electrophoresis was performed using the Mini-
PROTEANTM III System (Bio-Rad). Proteins were transferred from the gel to a 
nitrocellulose 0.45 µm membrane (Bio-Rad) using the Mini Trans-Blot® Electrophoretic 
Transfer Cell (Bio-Rad). The transfer was performed in transfer buffer (192 mM Tris, 25 
mM glycine, 20% methanol (v/v) and 0.02% (w/v) SDS) at 100 V and 4°C for 1 hour. 
Following the transfer, the membrane was incubated with membrane blocking buffer (5% 
(w/v) skim milk powder in 1x TBST buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl and 
0.1% TWEEN 20)) at room temperature for 1 hour. The blocked membrane was then probed 
with primary antibody (Table 2.2) at an optimised concentration in membrane blocking 
buffer with rocking and at 4°C overnight. For blots expected to have low signal intensity, 
the primary antibody was diluted in Solution 1 from the SignalBoostTM Immunoreaction 
Enhancer Kit (Merck). Following 3 washes in TBST, the blot was incubated with an 
appropriate DyLight-680/800-conjugated secondary antibody (Thermo Fisher Scientific) 
diluted 1:10,000 in TBST, or Solution 2 from the enhancer kit, with rocking and at room 
temperature in the dark for 1 hour. The blot was again washed 3 times in TBST and then 
imaged using the Odyssey® CLx Imager (LI-COR). Quantitative analysis of band intensity 
was performed using ImageJ software (http://fiji.sc). 
 
Table 2.2: Primary antibodies used for Western blotting. 
Target Source Concentration Company 
Catalogue 
no. 
GLIPR1 Polyclonal goat 1:250 R&D Systems AF4468 
HA-tag Monoclonal mouse 1:1,000 Cell Signalling Technology 2367S 
HS1 Polyclonal rabbit 1:1,000 Cell Signalling Technology 4557 
pHS1 Polyclonal rabbit 1:1,000 Cell Signalling Technology 4507 
SAMSN1 Polyclonal rabbit 1:500 Sigma-Aldrich HPA010645 
HSP90 Polyclonal rabbit 1:2,500 Santa Cruz Biotechnology 7947 






5TGM1 cells (2 x 107) were washed twice in ice-cold 1x PBS and lysed in 1 mL of 
immunoprecipitation (IP) lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% 
glycerol (v/v), 2 mM Na3VO4, 1x cOmpleteTM Protease Inhibitor Cocktail (Roche) and 1% 
NP-40/CHAPS (v/v)) for 30 minutes under rotation at 4°C. The lysate was cleared by 
centrifugation, as described in section 2.1.3.1, added to 50 µL packed volume of anti-HA 
antibody-conjugated agarose (clone 3F10, rat IgG1; Roche) and incubated under rotation 
and at 4°C for 2 hours. The agarose was then washed 5 times in 1 mL of IP lysis buffer and 
the associated proteins were eluted by boiling with 50 µL of 2x reducing buffer for 5 minutes. 
The supernatant was collected and split into two fractions (10% and 90% of the total 
volume), which were separately subjected to SDS-PAGE along with pre-IP and post-IP 
controls, as described in section 2.1.3.2. To assess the success of the IP, lanes of the gel 
containing pre-IP, post-IP and 10% of the eluates were transferred to a nitrocellulose 
membrane and subjected to Western blotting using an anti-HA-tag primary antibody, as 
described in section 2.1.3.2. The remaining portion of the gel containing most of the co-IP 
eluates was fixed and stained with SYPROTM Ruby Protein Gel Stain (Invitrogen), according 
to the manufacturer’s instructions, and then imaged using a Gel DocTM XR+ Imager (Bio-
Rad). 
 
2.2 Cell culture techniques 
2.2.1 Maintenance of cells in culture 
All cell lines were maintained in a humidified environment at 37°C in the presence of 5% 
CO2 and were manipulated within a class II biological safety cabinet. Unless otherwise 
specified, all cell culture reagents were sourced from Sigma-Aldrich and all media were 
supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 1 
mM sodium pyruvate, and 10 mM HEPES buffer. All cell lines were tested for mycoplasma 
infection using a MycoAlertTM Mycoplasma Detection Kit (Lonza) prior to use and were 
maintained in culture for a maximum of 4 weeks.  
 
2.2.1.1 Mouse myeloma 5TGM1 cell line 
The murine MM 5TGM1 PC line was originally kindly provided by Assoc Prof Claire 
Edwards (University of Oxford, UK). 5TGM1 cells expressing both green fluorescent 
protein (GFP) and luciferase were previously generated using the retroviral expression 





5TGM1 cells were previously injected i.v. into C57BL/KaLwRij (KaLwRij) mice (section 
2.3.5.1) and those present in the long bones of the hind limbs were purified and expanded. 
5TGM1 cells were maintained in Iscove’s Modified Dulbecco’s Medium (IMDM) with 20% 
fetal calf serum (FCS, Thermo Fisher Scientific), which is termed complete IMDM. The 
cells were sub-cultured every 2-3 days to maintain a concentration of 0.2-2 x 106 cells/mL. 
 
2.2.1.2 Human myeloma cell lines 
Human myeloma cell line (HMCL) RPMI-8226 was purchased from the American Type 
Culture Collection (ATCC), while the HMCLs LP-1, OPM2 and JJN3 were a kind gift from 
Prof Andrew Spencer (Monash University, Australia). All HMCLs were maintained in 
Roswell Park Memorial Institute 1640 (RPMI-1640) medium with 10% FCS (complete 
RPMI-1640 medium) and sub-cultured every 2-3 days to maintain a concentration of 0.2-1 
x 106 cells/mL. 
 
2.2.1.3 BM cell lines 
The mouse BM stromal cell (BMSC) line OP9 was obtained from the ATCC and was 
maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% FCS (complete 
DMEM). Medium was renewed every 2-3 days and confluent monolayers were split at a 
sub-cultivation ratio of 1:5. Briefly, cells were harvested by rinsing with sterile PBS and 
adding 0.05% (v/v) trypsin-EDTA. Cells were incubated at 37°C for 1-5 minutes, depending 
on the time taken to detach from the culture flask. Trypsin activity was then neutralised by 
the addition of FCS-containing medium and detached cells were pelleted at 400 x g for 5 
minutes. The cell pellet was resuspended in fresh complete DMEM and an appropriate 
aliquot of the cell suspension was added to a new culture flask.  
 
A transformed human BM endothelial cell (TrHBMEC)286 line was kindly provided by Prof 
Babette Walker (Cornell University, USA). TrHBMECs were maintained in gelatin-coated 
flasks and Medium 199 with 20% FCS and supplements  consisting of 0.1% sodium 
bicarbonate (w/v), 1 mM sodium pyruvate, 20 mM HEPES, 50 U/mL penicillin, 50 μg/mL 
streptomycin, 1 x non-essential amino acids, 15 mg/mL heparin and 15 mg/mL endothelial 
cell growth supplement (BD Biosciences). The medium was renewed every 2-3 days and 
confluent monolayers were harvested by trypsinisation and sub-cultured, as described above. 






2.2.1.4 Human embryonic kidney (HEK) 293T cell line 
HEK293T cells were cultured in complete DMEM and cells were sub-cultured every 2-3 
days by trypsinisation, as described in section 2.2.1.3. 
 
2.2.2 Generating primary KaLwRij BMSC-conditioned medium 
BMSCs were isolated by plastic adherence from bone chips of healthy adult KaLwRij mice 
and cryopreserved. Thawed BMSCs were seeded in Minimum Essential Medium Eagle, 
Alpha Modification (α-MEM) with 10% FCS and 100 mM L-ascorbate-2-phosphate. 
Medium was refreshed every 2-3 days until the BMSCs reached confluence. The regular 
medium was then replaced by serum-free α-MEM and the confluent BMSCs were incubated 
at 37°C with 5% CO2 for 24 hours. The conditioned medium was then collected and passed 
through a 0.45 µm filter to remove any cells. Concentration of the conditioned medium was 
achieved by centrifugation in Centriprep® Centrifugal Filter Units (Merck). Aliquots of 
concentrated conditioned medium were stored at -20°C.  
 
2.2.3 Generating genetically modified cell lines  
2.2.3.1 Generation of Samsn1-HA/Glipr1-overexpressing 5TGM1 cells 
HEK293T cells (1.5 x 106 cells/transfection) were seeded in 6 cm culture dishes in complete 
DMEM 24 hours prior to transfection. The cells were then transfected with 5 μg of the gene-
encoding or empty pRUFimCH2 plasmid and 5 μg of the murine ecotropic packaging 
plasmid pEQECO287 using Lipofectamine 2000 (Invitrogen), according to the 
manufacturer’s instructions. After 48 hours, medium containing retrovirus was collected 
from the transfected HEK293T cells and added dropwise through a 0.45 µm surfactant-free 
cellulose acetate membrane filter onto 5TGM1 cells (4 × 105 cells/infection) in complete 
IMDM containing polybrene (final concentration of 8 μg/mL) in a 6-well plate. The 5TGM1 
cell-virus mixture was centrifuged in the 6-well plate at 1,000 x g and room temperature for 
1 hour and then incubated at 37°C with 5% CO2 overnight. The cells were washed with 
complete IMDM and expanded in culture. Following another wash, the 5TGM1 cells 
underwent fluorescence activated cell sorting (FACS) for mCherry protein expression, 
which indicated successful transduction of the pRUFimCH2 plasmid, on a FACSAriaTM 
Fusion (BD Biosciences). Subsequent sorts were conducted, where appropriate, until a 
pooled cell line consisting of > 90% mCherry+ 5TGM1 cells was obtained. The basal 
luciferase activity of the modified 5TGM1 cells compared to the paired empty vector (EV) 





plate, adding 0.3 mg/mL D-luciferin (Biosynth) and performing bioluminescence imaging 
using the IVIS® Spectrum (PerkinElmer). No significant differences in luciferase activity 
were observed between the modified 5TGM1 cell lines. 
 
2.2.3.2 Generation of SAMSN1-overexpressing HMCLs 
HEK293T cells were prepared, as described in section 2.2.3.1, and transfected with 5 μg of 
the SAMSN1-encoding or empty pRUFiG2 plasmid and 5 μg of the amphotropic packaging 
plasmid pEQPAM3287. HMCLs were infected with the resultant retrovirus, as described in 
section 2.2.3.1, except the cells were not centrifuged after the addition of virus. Following 
washing and expansion, virus-exposed HMCLs were sorted for GFP expression, which 
indicated successful transduction of the pRUFiG2 plasmid, on a FACSAriaTM Fusion (BD 
Biosciences) and pooled cell lines were established, as described in section 2.2.3.1. 
 
2.2.3.3 Generation of SAMSN1 knockdown HMCLs using CRISPR-Cas9  
Firstly RPMI-8226 and JJN3 HMCLs constitutively expressing Cas9 were generated by 
transducing the HMCLs with the FUCas9mCh lentiviral vector284, which was a kind gift 
from Assoc Prof Marco Herold (WEHI, Australia). Lentiviral particles were produced using 
the psPAX2 lentiviral packaging plasmid and the pVSVG envelope protein-expressing 
plasmid and mCherry+ cell lines were established, as described in section 2.2.3.1. The Cas9-
expressing HMCLs were then transduced with an inducible gRNA-containing or empty 
pFH1tUTG vector, again using psPAX2 and pVSVG to produce lentivirus. Successfully 
transduced GFP+mCherry+ cells were isolated by FACS and gRNA expression was 
transiently induced by treating the HMCLs with doxycycline (Sigma-Aldrich) at a final 
concentration of 1 µg/mL for 72 hours. Following removal of doxycycline from the medium, 
the pools of treated cells were expanded to create SAMSN1 knockdown HMCLs. 
 
2.2.4 In vitro assays 
2.2.4.1 Co-culture luciferase proliferation assay 
5TGM1 cells were seeded in triplicate at 1 × 105 cells/mL in complete IMDM with, or 
without, a confluent layer of OP9 cells. After 72 hours of co-culture at 37°C with 5% CO2, 
the 5TGM1 cells were enumerated by measuring luciferase activity. Briefly, cells were 
collected with the aid of trypsin, washed in PBS and lysed in 40 uL of 1x Luciferase Cell 
Culture Lysis Reagent (Promega). The lysates were vortexed for 10 seconds, centrifuged at 





opaque 96-well plate. Bioluminescence was measured by adding 100 μL of luciferase 
reaction buffer (5 mM MgCl2, 30 mM HEPES, 150 μg/mL D-luciferin (Biosynth) and 150 
μM ATP) per well and reading the signal on a luminometer (Wallac 3000). A standard curve 
was produced for each cell line to determine the absolute number of cells present, which 
corrected for any differences in basal luciferase activity.   
 
2.2.4.2 WST-1 proliferation assay 
HMCLs were plated at 1 x 105 cells/mL in triplicate in 100 μL of complete RPMI-1640 
medium in 4 replicate 96-well plates and incubated at 37°C with 5% CO2. Every 24 hours 
from day 0 to 3, 10 μL of WST-1 Reagent (Roche) was added to all the relevant wells of one 
plate, which was then returned to the incubator for 2 hours. During the incubation, the WST-
1 tetrazolium salt was cleaved by cellular mitochondrial dehydrogenases to produce a 
formazan dye (max absorbance at ~440 nm). Following the incubation, the absorbance of 
each well at 450 nm was measured using the iMarkTM Microplate Absorbance Reader (Bio-
Rad) and the plate discarded. The background was subtracted from the absorbance values 
and the fold-change in absorbance was calculated relative to day 0. 
 
2.2.4.3 Colony formation assay 
5TGM1 cells were seeded (200 cells per 35 mm dish) in duplicate in MethoCultTM semi-
solid methylcellulose medium (StemCell Technologies), according to the manufacturer’s 
instructions. After 12 days of culture at 37 °C and 5% CO2, colonies were manually counted 
using a light microscope.  
 
2.2.4.4 Actin remodelling assay 
To assess filamentous actin (F-actin) formation, 5TGM1 cells were washed twice in serum-
free IMDM media and were stimulated with 200 ng/mL (final concentration) recombinant 
mouse CXCL12 (R&D Systems) in triplicate for the indicated times. 5TGM1 cells were 
immediately fixed in 2% paraformaldehyde (pH 8.0) at room temperature for 15 minutes, 
washed 3 times in wash buffer (0.2% saponin (w/v) and 5% FCS in PBS) and stained with 
1:20 Alexa FluorTM 680 phalloidin (200 U/mL; Life Technologies) on ice and in the dark for 
30 minutes. Cells were then washed 3 times with wash buffer and the mean fluorescence 
intensity (MFI) of phalloidin staining was quantitated on a LSRFortessaTM X-20 flow 






2.2.4.5 Transwell and transendothelial migration assays 
Transwell and transendothelial migration assays were performed in 24-well plates with 8 µm 
pore transwells (Corning). For transwell assays, 5 x 105 5TGM1 cells in serum-free IMDM 
were seeded in transwells in triplicate. The cells were allowed to migrate towards the lower 
chamber containing serum-free IMDM plus 5% (v/v) concentrated primary KaLwRij 
BMSC-conditioned medium for 24 hours. For transendothelial assays, 1 x 104 TrHBMECs 
were plated on gelatin-coated transwells and were allowed to adhere for 24 hours. HMCLs 
(5 x 105 cells) in RPMI-1640 medium with 1% FCS were then seeded into the BMEC-coated 
transwells in triplicate. The cells were allowed to migrate towards the lower chamber 
containing RPMI-1640 medium with either 20% FCS or 1% FCS and 100 ng/µL CXCL12 
for 20 hours. Following the incubation period, the transwells were discarded and the numbers 
of migrated cells present in the plate were enumerated using an Olympus CKX41 inverted 
light microscope and ImageJ software (http://imagej.nih.gov/ij/). 
 
2.2.4.6 Adhesion assay 
TrHBMECs (1 x 104 cells/well) were plated in opaque-walled and clear-bottomed 96-well 
plates and allowed to adhere overnight. 5TGM1 cells (1 x 105 cells/well) in complete IMDM 
were then overlaid onto the TrHBMECs in quadruplicate and allowed to adhere for 15 
minutes at 37°C and 5% CO2. Following this incubation, the wells were gently washed 3 
times with complete IMDM to remove nonadherent cells. The number of adherent 5TGM1 
cells in each well was enumerated by the addition of 0.3 mg/mL D-luciferin (Biosynth) 
followed by bioluminescence imaging using the IVIS® Spectrum (PerkinElmer). The 
bioluminescent signal from adhered 5TGM1 cells was normalised to the signal from the total 
cell input.  
 
2.2.4.7 5TGM1 single-colour immunofluorescence staining and flow cytometry 
5TGM1 cells were harvested from culture, washed and resuspended in ice-cold PFE buffer 
(2% FCS and 2 mM EDTA in PBS). 5TGM1 cells at 1 x 107 cells/mL were incubated with 
flow cytometry (FC) blocking buffer (1:100 mouse gamma globulin (Jackson 
ImmunoResearch) in PFE buffer) on ice for 30 minutes. Aliquots of 1 x 106 cells in 0.1 mL 
of FC blocking buffer were then incubated with 5 µL of primary antibody (Table 2.3) on ice 
for 1 hour. Cells were washed twice with 2 mL of chilled PFE buffer and then resuspended 
in 0.1 mL of 1:100 Streptavidin-BV421 secondary antibody (#563259, BD Biosciences) in 





twice with 2 mL of chilled PFE buffer and resuspended in 0.2 mL of FACS fixation buffer 
(1% (v/v) formalin, 2% (w/v) D-glucose, and 0.02% (w/v) NaN3 in PBS). The BV421 MFI 
was measured for 50,000 cells per sample on a LSRFortessaTM X-20 flow cytometer using 
FACSDivaTM software v8.0 (BD Biosciences) and the data was analysed using FlowJo 
v10.0.8 software (FlowJo, LLC). 
 
Table 2.3: Primary antibodies used for MHC immunostaining of 5TGM1 cells. 
Target Source Conjugate Concentration Company Cat no. 

























2.3 Animal techniques 
2.3.1 Generating knockout mice 
2.3.1.1 C57BL/Samsn1-/- mice 
C57BL/Samsn1-/- (Samsn1-/-) mice were generated by first backcrossing the 180 kb Samsn1 
deletion in the KaLwRij genome onto a C57BL/6 background for 10 generations. To 
genotype the backcrossed mice, genomic DNA samples were generated from ear notches 
and PCR was performed using AmpliTaq GoldTM DNA Polymerase, as described in section 
2.1.1.3. Separate primers were used to detect wildtype (WT) and deletion alleles of Samsn1 
(Table 2.4). The resultant heterozygous (Samsn1+/-) mice were intercrossed and then the 
progeny with a homozygous Samsn1 deletion were incrossed to generate a stock Samsn1-/- 
colony. 
 
2.3.1.2 C57BL/Glipr1-/- mice 
C57BL/Glipr1-/- (Glipr1-/-) mice were generated by the South Australian Genome Editing 
Facility (University of Adelaide, Australia) using CRISPR-Cas9. Briefly, gRNAs were 
designed that flanked the first exon of Glipr1 (gRNA 1: 5’-
ATCAGCGGCTCTCGACCCGT-3’ and gRNA 2: 5’-ATTGGTTCTTGCCAAATGGGC-
3’). These gRNAs and Cas9 mRNA were injected into C57BL/6 zygotes, which were then 





        Table 2.4: Sequences of primers for genotyping Samsn1 and Glipr1 knockout mice. 










Intergenic, within KaLwRij 
deletion (3' end) 
75,815,906 - 75,815,925 
341 60 
DEL+55kb.R CCGGAATGACAAGTGAGGCT 
Intergenic, within KaLwRij 
deletion (3' end) 
75,816,227 - 75,816,246 
Samsn1 Deletion 
SamDEL.F GGAGGTGATGATCTATTGTC 
Intergenic, outside KaLwRij 
deletion (3’ end) 
75,816,109 - 75,816,128 
178 60 
SamDEL.R CCATGATCATACAAGAAGCC 
Intergenic, outside KaLwRij 






Cas9 deletion (3’ end) 
111,998,442 - 111,998,469 
511 60 
P2 TGTGTGCCTTTGTCTGAGGTC 




P1 As above As above As above 
353# 60 
P4 ACACGGTAGCTTTTGTATGAAGGAACAGT 
Intron 1, outside CRISPR-Cas9 
deletion (5’ end) 
111,994,476 - 111,994,504 
         *This primer pair was previously described260. 






separate primers to detect WT and deletion alleles of Glipr1 (Table 2.4). This was performed 
according to section 2.3.1.1 except Phusion® High-Fidelity DNA Polymerase (New England 
BioLabs) was used to detect deletion alleles in the founder mice. PCR products from 
potential deletion alleles were Sanger sequenced, as described in section 2.1.2.6. A male 
founder that harboured a Glipr1 exon 1 deletion was crossed with female C57Bl/6 (WT) 
mice and the resultant Glipr1 deletion heterozygotes (Glipr1+/-) were intercrossed. The 
progeny that were homozygous for the Glipr1 deletion were then incrossed to generate a 
stock Glipr1-/- colony. 
 
2.3.1.3 C57BL/Samsn1-/-Glipr1-/- mice 
C57BL/Samsn1-/-Glipr1-/- (Samsn1-/-Glipr1-/-) mice were generated by first crossing    
Samsn1-/- mice with Glipr1-/- mice, resulting in double heterozygous deletion mice 
(Samsn1+/-Glipr1+/-). The double heterozygotes were then intercrossed to generate progeny, 
which were genotyped for both Samsn1 and Glipr1 deletions, as described above. The 
resultant double knockout Samsn1-/-Glipr1-/- mice were incrossed to produce a stock colony. 
The Samsn1-/-, Glipr1-/-, Samsn1-/-Glipr1-/- and C57BL/6 (WT) mice used for experiments 
were from separate stock colonies and were not littermates. 
 
2.3.2 Peripheral blood counts 
Peripheral blood (PB) samples were collected from mice by a tail bleed into EDTA-coated 
microvette tubes (Sarstedt). Complete blood counts were performed using a HEMAVET950 
automated blood analyser (Drew Scientific), according to the manufacturer’s instructions. 
 
2.3.3 Multi-colour flow cytometry analyses of primary mouse cells 
2.3.3.1 Preparing single cell suspensions from the BM, spleen and PB  
BM was collected from cleaned femora and tibiae by repeatedly flushing the bones with 5 
mL of chilled PFE buffer using a 10 mL syringe and 21 G needle or crushing the bones in 
PFE buffer using a mortar and pestle. The BM cell-containing solution was then 
homogenised and passed through a 70 µm filter. Spleens were excised and cleaned of any 
connective tissue prior to being pushed through a pre-wet 70 µm filter using the plunger of 
a 3 mL syringe. To generate a splenic single cell suspension, the filter was then washed with 
5 mL of chilled PFE buffer. PB was collected by a terminal cardiac bleed using a 25 G needle 
and a 1 mL syringe containing 0.05 mL of 50 mM EDTA. The PB was then twice incubated 





EDTA in milli-Q water) at room temperature for 10 minutes, followed by washing in 10 mL 
of chilled PFE buffer. 
 
2.3.3.2 Antibody staining and flow cytometry 
A defined number of cells (1-2 million depending on the tissue source) was stained with 
Fixable Viability Stain 700 (BD Biosciences) or hydroxystilbamidine (Invitrogen), 
according to the manufacturer’s instructions. These cells were incubated in FC blocking 
buffer (section 2.2.4.7) on ice for 30 minutes and then stained with the relevant panel of 
fluorochrome-conjugated antibodies on ice and in the dark for 30 minutes (Table 2.5). 
Unstained, single-colour and fluorescence minus one (FMO) controls were also prepared for 
each panel to assist with gating cell populations. Following staining, the cells were washed 
twice with 2 mL of PFE buffer and stored in FACS fixation buffer prior to analysis. 
Typically, at least 100,000 events per sample were run on a LSRFortessaTM X-20 flow 
cytometer using FACSDivaTM software v8.0 (BD Biosciences) and the data was analysed, 
including calculating compensation, using FlowJo v10.0.8 software (FlowJo, LLC). 
 
 
Table 2.5: Primary antibodies used in multi-colour flow cytometry panels for analysing 
primary mouse cells. 
Target Panel Source Conjugate Conc Company Cat no. 
B220 
BM/spleen B 
cells and PB 
Rat monoclonal 
(RA3-6B2) 







































PE-Cy7 1:80 Biolegend 127618 
CD49b NK/T cells 
Rat monoclonal 
(DX5) 
PE-Cy7 1:100 eBioscience 25597182 




AF647 1:100 Biolegend 104518 
CD8a CD8 MACS 
Rat monoclonal 
(53-6.7) 
PE-Cy5 1:200 Biolegend 100710 
 







2.3.4 Isolation of primary murine PC 
BM was collected by flushing the long bones of the hind limbs from C57BL/6 and KaLwRij 
mice, as described in section 2.3.3.1. PCs were isolated from the BM by staining with a rat 
anti-CD138 primary antibody (#300506, R&D Systems) and an anti-rat IgG-PE secondary 
antibody (#3030-09, Southern Biotech), followed by FACS for PE+ cells using the 
FACSAriaTM Fusion (BD Biosciences). 
 
2.3.5 In vivo models of MM tumour growth 
KalwRij mice, originally kindly provided by Prof Andrew Spencer (Monash University, 
Australia) were rederived, bred and housed at the SAHMRI Bioresources Facility. NOD 
SCID gamma (NSG) and C57BL/6 mice were purchased from the SAHMRI Bioresources 
Facility. All procedures were performed with the approval of the SAHMRI, or University of 
Adelaide, Animal Ethics Committee. In all studies, the mice in different experimental groups 
were age- and sex-matched. 
 
2.3.5.1 5TGM1 cells in KaLwRij/NSG mice intravenous and intratibial models 
For i.v. delivery, 5TGM1 cells were washed and resuspended in sterile PBS at a 
concentration of 5 x 106 cells/mL. KaLwRij or NSG mice between 6 and 8 weeks old were 
injected with 0.1 mL of 5TGM1 cell suspension (5 × 105 cells) via the tail vein. The injected 
mice underwent in vivo bioluminescence imaging (BLI, section 2.3.6) 2, 3 and 4 weeks post-
tumour cell injection and were humanely euthanised after 4 weeks. For intratibial (i.t.) 
delivery, 5TGM1 cells were washed and resuspended in sterile PBS at a concentration of 1 
x 107 cells/mL. KaLwRij or NSG mice between 5 and 6 weeks old were anaesthetised by 
isoflurane inhalation for the duration of the procedure. A gas-sterilised 25 µL Hamilton 
syringe with a 27-gauge needle and containing 10 µL of cell suspension was inserted through 
the cortex of the anterior tuberosity of the left tibia. Once the bone cortex was traversed, the 
needle was inserted 3 to 5 mm down the diaphysis of the tibia, and the cell suspension (1 x 
105 cells per inoculum) was injected into the marrow space. The injected mice underwent 
weekly in vivo BLI beginning on day 9 post-tumour cell injection and were humanely 
euthanised after 23 days. Mice with extensive extramedullary tumour growth in the injected 








2.3.5.2 5TGM1 cells in C57BL/6 mice intravenous model 
5TGM1 cells were prepared for injection, as described in section 2.3.5.1, and the same 
amount was injected i.v. into 6-8-week-old C57BL/6 mice via the tail vein. The injected 
mice underwent in vivo BLI weekly or fortnightly starting 2-weeks post-tumour cell 
injection and were humanely euthanised after 4 or 7 weeks. 
 
2.3.5.3 HMCLs in NSG mice intratibial model  
HMCLs were washed and resuspended in sterile PBS at a concentration of 5 x 107 cells/mL. 
NSG mice between 5 and 6 weeks old received an i.t. injection of 10 µL of cell suspension 
(5 x 105 cells per inoculum), as described in section 2.3.5.1. The endpoint of the experiment 
was determined based on the first sign of morbidity, which was dependent on the HMCL 
injected. The experimental endpoint for mice injected with OPM2, JJN3, RPMI-8226 or LP-
1 cells was 3, 3, 5 or 8 weeks, respectively. Mice with extensive extramedullary tumour 
growth in the injected leg, which indicated that the injection was misdirected, were excluded 
from the experiment. 
 
2.3.6 In vivo bioluminescence imaging 
Mice injected with luciferase-expressing 5TGM1 cells were shaved under anaesthesia prior 
to in vivo BLI. To measure tumour burden, the mice were administered firefly D-Luciferin 
substrate (30 mg/mL in PBS, Biosynth) by intraperitoneal injection at a concentration of 150 
mg/kg. After 10 minutes, during which time the mice were anaesthetised by isoflurane 
inhalation, the dorsal, ventral and/or lateral aspects of the mice were scanned using the IVIS® 
Spectrum In Vivo Imaging System and Living Image® Software v4.5.5 (PerkinElmer), 
which was also used to quantitate the bioluminescence signal in the mice. 
 
2.3.7 Serum protein electrophoresis  
At the experimental endpoint, PB was collected from the 5TGM1-injected mice either by a 
tail bleed or terminal cardiac bleed. The blood was allowed to clot at room temperature and 
then centrifuged at 2,000 x g and 4°C for 10 minutes. The serum supernatant was collected 
and stored at -20°C. Subsequently, the serum samples were thawed and the levels of M 
protein/paraprotein were assessed by performing serum protein electrophoresis (SPEP) 
using the Hydragel Protein(E) Kit (Sebia), according to the manufacturer’s instructions. The 





the paraprotein band/M-spike was quantitated and normalised to the albumin band using 
Image Lab Software v6.0.1 (Bio-Rad).  
 
2.3.8 Detection of GFP+ tumour cells in mouse tissues by flow cytometry 
Single cell suspensions of BM, spleen and PB from tumour cell-injected mice were obtained, 
as described in section 2.3.3.1. Cells from a mouse not injected with tumour cells were also 
analysed to act as a negative control for gating cell populations. The cells were pelleted, 
resuspended in PFE buffer and immediately analysed for the presence of GFP+ tumour cells 
by flow cytometry on the FACSCantoTM II (BD Biosciences) using FACSDivaTM software 
v8.0 (BD Biosciences). 
 
2.3.9 Immunohistochemistry  
Tibiae that were directly injected with 5TGM1 cells were collected from KaLwRij mice at 
the experimental endpoint (day 23) and fixed in 10% (v/v) buffered formalin. The bones 
were decalcified by incubation with decalcification solution (0.5 M EDTA and 0.5% (w/v) 
paraformaldehyde in PBS at pH 8.0) at 4°C and the solution was refreshed twice weekly. 
The decalcified bones were then paraffin-embedded and 5 µm longitudinal sections were 
prepared. Sections were deparaffinised and stained with hematoxylin and eosin (H&E) or an 
anti-GFP antibody. For anti-GFP staining, endogenous peroxidase activity was neutralised 
by incubation with 0.5% H2O2 (v/v) in methanol for 30 minutes and the sections were then 
incubated with immunohistochemistry (IHC) blocking buffer (3% normal horse serum in 
PBS) at room temperature for 2 hours. The slides were incubated with a goat anti-GFP 
monoclonal antibody (#A600-101-215, Rockland) at 1:5,000 in IHC blocking buffer at 4°C 
overnight. After washing in 1x PBS, the slides were incubated with a biotinylated rabbit anti-
goat IgG antibody (#BA5000, Vector Lab) 1:250 in IHC blocking buffer at room 
temperature for 30 minutes. This was followed by incubation with a streptavidin-peroxidase 
conjugate at 1:100 in blocking buffer at room temperature for 1 hour. The bound antibody 
was then visualised by incubating the slides with 3,3'-diaminobenzidine (Sigma-Aldrich) at 
room temperature and in the dark for 10 minutes. Slides were briefly counterstained with 









2.3.10 In vivo BM homing assay  
5TGM1 cells (5 x 106 in 0.2 mL of PBS) were injected i.v. into 6-8-week-old KaLwRij mice 
via the tail vein. After 1 or 21 days, the mice were culled and both femora and tibiae from 
each mouse were collected and cleaned. These bones were flushed with PFE buffer and the 
marrow was collected. While in chilled PFE buffer, the bones were cut longitudinally, 
scraped and minced with a scalpel blade. All the cells were then filtered through a 70-µm 
cell strainer, pelleted and resuspended in PFE buffer. The samples were immediately 
analysed for the presence of GFP+ tumour cells by flow cytometry on a FACSCantoTM II 
(BD Biosciences) using FACSDivaTM software v8.0 (BD Biosciences). 
 
2.3.11 Ex vivo CD8+ T cell cytotoxicity assay 
To prevent proliferation of tumour cells, 5TGM1-Samsn1 and 5TGM1-EV cells were 
gamma-irradiated (30 Gy) prior to being injected (1 x 106 in 0.1 mL of PBS) i.v. into 6-8-
week-old KaLwRij mice on days 0 and 14. On day 19, the mice were humanely euthanised 
and single cell suspensions from the spleen were prepared, as described in section 2.3.3.1. 
CD8+ splenic T cells were purified by negative selection using the magnetic-activated cell 
sorting (MACS) CD8a+ T Cell Isolation Kit (Miltenyi Biotec), according to the 
manufacturer’s instructions. The purified T cells were re-stimulated by co-culture with 
irradiated 5TGM1-Samsn1/5TGM1-EV cells at a 10:1 ratio in T cell medium (complete 
RPMI-1640 medium supplemented with 0.05 mM β-mercaptoethanol, 1x non-essential 
amino acids and 2 ng/mL recombinant human IL-2 (R&D Systems)). After 5 days of co-
culture, the T cells were harvested and seeded in T cell medium in triplicate with 1 x 104 
irradiated 5TGM1-Samsn1/5TGM1-EV cells at a ratio of 4:1 or 2:1 in a 96-well plate. 
Following 24 hours of incubation at 37°C with 5% CO2, the amount of tumour cell-specific 
lysis was measured using a lactate dehydrogenase release assay (CytoTox 96® Non-
Radioactive Cytotoxicity Assay, Promega), according to the manufacturer’s instructions. 
The maximum LDH release control for each target was determined by adding 10μl of 10X 
Lysis Solution to target cell-only wells 45 minutes before adding the CytoTox 96® Reagent. 
The background absorbance was subtracted from the readings and the percentage of specific 
cytotoxicity was calculated using the equation below. 
 
% Cytotoxicity =  
Experimental − Effector spontaneous − Target spontaneous
Target maximum − Target spontaneous







2.3.12 Detection of anti-Samsn1 antibodies in serum 
To potentially generate an anti-Samsn1 humoral immune response, 6-8-week-old KaLwRij, 
Samsn1-/- and C57BL/6 mice were injected i.v. with 5TGM1-Samsn1 cells or control 
5TGM1-EV cells (5 × 105 in 0.1 mL of PBS) on days 0 and 14. On day 19, the mice 
underwent a terminal cardiac bleed and serum was collected, as described in section 2.3.7. 
To generate blots of size-resolved Samsn1 protein, IPs of Samsn1-HA from 5TGM1-Samsn1 
cells were performed, as described in section 2.1.3.3. The only alteration was that 5 x 107 
cells were lysed in 2 mL of 1% NP-40 IP lysis buffer. Identical IPs were also performed for 
5TGM1-EV cells to act as a negative control. The immunoprecipitated eluates were split 
into 3 fractions (10%, 45% and 45%), which were subjected to SDS-PAGE in separate lanes 
of a 10% gel. The proteins in the gel were then transferred to a nitrocellulose membrane, 
which was divided into 3 sections. To confirm the successful IP of Samsn1 and indicate its 
position, the section of the membrane containing 10% of the IPs was probed with an anti-
HA antibody. The remaining sections of membrane were probed with fresh serum from mice 
inoculated with either 5TGM1-Samsn1 or 5TGM1-EV cells, which was diluted 1:10 in 
Solution 1 from the SignalBoostTM Immunoreaction Enhancer Kit (Merck), at 4°C overnight. 
Following removal of unbound antibody, the blots were incubated with goat anti-mouse IgG 
(H+L) secondary antibody conjugated to DyLightTM 680 (Thermo Fisher Scientific) diluted 
1:10,000 in Solution 2 from the enhancer kit at room temperature for 1 hour. The blots were 
then scanned using the Odyssey® CLx Imager (LI-COR). 
 
2.4 In silico analyses and statistics 
2.4.1 Publicly available microarray data  
For analysis of gene expression differences in CD138+ BM PCs from MM patients with low 
(< 5 Affymetrix intensity value) vs normal/high levels (> 5 Affymetrix intensity value) of 
SAMSN1 mRNA expression, a total of 1,191 patients from 3 independent publicly available 
microarray datasets were used: GSE19784 (n = 320)180, GSE24080 (n = 554)288 and 
GSE26760 (n = 304)147. Gene expression was normalised with the robust multi-array average 
(RMA) algorithm and differential gene expression was performed using linear models for 
microarray data (LIMMA) with array weight using R packages. For analysis of mRNA 
expression levels in CD138+ BM PCs from MGUS patients, MM patients and normal 
controls, the publicly available microarray dataset GSE6477 was used (normal, n = 15; 
MGUS, n = 22; MM, n = 133)289. GSE19784, GSE24080 and GSE26760 were conducted 





conducted on Affymetrix GeneChipTM Human Genome U133A arrays. Raw microarray data 
(CEL files) were downloaded from Gene Expression Omnibus (NCBI) and were normalized 
by RMA using the Bioconductor package affy and R (version 3.03) and log2 transformed. 
  
2.4.2 Statistics 
Unless otherwise described, statistical analysis was performed using GraphPad Prism v8.0.0 
(GraphPad Software). The Fisher’s exact test was used to determine whether the proportions 
of one categorical variable were different depending on the value of the other categorical 
variable. When three or more groups were being compared for a single variable, a parametric 
one-way ANOVA with Tukey’s post-hoc multiple comparisons test or a non-parametric 
Kruskal-Wallis test with Dunn’s multiple comparisons test was used. For time-course 
experiments, groups were compared using a two-way ANOVA with Sidak’s or Tukey’s 
multiple comparisons test. When two groups were being compared for a single variable, a 
parametric paired t test, a parametric unpaired t test or a non-parametric Mann-Whitney U 











3 INVESTIGATION OF THE 
POTENTIAL CO-OPERATIVE TUMOUR 
SUPPRESSOR EFFECTS OF SAMSN1 







Multiple myeloma (MM) is an incurable haematological malignancy characterised by the 
uncontrolled proliferation of antibody-producing plasma cells (PCs) within the bone marrow 
(BM). MM is defined by the presence of 10% or more clonal PCs in the BM and one or more 
myeloma-defining events21. For example, evidence of end-organ damage that can be 
attributed to the malignant PC expansion, such as hypercalcemia, renal insufficiency, 
anaemia, and bone lesions. Almost all MM cases are preceded by the premalignant condition 
monoclonal gammopathy of undetermined significance (MGUS), a benign clonal PC 
proliferation characterised by less than 10% PCs in the BM and the absence of end-organ 
damage19,20. Approximately 3-4% of people over 50 years of age have MGUS and they have 
a 1% risk of progressing to MM per year, although the time to progression is variable24.  
 
The development of MGUS is thought to be initiated in a post-germinal centre B cell by one 
of two types of primary cytogenetic event; hyperdiploidy or a chromosomal translocation 
involving the immunoglobulin heavy-chain gene110. Malignant transformation and MM 
disease progression is then thought to occur due to the accumulation of secondary genetic 
hits, including further chromosomal rearrangements, DNA mutations, as well as 
transcriptional and epigenetic changes110. In terms of the abnormalities present in MM 
tumours, recent studies have revealed that there is significant interpatient heterogeneity, with 
low recurrence rates for many mutations120,147-150. In addition, there is considerable 
intrapatient heterogeneity, with most patients displaying a complex subclonal architecture 
that is dynamic and can evolve over time148,149,212,214-216,221,231,232. Notably, many of the 
chromosomal abnormalities and genetic lesions identified in MM PCs are also found at the 
MGUS stage215,227,232, which highlights the possibility that novel epigenetic changes and/or 
PC-extrinsic factors are involved in driving the progression from asymptomatic MGUS to 
malignant MM. 
 
In order to identify novel genetic changes that may be involved in promoting MM 
development, our group, and one other, compared the genetics of the closely related 
C57BL/6 and C57BL/KaLwRij (KaLwRij) mouse strains260,261. Both KaLwRij and 
C57BL/6 mice develop benign monoclonal gammopathy at a similarly high rate (60-70% by 
two years old), but the KaLwRij mice are unique in their ability to spontaneously develop 
an MM-like disease, albeit at a low frequency and with late onset (0.5% in mice over two 





transcriptomic analyses, revealed many DNA sequence and gene expression differences 
between the two strains260,261. However, the most striking difference was a 180 kb 
homozygous genomic deletion on chromosome 16, which specifically encompasses 
Samsn1260,261. Samsn1 encodes a putative adaptor protein, which is most highly expressed in 
the haematopoietic compartment, including the B cell lineage240. Notably, SAMSN1 
expression was found to be lower in CD138+ PCs from MM patients compared to normal 
controls and MM patients with below median SAMSN1 expression were found to have 
reduced overall survival260,261. Hence, it was hypothesised that the down-regulation of 
SAMSN1 expression in PCs may promote MM development.  
 
In order to test the functional effect of Samsn1 loss in the context of MM, our group used 
the 5TGM1/KaLwRij model of MM264,267. In this model, the 5TGM1 murine MM cell line, 
which was established from a spontaneous KaLwRij PC tumour and thus is Samsn1-/-, is 
injected i.v. into syngeneic KaLwRij mice and the tumour cells home to the BM. Once there, 
the 5TGM1 cells rapidly expand to cause substantial tumour burden throughout the skeleton 
in just 4 weeks. As the 5TGM1 cells were engineered to express luciferase, tumour burden 
can be assessed non-invasively by bioluminescence imaging (BLI)260,290-292. Notably, the 
forced expression of Samsn1 in 5TGM1 cells was found to completely inhibit tumour 
development in KaLwRij mice, suggesting that Samsn1 may have a tumour suppressor role 
in MM260.  
 
The development of cancer is a multistep process in which the gradual accumulation of 
genetic driver events within a cell leads to the deregulation of the normal restrictions on its 
growth and survival293. Next generation sequencing (NGS) studies of large cohorts of MM 
patients have revealed that specific pairs of genetic lesions recurrently co-occur within PC 
tumours120,122,150. In addition, convergent evolution of genetic lesions has been recurrently 
found in MM, whereby independent mutations in the same gene were present in different 
subclones of the same tumour150,216,232,294. Furthermore, transgenic mouse studies have 
demonstrated the importance of co-operation between genetic lesions in promoting the 
development of MM in vivo158,236,237,239,295. For example, the over-expression of MYC by the 
Vk*MYC transgene caused MM tumour development in MGUS-prone C57BL/6 mice but 
not MGUS-resistant BALB/c mice, suggesting that MYC activation must co-operate with 
other genetic lesions to drive the malignant transformation of PCs158,239. Together, these data 





important role in promoting the development and progression of MM. However, the identity 
of co-operating lesions in MM and the mechanism by which they work together to drive 
disease development and/or progression is poorly understood.  
 
As discussed above, Samsn1 was found to be a potent tumour suppressor in the 
5TGM1/KaLwRij model of MM260, but the KaLwRij mouse strain only rarely spontaneously 
develops PC tumours, despite being Samsn1-/-264. This suggests that the loss of Samsn1 is 
necessary, but not sufficient, for the development of MM in KaLwRij mice. Hence, the 
down-regulation of SAMSN1 is likely to co-operate with another genetic lesion(s) to 
promote MM development, which remains to be identified. In this chapter, in silico analysis 
was used to identify reduced expression of GLIPR1, which has previously been described as 
a tumour suppressor gene296-298, in MM patients who display low SAMSN1 expression. In 
addition, GLIPR1 was found to be expressed at lower levels in the PCs of MM patients 
compared to normal controls and the 5TGM1/KaLwRij model was used to investigate 
whether Glipr1 possessed tumour suppressor activity in MM. Furthermore, Samsn1 and 
Glipr1 double knockout mice were generated and the potential co-operative effect of losing 
both genes on MM disease development in vivo was examined. 
 
3.2 Results 
3.2.1 Reduced GLIPR1 expression is associated with reduced SAMSN1 
expression in the PCs of MM patients  
In order to identify genetic changes that may co-operate with reduced SAMSN1 expression 
levels to drive MM disease development, an in silico analysis was performed on 1,178 
diagnostic human MM CD138+ PC samples from three independent publicly available 
microarray gene expression datasets (GSE24080, GSE26760 and GSE19784). Only two 
genes were found to have significantly different expression levels in the PCs of MM patients 
with low SAMSN1 expression (probe intensity < 5) compared to normal/high SAMSN1 
expression (probe intensity > 5) across all three datasets. The expression of the histone 
cluster 3 H2A (HIST3H2A) gene was found to be higher, and the expression of the glioma 
pathogenesis-related protein 1 (GLIPR1) gene was found to be lower, in MM PCs with low 
SAMSN1 mRNA levels versus normal/high SAMSN1 mRNA levels (Padj < 0.05, LIMMA; 










Figure 3.1: The expression levels of HIST3H2A and GLIPR1 are altered in the PCs of 
MM patients with low SAMSN1 expression. (A&B) In silico analysis was performed to 
identify genes with significantly different mRNA expression levels in CD138+ PCs from 
MM patients with low (probe intensity value < 5) versus normal/high (probe intensity value 
> 5) SAMSN1 expression in three microarray datasets: GSE19784 (low n = 22, normal/high 
n = 206), GSE26760 (low n = 57, normal/high n = 247) and GSE24080 (low n = 41, 
normal/high n = 518). Across all three datasets, the mRNA expression of HIST3H2A was 
found to be significantly higher (A), and the mRNA expression of GLIPR1 was found to be 
significantly lower (B), in MM tumours with low versus normal/high SAMSN1 expression. 






To determine whether the expression of HIST3H2A and/or GLIPR1 was deregulated in MM, 
in silico analysis of the mRNA levels of both genes in PCs from normal individuals (n = 15), 
MGUS patients (n = 22) and MM patients (n = 69) was performed using the GSE6477 
microarray dataset. HIST3H2A expression was found to not be aberrantly expressed in the 
PCs of MM patients compared to normal controls (P = 0.5911, one-way ANOVA with 
Tukey’s multiple comparisons test; Figure 3.2A), while GLIPR1 mRNA expression was 
significantly reduced in the PCs of MM patients compared to normal controls (P < 0.0001, 
one-way ANOVA with Tukey’s multiple comparisons test; Figure 3.2B). In fact, ~70% (n = 
48/69) of newly diagnosed MM patients were found to have GLIPR1 expression levels below 
the normal range in the PCs of normal individuals. Notably, GLIPR1 was previously found 
to have reduced expression in another PC malignancy, light-chain amyloidosis299, and its 
absence was shown to promote the development of localised PC tumours in mice298. 
Collectively, these data suggest that GLIPR1 may be a tumour suppressor gene in MM, the 
down-regulation of which may co-operate with reduced SAMSN1 expression to promote 
disease development. 
 
3.2.2 Re-expression of Glipr1 in 5TGM1 cells reduces MM disease 
development in vivo 
To investigate the potential role of Glipr1 in the 5TGM1/KaLwRij murine model of MM, 
the expression of Glipr1 in normal and malignant PCs was assessed by reverse transcription 
(RT)-PCR. Glipr1 mRNA was found to be undetectable in the 5TGM1 MM PC line, while 
it was found to be present in normal PCs from KaLwRij mice and C57BL/6 mice (Figure 
3.3A). This finding suggests that the loss of Glipr1 may co-operate with the absence of 
Samsn1 to drive MM development in KaLwRij mice. The next aim was to determine whether 
restoration of Glipr1 expression in 5TGM1 cells affects their growth in vitro and/or in vivo. 
5TGM1 cells were transduced with a mCherry-labelled Glipr1 expression construct 
(5TGM1-Glipr1) or empty vector control (5TGM1-EV), and re-expression of Glipr1 in the 
5TGM1-Glipr1 cells was confirmed by quantitative reverse transcription PCR (RT-qPCR; 
data not shown) and Western blot (Figure 3.3B). Glipr1 re-expression was not found to affect 
the proliferation of 5TGM1 cells following either mono-culture (P = 0.910, paired t test; 
Figure 3.3C) or co-culture with the OP9 murine BM stromal cell line (P = 0.683, paired t-
test; Figure 3.3D). In addition, the number of colonies formed by 5TGM1-Glipr1 cells in 
semi-solid medium did not differ from that of 5TGM1-EV control cells after 12 days (P = 










Figure 3.2: GLIPR1 mRNA expression is down-regulated in PCs from MM patients.  
(A&B) In silico analysis was performed on publicly available microarray dataset GSE6477 
analysing HIST3H2A (A) and GLIPR1 (B) mRNA expression in CD138+ PCs isolated from 
normal controls (n = 15), MGUS patients (n = 22) and MM patients (n = 69). Scatter dot 










Figure 3.3: Glipr1 expression is lost in 5TGM1 cells but its re-expression does not affect 
cell proliferation in vitro. (A) The expression of Glipr1 mRNA was assessed in normal 
CD138+ PCs from C57Bl/6 and KaLwRij mice and the KaLwRij-derived 5TGM1 MM PC 
line by RT-PCR. The products were run on a 2% agarose gel and stained with GelRed®. Actb 
was used as a positive control. NTC = no template control. (B) The expression of Glipr1 
protein in 5TGM1-Glipr1 (Glipr1) and control 5TGM1-EV (EV) cells was assessed by 
Western blot. Hsp90 was used as the loading control. The number of 5TGM1-Glipr1 cells 
in mono-culture (C) or co-culture with OP9 bone marrow stromal cells (D) was assessed by 
bioluminescence after 3 days. Cell number is expressed relative to the EV control cells. (E) 
Colony formation by 5TGM1-Glipr1 cells versus 5TGM1-EV cells was assessed in semi-
solid methylcellulose-containing medium after 12 days. Colony number is expressed relative 
to the EV control cells. Graphs depict the mean + SD of three independent experiments. P > 





To determine the effect of Glipr1 on MM tumour growth in vivo, the 5TGM1-Glipr1 and 
5TGM1-EV cell lines were injected i.v. into KaLwRij mice and tumour burden was 
monitored at weekly intervals by BLI. There was a trend towards reduced tumour burden in 
the KaLwRij mice inoculated with 5TGM1-Glipr1 cells compared to mice inoculated with 
5TGM1-EV cells at 4 weeks, but this decrease did not reach statistical significance (P = 
0.2464, two-way ANOVA with Sidak’s multiple comparisons test; Figure 3.4A). Tumour 
burden was also independently assessed at 4 weeks by measuring monoclonal paraprotein 
(M-spike) levels using serum protein electrophoresis (SPEP). The M-spike intensity showed 
the same trend toward reduced tumour burden in the 5TGM1-Glipr1 compared to the 
5TGM1-EV group, but it did not reach statistical significance (P = 0.4509, Mann-Whitney 
U test; Figure 3.4B). These data suggest that restoring Glipr1 levels in 5TGM1 cells does 
not affect murine MM PC proliferation in vitro but may have some inhibitory effect on 
tumour development in vivo. 
 
3.2.3 Samsn1 expression in the BM microenvironment does not affect 
MM tumour growth in vivo 
Given that GLIPR1 and SAMSN1 are concomitantly down-regulated in MM PCs and both 
genes have a tumour suppressor effect on 5TGM1 tumour growth in vivo260, it was 
hypothesised that these genes co-operate to inhibit the malignant transformation of PCs. In 
order to test this, the aim was to generate Glipr1 and Samsn1 double knockout mice     
(Glipr1-/-Samsn1-/-) that would be monitored for MM development as they aged. The 
C57BL/6 mouse strain was selected as the genetic background for these modifications, 
because it possesses high rates of age-related spontaneous MGUS, and thus is ideal for 
determining whether genetic alterations drive the malignant transformation of PCs262. 
Firstly, Samsn1 knockout mice were produced by backcrossing the Samsn1 deletion present 
in the genome of KaLwRij mice onto a C57BL/6 background for 10 generations. The 
absence of Samsn1 mRNA expression in the BM of the backcrossed C57BL/Samsn1-/- 
(Samsn1-/-) mice was confirmed by RT-PCR (Figure 3.5A).  
 
A previous study showed that the injection of macrophages from Samsn1-/- mice versus 
wildtype (WT) C57BL/6 mice increased the growth of subcutaneous 5TGM1 tumours, 
suggesting that the loss of Samsn1 in PC-extrinsic cells of the BM microenvironment may 
promote the development of MM in KaLwRij mice261. To further investigate this hypothesis, 








Figure 3.4: Glipr1 overexpression in 5TGM1 cells reduces tumour growth in vivo. 
(A&B) KaLwRij mice were injected i.v. with 5 x 105 5TGM1-Glipr1 or 5TGM1-EV control 
cells. (A) Tumour burden in the mice was measured weekly from week 2 post-tumour cell 
inoculation by BLI and the signal from the ventral and dorsal scans were summed for each 
mouse. A graph of the total flux for the mice injected with 5TGM1-Glipr1 or 5TGM1-EV 
cells (left) and representative ventral scans of one mouse per cell line over time (right) are 
shown. (B) Serum was collected from the mice after four weeks and the M-spikes were 
measured by SPEP. M-spikes (^) on the SPEP gel (left) and the quantitated M-spike intensity 
(right), normalised to albumin and expressed relative to the EV control, are shown. Graphs 
depict the mean ± SEM of n = 14-15 mice per cell line from three independent experiments. 
P > 0.05, two-way ANOVA with Sidak’s multiple comparisons test (A) or Mann-Whitney 











Figure 3.5: Samsn1 levels in the BM microenvironment do not affect 5TGM1 tumour 
growth in vivo. (A) The mRNA expression of Samsn1 was assessed in the BM of Samsn1-/- 
mice and WT control mice by RT-PCR. The products were run on a 2% agarose gel and 
stained with GelRed®. Actb was used as a positive control. Samsn1-/- and WT mice were 
injected i.v. with 5TGM1 cells and tumour burden was measured by BLI (n = 11-12 mice 
per genotype from two independent experiments). (B) The number of Samsn1-/- and WT mice 
with and without tumour development at 4 weeks post-5TGM1 inoculation are shown. (C) 
For the tumour-bearing mice, ventral and dorsal scans (left) and the total flux from the 
summed ventral and dorsal scans (right) at 4 weeks are shown. The graph depicts the mean 






tumour development in the BM was monitored by BLI for 4 weeks. Although the 
conventional wisdom is that 5TGM1 cells do not grow in mice with a C57BL/6 
background264,300, tumour was detected in 9 of the 23 (39.1%) Samsn1-/- and WT mice in this 
experiment (Figure 3.5B). This may be attributable to the fact that our 5TGM1 cell line was 
established from BM-resident 5TGM1 cells passaged in mice, which may have greater BM 
tropism compared to the 5TGM1 cells used by others. Notably, 45.5% (n = 5/11) and 33.3% 
(n = 4/12) of WT and Samsn1-/- mice, respectively, developed 5TGM1 tumours, which does 
not constitute a significant difference in tumour penetrance between the strains (P = 0.6802, 
Fisher’s exact test; Figure 3.5B). In addition, of those mice that did develop tumour, there 
was no difference in tumour burden between the WT mice and Samsn1-/- mice (P = 0.9048, 
Mann-Whitney U test; Figure 3.5C). This finding suggests that the loss of Samsn1 in PC-
extrinsic cells of the BM microenvironment does not affect the growth of MM tumours in 
KaLwRij mice. 
 
3.2.4 Generation of Glipr1 knockout mice using CRIPSR-Cas9 genome 
editing 
In order to produce Glipr1-/-Samsn1-/- double knockout mice, Glipr1-/- mice were generated 
using CRISPR-Cas9 genome editing technology. The strategy was to delete the first exon of 
the Glipr1 gene using two guide RNAs (gRNAs), one upstream of the conserved promoter 
region and the other in the first intron of Glipr1 (Figure 3.6A). WT mouse zygotes were 
injected with Cas9 mRNA and both gRNAs before being transferred to pseudopregnant 
recipients, which resulted in the birth of four founder pups. PCR genotyping coupled with 
Sanger sequencing revealed that three of the founders had at least one Glipr1 allele in which 
the first exon was successfully deleted (Figure 3.6B). The Glipr1 deletion allele of founder 
3, a ~3.6 kb deletion encompassing exon 1 (Figure 3.6B), was selected for breeding to 
homozygosity because it did not involve any random insertions/deletions and belonged to 
the only male founder. This Glipr1 deletion allele was backcrossed onto a C57BL/6 
background for one generation and then bred to homozygosity to generate C57BL/Glipr1-/- 
(Glipr1-/-) mice.  
 
To confirm successful gene knockout in the Glipr1-/- mice, RT-PCR for Glipr1 mRNA was 
performed on RNA from BM and spleen cells. Two sets of PCR primers were used; one with 
primers in Glipr1 exons 1 and 2 (ex1-2) and the other with primers in Glipr1 exons 3 and 4 










Figure 3.6: Generating Glipr1 knockout mice using CRISPR-Cas9 genome editing. (A) 
Schematic showing the location of the gRNAs used for CRISPR-Cas9-mediated deletion of 
Glipr1 exon 1 and the PCR primers (P1 & P4) used to screen founder mice for deletions. 
The direction of gene transcription is indicated by the arrow. (B) DNA samples from the 
four founder mice (F1-4) were screened for deletions of Glipr1 exon 1 by PCR using primers 
P1 and P4 and the products were run on a 1% agarose gel (left). Sanger sequencing of the 
highlighted deletion band in F3 showed a 3,641 bp deletion between the two gRNA sites, 

















Figure 3.7: Confirming Glipr1 knockout in CRISPR-Cas9-generated Glipr1-/- mice. (A) 
RT-PCR for Glipr1 mRNA was performed on RNA from the BM and spleen of Glipr1-/- and 
WT control mice using either primers in exons 1 and 2 (ex1-2) or primers in exons 3 and 4 
(ex3-4). PCR products were run on a 2% agarose gel and stained with GelRed®. Actb was 
used as a positive control. (B) Glipr1 primers ex3-4 were used to perform RT-qPCR on RNA 
from the BM and spleen of Glipr1-/- and WT mice. Glipr1 expression levels were normalised 
to Actb and were expressed relative to WT mice. (C) The levels of Glipr1 protein in the BM 
and spleen of Glipr1-/- and WT mice was assessed by Western blot. Hsp90 was used as the 
loading control. The graph depicts the mean + SD of n = 2 mice per genotype. ****P < 












which was expected, given that one of the primers binds within the Glipr1 deletion region. 
However, products of the expected size were generated using the ex3-4 primers, suggesting 
that there was transcription of Glipr1 downstream of exon 1 (Figure 3.7A). However, RT-
qPCR using the ex3-4 primers showed that the expression of Glipr1 mRNA transcripts in 
the BM and spleen of Glipr1-/- mice was significantly reduced compared to WT mice (Figure 
3.7B). In addition, there was no full-length or truncated Glipr1 protein detected in the BM 
or spleen of the Glipr1-/- mice by Western blot using a polyclonal α-Glipr1 antibody (Figure 
3.7C). Hence, the truncated Glipr1 mRNA transcripts generated in the Glipr1-/- mice were 
not translated into protein, which is consistent with the absence of alternative start codons 
downstream of exon 1. Together, these data indicate that a Glipr1 knockout mouse was 
successfully generated using CRISPR-Cas9 genome editing. 
 
3.2.5 Analysis of B cell development in Glipr1 and/or Samsn1 knockout 
mice 
In order to generate Glipr1-/-Samsn1-/- double knockout mice, the Glipr1-/- mice and    
Samsn1-/- mice were crossed and the resultant heterozygous mice (Glipr1+/-Samsn1+/-) were 
crossed again. From these matings, 3.8% (n = 4/105) of the progeny were found to be      
Glipr1-/-Samsn1-/- by PCR genotyping, which does not significantly differ from the expected 
Mendelian frequency of 6.25% (P = 0.5377, Fisher’s exact test). The Glipr1-/-Samsn1-/- mice 
were viable, fertile and had no overt phenotypic traits. In order to examine the effect of 
Glipr1 and/or Samsn1 knockout on normal haematopoiesis in adult mice, peripheral blood 
(PB) from 12-week-old Glipr1-/-, Samsn1-/-, Glipr1-/-Samsn1-/- and WT mice was assessed 
using a HEMAVET analyser. No differences in the number of white blood cells, the number 
of red blood cells, haemoglobin concentration, or other parameters were observed in the 
Glipr1 and/or Samsn1 knockout mice compared to the WT mice (P > 0.05, Kruskal-Wallis 
test with Dunn’s multiple comparisons test; Figure 3.8 and Table 3.1). In addition, flow 
cytometry analysis of B cells from the BM of 12-week-old Glipr1-/-, Samsn1-/-, Glipr1-/-
Samsn1-/- and WT mice was performed. No differences in the populations of pre-pro B cells, 
immature B cells, mature B cells, total B cells and PCs were observed in the Glipr1-/-, 
Samsn1-/-, and Glipr1-/-Samsn1-/- mice compared to the WT mice (P > 0.05, Kruskal-Wallis 
test with Dunn’s multiple comparisons test; Figure 3.9A-F). The knockout mice also 
demonstrated similar splenic populations of total B cells and PCs compared to WT mice (P 


















Figure 3.8: Glipr1 and/or Samsn1 knockout does not affect PB counts in adult mice.    
(A-F) PB was collected by tail bleed from 12-week-old Glipr1-/-, Samsn1-/-,                        
Glipr1-/-Samsn1-/- and WT mice and white blood cell (WBC) number (A), lymphocyte 
number (B), monocyte number (C), neutrophil number (D), red blood cell (RBC) number 
(E) and haemoglobin concentration (F) were assessed using a HEMAVET analyser. Graphs 
depict the mean ± SEM of n = 7 mice per genotype. P > 0.05, Kruskal-Wallis test with 














Table 3.1: Haematological parameters in the PB of 12-week-old Glipr1-/-, Samsn1-/-, 
Glipr1-/-Samsn1-/- and WT mice. PB was collected by a tail bleed from 12-week-old   
Glipr1-/-, Samsn1-/-, Glipr1-/-Samsn1-/- and WT control mice and was analysed on a 





SD = standard deviation, # = number, % = percentage, WBC = white blood cell, NE = neutrophil, LY = 
lymphocytes, MO = monocytes, EO = eosinophils, BA = basophils, RBC = red blood cell, HB = haemoglobin, 
HCT = haematocrit, MCV = mean corpuscular volume, MCH = mean corpuscular haemoglobin, MCHC = 
mean corpuscular haemoglobin concentration, RDW = red blood cell distribution width, PLT = platelet, MPV 
















Figure 3.9: Glipr1 and/or Samsn1 knockout does not affect B cell populations in the BM 
or spleen of 12-week-old mice. Single cell suspensions from the BM (A-F) and spleen       
(G-I) were obtained from 12-week-old Glipr1-/-, Samsn1-/-, Glipr1-/-Samsn1-/- and WT 
control mice. The cells were stained with anti-B220, anti-IgM and anti-CD138 antibodies 
and analysed by flow cytometry. (A-F) BM cells were gated, as represented in (A), to show 
the percentage of total B cells (B; B220+), mature B cells (C; B220highIgMlow), immature B 
cells (D; B220lowIgM+), pre-pro B cells (E; B220lowIgM-), and PCs (F; B220-IgM-CD138+) 
among total leukocytes. (G-I) Spleen cells were gated, as represented in (G), to show the 
percent of total B cells (H; B220+) and PCs (I; B220-IgM-CD138+) among total leukocytes. 
Graphs depict the mean ± SEM of n = 9-12 mice per genotype. *P <0.05, **P < 0.01, 












Figure 3.9G-I). Collectively, these data suggest that the loss of Glipr1 and/or Samsn1 does 
not significantly affect B cell development, including PC production, in vivo. 
 
3.2.6 Glipr1 and/or Samsn1 knockout does not result in MM disease 
development in vivo 
KaLwRij mice, which are Samsn1-/-, and Glipr1-/- mice are prone to developing PC 
dyscrasias, albeit with late onset and incomplete penetrance264,298. Hence, it was 
hypothesised that the concomitant loss of Glipr1 and Samsn1 would result in increased 
penetrance, decreased time to onset and/or increased progression of abnormal PC expansions 
in vivo. To test this, Glipr1-/-, Samsn1-/-, Glipr1-/-Samsn1-/- and WT mice were aged for one 
year and monitored for B cell/PC abnormalities using a HEMAVET analyser, SPEP and 
flow cytometry analyses (Figure 3.10A). Haematological parameters were measured in serial 
samples of PB from the Glipr1-/-, Samsn1-/-, Glipr1-/-Samsn1-/- and WT mice at 6, 9 and 12 
months of age using a HEMAVET analyser (Figure 3.10B-E and Table 3.2). There was a 
significant increase in the number of lymphocytes at 9 months of age, and monocytes at 6 
months of age, in PB from the Glipr1-/- mice compared to the WT mice (P < 0.05, Kruskal-
Wallis test with Dunn’s multiple comparisons test; Figure 3.10C&D). In addition, the 
number of monocytes was significantly higher in the Glipr1-/-Samsn1-/- mice compared to 
the WT mice at 9 months of age (Figure 3.10D). These data suggested that Glipr1 knockout 
may promote progressive expansion of lymphocyte and monocyte populations over time. 
However, increased lymphocyte and monocyte populations were not observed in the   
Glipr1-/- mice or Glipr1-/-Samsn1-/- mice compared to the WT mice at 12 months of age 
(Figure 3.10B-E and Table 3.2). This was confirmed by flow cytometry analysis of white 
blood cell populations in PB from the 12-month-old mice, which showed similar lymphocyte 
(B and T cell), monocyte and granulocyte populations in the Glipr1-/-, Samsn1-/- and     
Glipr1-/-Samsn1-/- mice compared to the WT mice (P > 0.05, Kruskal-Wallis test with Dunn’s 
multiple comparisons test; Figure 3.11). These data suggest that Glipr1 and/or Samsn1 
knockout does not cause consistent or progressive changes to PB cell populations in ageing 
mice. 
 
The ageing Glipr1 and/or Samsn1 knockout mice were specifically monitored for expansions 
of antibody-producing PCs relative to WT control mice by SPEP at 10-week intervals. 
Across the genotypes, there were more M-spikes in the female mice compared to the male 

















Figure 3.10: Longitudinal analysis of PB counts in ageing Glipr1-/-, Samsn1-/- and   
Glipr1-/-Samsn1-/- mice. (A) Schematic illustrating the experimental design for monitoring 
Glipr1-/-, Samsn1-/-, Glipr1-/-Samsn1-/- and WT mice for B cell/PC abnormalities. (B-E) 
Blood samples were serially collected by a tail bleed from Glipr1-/-, Samsn1-/-,                 
Glipr1-/-Samsn1-/- and WT mice at 6 (left), 9 (middle) and 12 (right) months of age. Complete 
blood counts, including WBC (B), lymphocyte (C), monocyte (D) and neutrophil (E) 
numbers, were measured using a HEMAVET analyser. Graphs depict the mean ± SEM of   












Table 3.2: Haematological parameters in the PB of ageing Glipr1-/-, Samsn1-/- and Glipr1-/-Samsn1-/- mice. PB was collected by a tail bleed from   
Glipr1-/-, Samsn1-/-, Glipr1-/-Samsn1-/- and WT control mice at 6, 9 and 12 months of age and was assessed using a HEMAVET analyser (n = 10/genotype). 
Data are shown as mean ± SD. *P < 0.05, **P < 0.01 compared to WT, Kruskal-Wallis test with Dunn’s multiple comparisons test. 
 
 
WBC = white blood cell, NE = neutrophil, LY = lymphocytes, MO = monocytes, EO = eosinophils, BA = basophils, RBC = red blood cell, HB = haemoglobin, HCT = haematocrit, MCV = 
mean corpuscular volume, MCH = mean corpuscular haemoglobin, MCHC = mean corpuscular haemoglobin concentration, RDW = red blood cell distribution width, PLT = platelet, MPV 

















Figure 3.11: Flow cytometry analysis of leukocyte populations in the PB of 12-month-
old Glipr1-/-, Samsn1-/- and Glipr1-/-Samsn1-/- mice. (A-E) PB was collected from 12-
month-old Glipr1-/-, Samsn1-/-, Glipr1-/-Samsn1-/- and WT control mice and single cell 
leukocyte suspensions were prepared. The cells were stained with anti-B220, anti-CD3, anti-
CD11b and anti-Ly6G antibodies and analysed by flow cytometry. (A) Representative flow 
plots showing the gating strategy used to define B cells (B220+), T cells (CD3+), monocytes 
(CD11b+Ly6G-) and granulocytes (CD11b+Ly6G+). The percentage of B cells (B), T cells 
(C), monocytes (D) and granulocytes (E) among total leukocytes in the PB are shown in the 
graphs. Graphs depict the mean ± SEM of n = 10 mice per genotype. P > 0.05, Kruskal-













compared to the albumin and other globulin bands in the 50-week-old mice (Figure 3.12A). 
Although the M-spike incidence was higher in the Glipr1 and/or Samsn1 knockout mice 
compared to the WT mice at the earlier time points, this difference was not evident at 50 
weeks of age (Figure 3.12B). In addition, flow cytometry analysis revealed that the B cell 
populations in the BM and spleen of the 12-month-old Glipr1-/-, Samsn1-/- and                  
Glipr1-/-Samsn1-/- mice were similar to those in the WT mice, except for a significant 
reduction in the BM immature B cell population in the Samsn1-/- mice (P = 0.042, Kruskal-
Wallis test with Dunn’s multiple comparisons test; Figure 3.13A-D&F). Notably, no 
differences were found in the BM and splenic PC populations of the Glipr1-/-, Samsn1-/- and 
Glipr1-/-Samsn1-/- mice compared to the WT mice (P > 0.05, Kruskal-Wallis test with Dunn’s 
multiple comparisons test; Figure 3.13E&G). Together, these data suggest that the loss of 
Samsn1 and Glipr1 does not promote the development of abnormal clonal PC expansions, 
or other B cell abnormalities, in mice up to one year of age. 
 
3.3 Discussion 
Although Samsn1 was found to be a tumour suppressor in the 5TGM1/KaLwRij murine 
model of myeloma260, Samsn1-/- KaLwRij mice only spontaneously develop MM with late 
onset and very low penetrance264. This suggests that the loss of Samsn1 is not sufficient to 
drive malignant transformation and must co-operate with other genetic lesions to promote 
MM development. In this chapter, it was aimed to identify genetic aberrations that 
potentially co-operate with reduced SAMSN1 expression to promote MM. To achieve this, 
gene expression differences between MM PCs with low versus normal/high SAMSN1 levels 
were examined and only two changes in the SAMSN1low tumours across multiple microarray 
datasets were found: up-regulation of HIST3H2A and down-regulation of GLIPR1. 
HIST3H2A encodes a replication-dependent H2A core histone, which is mainly expressed 
during S phase of the cell cycle301. The expression of this gene was found to not differ in 
MM PCs compared to normal PCs and HIST3H2A has not previously been described to 
have a role in cancer. As such, increased HIST3H2A expression was deemed unlikely to 
constitute a co-operative driver of MM development.  
 
GLIPR1 is a ubiquitously expressed gene that encodes a member of the cysteine-rich 
secretory proteins, antigen 5, and pathogenesis-related 1 proteins (CAP) superfamily with 
unspecified function302,303. GLIPR1 expression was found to be significantly decreased in 








Figure 3.12: Glipr1 and/or Samsn1 knockout does not affect M-spike incidence in one-
year-old mice. (A&B) Serum was serially collected by tail bleed from ageing Glipr1-/-, 
Samsn1-/-, Glipr1-/-Samsn1-/- and WT control mice every 10 weeks and the presence of M-
spikes were detected using SPEP (n = 10 mice per genotype). (A) SPEP gels for sera 
collected from 50-week-old mice are shown. The position of the albumin and the different 
globulin components of the serum are indicated by brackets. * denotes mice with an M-







Figure 3.13: Glipr1 and/or Samsn1 knockout does not affect PC populations in one-
year-old mice. BM and spleen cells were collected from 12-month-old Glipr1-/-, Samsn1-/-, 
Glipr1-/-Samsn1-/- and WT control mice and single cell suspensions were prepared. B cell 
populations were analysed by flow cytometry through staining cells with anti-B220, anti-
IgM and anti-CD138 antibodies. Stained cells were gated to show the percentage of total B 
cells (A&F; B220+), mature B cells (B; B220highIgMlow), immature B cells (C; 
B220lowIgM+), pre-pro B cells (D; B220lowIgM-), and PCs (E&G; B220-IgM-CD138+) 
among total leukocytes. Graphs depict the mean ± SEM of n = 10 mice per genotype. *P < 






express GLIPR1 below the normal range. A reduction in GLIPR1 expression has also been 
observed in several solid cancers, including prostate cancer304, lung cancer305, sarcoma306 
and bladder cancer 307. Notably, down-regulation of GLIPR1 was one of only 38 gene 
expression changes identified in PCs from patients with the MM-related malignancy light-
chain amyloidosis299. Together, these findings suggested that GLIPR1 may be a novel 
tumour suppressor gene in MM, the down-regulation of which may co-operate with reduced 
expression of SAMSN1 to promote MM disease development.   
 
In the context of murine MM, the expression of Glipr1 was found to be lost in the KaLwRij 
tumour-derived 5TGM1 MM cell line compared to normal PCs from KaLwRij mice. This is 
consistent with the loss of Glipr1 being a change that co-operates with the pre-existing 
absence of Samsn1 in KaLwRij PCs to promote malignant transformation. To investigate 
whether loss of Glipr1 expression is a common occurrence in the spontaneous MM tumours 
that arise in KaLwRij mice, other independently-established, KaLwRij PC tumour-derived 
MM cell lines, such as 5T2263-266, could be analysed. The mechanism(s) by which 
Glipr1/GLIPR1 expression is down-regulated in the context of murine/human MM is 
unknown. Reduced GLIPR1 expression in prostate cancer was shown to be primarily caused 
by aberrant DNA hypermethylation304. In addition, hemizygous chromosomal deletions 
encompassing GLIPR1 have been reported in 9.4% of MM patients308. Hence, future studies 
should investigate DNA methylation and genomic deletion as potential mechanisms that 
cause down-regulation of GLIPR1 expression in MM PCs. Notably, the overexpression of 
Glipr1 in 5TGM1 cells was found to not affect cell proliferation in vitro but to reduce tumour 
burden in vivo, suggesting a possible tumour suppressor role for Glipr1 in MM. However, 
the reduction in 5TGM1-Glipr1 tumour burden did not reach statistical significance, which 
may have been due to the rapidly progressive nature of the 5TGM1/KaLwRij MM model267. 
Hence, further exploration of the potential tumour suppressor role of GLIPR1 in MM using 
less aggressive in vivo disease models, such as the human myeloma cell line U266 in 
immunodeficient mice309, is warranted.  
 
GLIPR1 has been shown to act as a tumour suppressor in several other malignancies, both 
in vitro and in vivo296-298,304-307. In addition, previously generated Glipr1-/- mice were shown 
to have reduced survival due to increased rates of spontaneous malignancy298. Notably, 40% 
of the tumours in the Glipr1-/- mice were classified as plasmacytomas, which is a localised 





KaLwRij mice, tumour development in Glipr1-/- mice was found to be of late onset (no 
mortality until 15 months of age) and incomplete penetrance (~17%)239, which suggests that 
the loss of Glipr1 co-operates with additional genetic aberrations to promote malignancy. 
GLIPR1 has been found to mediate its tumour suppressor effects through several different 
mechanisms in prostate cancer cells298,312,313. For example, it was shown to promote 
apoptosis by increasing reactive oxygen species production298 and by modulating HSC70’s 
regulation of apoptosis-related gene expression312. In addition, GLIPR1 was found to cause 
cell cycle arrest by decreasing expression of the oncogenic MYC transcription factor313. 
Whether GLIPR1 performs these tumour suppressor functions in PCs is unknown and 
warrants future investigation. 
 
Samsn1 knockout mice and Glipr1 knockout mice on a MGUS-prone C57BL/6 background 
were generated by backcrossing the KaLwRij-derived Samsn1 deletion or CRISPR-
mediated genetic editing of Glipr1, respectively. These single knockout mice were then 
crossed to generate Glipr1-/-Samsn1-/- double knockout mice, which were used to examine 
whether the concomitant loss of Samsn1 and Glipr1 induces MM development. After one 
year, the incidence of M-spikes in the WT mice was 30%, which was in agreement with the 
previously reported M-spike frequency of ~25-30% in one-year-old C57BL/6 mice239,262. 
Notably, the Glipr1-/-, Samsn1-/- and Glipr1-/-Samsn1-/- mice were found to have an M-spike 
frequency equal to or less than that of the WT mice. In addition, there was no significant 
difference in the proportion of PCs in the BM or spleen of the Glipr1-/-, Samsn1-/- or      
Glipr1-/-Samsn1-/- mice compared to the WT mice at one year of age. Notably, the expression 
of putative myeloma-promoting transgenes in early B cells was previously shown to cause 
the development of lymphomas, not MM, in mice 236-238. Hence, it was considered a 
possibility that the Glipr1 and/or Samsn1 knockout mice may develop B cell malignancies 
with a less-differentiated cell of origin. However, analyses of B cell populations in the blood, 
BM and spleen from the Glipr1-/-, Samsn1-/- and Glipr1-/-Samsn1-/- mice showed that there 
were no expansions of any B cell subsets. Together, these data suggest that the loss of Glipr1 
and/or Samsn1 did not promote the development of PC, or other B cell, proliferative 
disorders in C57BL/6 mice up to one year of age.  
 
The finding that there was no difference in clonal PC expansions between Samsn1-/- mice 
and WT mice was consistent with a previous study that showed no evidence of increased 





Glipr1-/- mice also did not display increased development of PC dyscrasias compared to WT 
mice appears to conflict with the previous finding that Glipr1-/- mice had a greater propensity 
to develop plasmacytomas298. However, the low penetrance and late onset of the PC tumours 
observed in the previous Glipr1-/- mice suggests that the cohort size (n = 10) and length of 
monitoring (one year) of the Glipr1 knockout mice in this study may have been insufficient 
to observe enhanced tumorigenesis. In addition, previous studies have shown that tumour 
penetrance and onset is increased in transgenic mice with a 129Sv background compared to 
a C57BL/6 background314-317. Hence, as the previously described Glipr1 knockout mice were 
on a C57BL6/129Sv (1:1) hybrid background, they may have been more susceptible to 
developing PC malignancies compared to the Glipr1-/- mice generated in this study, which 
were on a pure C57BL/6 background. Notably, the Samsn1-/-Glipr1-/- mice did not display 
evidence of enhanced PC expansions compared to WT mice up to one year of age, suggesting 
that the loss of both Samsn1 and Glipr1 do not co-operate to drive MM development in 
MGUS-prone C57BL/6 mice. However, the incidence of MGUS in C57BL/6 mice is known 
to increase from 25-30% at one year of age to 60-70% by two years of age239,262. This 
suggests that the Glipr1-/-Samsn1-/- mice may need to be aged for longer than one year in 
order to observe any potential increase in MM development due to the loss of both genes.  
 
A previous study demonstrated that Glipr1 loss and MYC overexpression co-operated to 
induce invasive prostate carcinomas in mice313. Given that MYC activation has been 
demonstrated to drive MM development and progression158,160, it is a possibility that MYC 
overexpression and GLIPR1 down-regulation may co-operate to drive the malignant 
transformation of PCs. While this remains to be determined, generating Glipr1-/-Samsn1-/- 
knockout mice that also harbour the Vk*MYC transgene could enable the potential co-
operative tumour suppressor effect of these genes in PCs to be assessed over a shorter 
timeframe in vivo. Furthermore, previous studies have shown that SAMSN1 and GLIPR1 
expression are both down-regulated in other cancers, such as lung cancer271,305. In silico 
analysis revealed that GLIPR1 expression is significantly reduced in lung tumours that have 
SAMSN1 expression below the normal range (GSE19804, data not shown), which suggests 
that these genes may also co-operate to suppress lung cancer and potentially other 
malignancies. Hence, the effect of Glipr1 and Samsn1 knockout on the development of lung 






GLIPR1 has been shown to be highly expressed in normal BM and spleen318, but its function 
in normal lymphocytes, including B cells remains to be elucidated. Glipr1 and/or Samsn1 
knockout was found to not affect PB counts or B cell populations, including PC, in the BM 
or spleen of adult 12-week-old mice. The similarity of B cell populations between the 
Samsn1-/- and WT mice is consistent with the previous finding that there were no defects in 
B cell development in Samsn1 knockout245 or transgenic249 mice. This suggests that Glipr1 
and/or Samsn1 do not play significant roles in haematopoiesis, especially B cell 
development, in mice. However, it was previously shown that Samsn1 knockout mice 
display enhanced B cell function, including increased proliferation in response to antigen 
stimulation ex vivo and increased antigen-specific antibody production in vivo245. Hence, 
despite Glipr1 knockout not affecting the relative size of B cell populations in mice, Glipr1 
may have a role in regulating normal B cell function, which is an area for further 
investigation.  
 
Previous studies have shown that genetic changes in stromal cells, including within the BM, 
can promote tumour development in surrounding cell types in a process called niche-
mediated oncogenesis319-324. In the context of MM, the importance of the BM 
microenvironment in regulating the growth and survival of malignant PCs is well-
established325. A previous study found that the intratumoral injection of ex vivo M2-polarised 
macrophages from Samsn1-/- mice versus WT mice significantly increased the growth of 
established sub-cutaneous 5TGM1 tumours in immunodeficient mice, suggesting that 
Samsn1 expression in PC-extrinsic cells may promote MM development in KaLwRij 
mice261. However, a limitation of the previous study was that the proliferation of 5TGM1 
cells in vivo was assessed by measuring tumour volume, which included both the 5TGM1 
cells and the injected macrophages. Given that the study also showed that Samsn1-/- 
macrophages proliferate faster than WT macrophages, it is possible that at least part of the 
increased tumour volume observed following injection of Samsn1-/- versus WT macrophages 
was due to differences in the growth of the macrophages, not the tumour cells. Hence, the 
effect of Samsn1 loss in PC-extrinsic cells of the BM microenvironment was further 
investigated in this study by comparing 5TGM1 tumour growth following i.v. inoculation in 
the newly-generated Samsn1-/- mice compared to the WT mice. No significant difference in 
5TGM1 tumour development was observed in the Samsn1-/- mice compared to the WT mice, 
suggesting that the absence of Samsn1 in PC-extrinsic cells of the BM microenvironment, 






In summary, the key genetic abnormalities involved in promoting the transformation from 
benign MGUS to malignant MM, and how they are interdependent, remain incompletely 
understood. In this study, GLIPR1 was identified as a gene that is down-regulated in the 
clonal PCs of MM patients with low SAMSN1 expression and the PCs of most MM patients 
compared to normal controls. Future studies examining the mechanism(s) by which GLIPR1 
expression is reduced and whether this is a cause, consequence or independent of SAMSN1 
down-regulation in MM PCs are warranted. Glipr1 expression was also found to be lost in 
the 5TGM1 murine MM cell line and restoration caused a trend towards reduced tumour 
growth in KaLwRij mice. Further investigation of the potential tumour suppressor role of 
GLIPR1, and its underlying molecular mechanism of action, in human MM is required. 
Glipr1 and Samsn1 knockout mice were generated and did not show a propensity for 
enhanced MM disease development up to one year of age. However, further analyses of 
these mice over a longer timeframe may yet uncover a co-operative tumour suppressor role 
for Samsn1 and Glipr1 in PCs. Given that SAMSN1 and GLIPR1 are concomitantly down-
regulated in other malignancies, an improved understanding of the functional relationship 
between these genes in MM could provide critical insight into the mechanisms of 












4 INVESTIGATING THE TUMOUR 
SUPPRESSOR MECHANISM OF SAMSN1 







The SAM domain, SH3 domain and nuclear localization signals 1 (SAMSN1) gene, also 
known as SASH2/NASH1/HACS1/SLy2, encodes a member of the SH3-domain protein 
expressed in the lymphocyte (SLy) family of evolutionarily conserved proteins, which also 
includes and SASH1 and SASH3240,242. These proteins contain Src homology 3 (SH3) and 
sterile alpha motif (SAM) domains, both of which mediate protein-protein interactions, and 
thus have putative adaptor/scaffolding functions240,242. SAMSN1 also harbours an N-
terminal nuclear localisation signal and a nuclear export signal but is predominantly 
localised to the cytoplasm240,241. The gene is most highly expressed in normal haematopoietic 
tissues, including BM, spleen, lymph nodes, thymus and PB240. SAMSN1 is also expressed 
at lower levels in the heart, brain, lung, muscle and placenta240. The gene is located on 
chromosome 21 (21q11.2) and there are three alternative transcripts, with the canonical 
sequence encoding a polypeptide that is 373 amino acids in length. The orthologous murine 
Samsn1 gene is located on chromosome 16 and is highly conserved, sharing 84% homology 
with human SAMSN1.  
 
The molecular functions of SAMSN1 are poorly understood, but SAMSN1/Samsn1 protein 
was shown to be strongly up-regulated in primary human/mouse B cells following B cell 
receptor (BCR) engagement241. Notably, the overexpression of Samsn1 in primary murine 
splenic B cells resulted in decreased cellular activation and proliferation in response to BCR 
stimulation241. In addition, primary splenic B cells from Samsn1-/- mice were found to have 
increased proliferation upon BCR stimulation in vitro245. These Samsn1-/- mice also 
displayed enhanced adaptive immunity in vivo, producing significantly higher levels of 
antigen-specific immunoglobulins following immunisation245. Taken together, these data 
suggest that SAMSN1 is an immunoinhibitory adaptor that has a role in regulating the 
development and moderating the immune response of B cells. This is consistent with the 
important role that a range of adaptor/scaffolding proteins, such as kinase suppressor of Ras 
(KSR) and discs large homolog 1 (DLG1), have been shown to play in regulating immune 
cell signalling326. 
 
Investigation of the molecular mechanisms underlying the immunoinhibitory role of Samsn1 
in B cells identified the paired Ig-like receptor B (PIR-B) protein, a receptor that negatively 
regulates BCR signalling, as a potential binding partner of SAMSN1 through a yeast-2-





recruitment of SHP-1 phosphatase and the attenuation of BCR signalling327. Hence, Samsn1 
may inhibit B cell activation/proliferation by binding to PIR-B and amplifying its negative 
regulation of BCR signalling245. However, a physical association between Samsn1 and 
endogenous PIR-B was not detected in primary murine B cells241. The immunoinhibitory 
effect of Samsn1 has also been attributed to its demonstrated role in actin cytoskeletal 
remodelling249. Notably, the actin reorganisation-mediated spreading of lymphocytes, which 
is crucial for antigen gathering and subsequent cell activation257, was found to be drastically 
reduced for splenic B cells from Samsn1 transgenic mice compared to WT mice249. The 
lymphocyte-specific homolog of the actin regulator cortactin, Hs1, which is required for T 
cell spreading328, was found to interact with Samsn1 in B cells from the transgenic mice249. 
These findings suggest that Samsn1 may inhibit B cell responses by limiting Hs1-mediated 
B cell spreading. Furthermore, SAMSN1 has been implicated in epigenetic regulation of 
gene expression, as two members of the Sin3 co-repressor complex, SAP30 and histone 
deacetylase 1 (HDAC1), co-immunoprecipitated with SAMSN1 when overexpressed in 
HEK293T cells251. While the effect of SAMSN1 on the transcriptome was not assessed, 
these findings suggest that SAMSN1 may also have an inhibitory effect on B cell function 
by directly regulating gene expression.  
 
In addition to its role in regulating humoral immune responses, SAMSN1 has been implicated 
as a tumour suppressor gene in several cancers, including the plasma cell (PC) malignancy 
multiple myeloma (MM). A putative tumour suppressor role was first attributed to SAMSN1 
in lung cancer, owing to its location within a region on chromosome 21 that is frequently 
affected by loss of heterozygosity271. Furthermore, SAMSN1 expression was found to be 
reduced in lung cancer cell lines compared to normal tissue271. SAMSN1 was subsequently 
found to have reduced expression in tumour versus normal tissue in the context of other 
malignancies, including ulcerative colitis-associated colon cancer272, hepatocellular 
carcinoma273, gastric cancer274 and also MM260. Furthermore, low SAMSN1 expression was 
associated with negative clinical parameters in MM and other cancers, including increased 
tumour size and decreased disease-related survival260,273,274. In the context of MM, 
C57BL/KaLwRij (KaLwRij) mice, a small proportion of which spontaneously develop an 
MM-like disease as they age, were found to be Samsn1-/- due to a 180 kb homozygous 
genomic deletion on chromosome 16260,261. Our group assessed the functional effect of 
Samsn1 loss in MM PC using the 5TGM1/KaLwRij mouse model of MM, in which the 





mice260. Once in the circulation, the injected 5TGM1 cells home to and colonise the BM of 
the mice, resulting in rapid tumour development throughout the skeleton within 4 weeks268. 
Notably, enforced Samsn1 expression in 5TGM1 cells was found to significantly reduce 
tumour development to undetectable levels in vivo, suggesting that SAMSN1 may be a 
tumour suppressor gene in MM260.  
 
The mechanism(s) by which Samsn1 completely inhibits 5TGM1 tumour development in 
KaLwRij mice, which may also be relevant in human MM, is yet to be fully elucidated. Re-
expressing Samsn1 in 5TGM1 cells has been shown to reduce cellular proliferation in vitro, 
but there are conflicting reports regarding the conditions under which this effect was 
observed260,261. One group found that Samsn1 reduced the proliferation of 5TGM1 cells by 
~25% under basal conditions261, while our group observed a ~15% decrease only when the 
tumour cells were co-cultured with primary KaLwRij-derived BM stroma260. In addition, 
our group found that Samsn1 increased the adhesion of 5TGM1 cells to BM stroma in 
vitro260. Together, these data suggest that Samsn1 may suppress in vivo tumour development 
through a cell adhesion-mediated anti-proliferative effect on 5TGM1 cells in the BM 
microenvironment260. However, given that Samsn1 only modestly reduced 5TGM1 
proliferation in vitro, it is possible that there may be other mechanisms that contribute to its 
abrogation of MM tumour growth. For example, as Samsn1 has been implicated in actin 
cytoskeletal remodelling249, it could be suppressing MM tumour development through 
inhibiting 5TGM1 migration/BM homing, but this remains to be determined. In this chapter, 
the tumour suppressor mechanism of Samsn1 in 5TGM1 cells was investigated through 
protein binding partner and transcriptome analyses. In addition, the effect of Samsn1 on the 
tumourigenic behaviour of 5TGM1 cells was further explored through in vitro actin 
remodelling and migration assays and in vivo metastasis and BM homing experiments. 
 
4.2 Results 
4.2.1 Identifying novel binding partners of Samsn1 in 5TGM1 cells 
To gain a better understanding of the mechanism(s) by which Samsn1, a putative adaptor 
protein, acts as a tumour suppressor in the 5TGM1 murine MM PC line, it was aimed to 
identify its protein binding partners in these cells by co-immunoprecipitation (co-IP) coupled 
with mass spectrometry. As an IP-capable antibody for Samsn1 was unavailable, 5TGM1 
cells expressing C-terminal HA-tagged Samsn1 were generated, enabling the IP of Samsn1 





Western blot in 5TGM1-Samsn1-HA cells at the predicted size of 43 kD, confirming 
successful overexpression of the tagged protein (Figure 4.1A). In addition, 46 kD and 36 kD 
proteins were also recognised by both anti-Samsn1 and anti-HA antibodies in the 5TGM1-
Samsn1-HA cells. The larger molecular species most likely corresponds to the 
phosphorylated form of Samsn1251,329, but the identity of the smaller species is unknown. To 
assess whether the addition of a HA-tag disrupted the tumour suppressor effect of Samsn1 
on 5TGM1 cells in vivo, the 5TGM1-Samsn1-HA and 5TGM1-EV cell lines were injected 
i.v. into C57BL/KaLwRij mice and tumour development was monitored for 4 weeks. At the 
endpoint, there was a significant decrease in tumour burden for the mice inoculated with 
5TGM1-Samsn1-HA cells compared to EV control 5TGM1 cells, as measured by BLI (P = 
0.0079, Mann-Whitney U test; Figure 4.1B) and SPEP (P = 0.0079, Mann-Whitney U test; 
Figure 4.1C). These data demonstrated that adding a C-terminal HA-tag to Samsn1 in 
5TGM1 cells does not interfere with its previously observed ability to completely inhibit 
MM tumour development in vivo.  
 
To identify proteins associated with Samsn1 in 5TGM1 cells, 5TGM1-Samsn1-HA and 
5TGM1-EV control cells were lysed with a buffer containing 1% NP-40 and co-IPs were 
performed using an anti-HA antibody. The isolated proteins were separated into two 
fractions and resolved separately by SDS- PAGE. The smaller fraction was transferred onto 
a membrane and the successful IP of HA-tagged Samsn1 was confirmed by Western blot 
(Figure 4.2A). Gel staining of proteins from the larger co-IP fraction revealed bands 
corresponding to the size of Samsn1 and several other bands representing co-IPed proteins 
of different sizes (Figure 4.2B). However, there were no bands that were present in the co-
IP from the 5TGM1-Samsn1-HA cells but absent in the negative control co-IP from the 
5TGM1-EV cells. This indicated that the co-IPed proteins did not represent genuine binding 
partners of Samsn1 but rather non-specific background. With the aim of trying to better 
preserve the interactions between Samsn1 and its binding partners, the co-IP was repeated 
using a lysis buffer containing 1% CHAPS, which is a detergent with lower stringency than 
NP-40. However, no co-IPed proteins that were unique to the 5TGM1-Samsn1 cells, and 
thus potential Samsn1 interactors, were observed on the gel, which negated the use of mass 
spectrometry to identify them (Figure 4.2C). Overall, proteins representing putative binding 








Figure 4.1: HA-tagged Samsn1 significantly inhibits the growth of 5TGM1 cells in vivo. 
(A) Protein lysates from 5TGM1-Samsn1-HA and 5TGM1-EV cells were subjected to 
Western blotting using anti-HA and anti-Samsn1 antibodies. Hsp90 was used as a loading 
control. (B&C) KaLwRij mice were injected i.v. with 5 × 105 5TGM1-EV or 5TGM1-
Samsn1-HA cells. At 4 weeks, tumour burden was measured by BLI and SPEP. (B) Ventral 
BLI scans of the mice (left) and the total flux (right) are shown. (C) M-spikes (^) on the 
SPEP gel (left) and the M-spike intensity (right), normalised to albumin and expressed 
relative to the EV control, are shown. The graphs depict the mean + SEM of n = 5 mice per 












Figure 4.2: Identifying Samsn1 binding partners in 5TGM1 cells by co-IP. 5TGM1-
Samsn1-HA or 5TGM1-EV cells were lysed in buffer containing 1% NP-40 (A&B) or 1% 
CHAPS detergent (C) followed by co-IP using anti-HA antibody-conjugated agarose. (A) 
An equal amount of lysate from the Samsn1-HA cells pre-IP and post-IP, as well as 10% of 
the co-IPed proteins from the Samsn1-HA and EV 5TGM1 cells were resolved by SDS-
PAGE. The proteins were transferred to a membrane, which was probed with an anti-HA 
antibody. The remaining 90% of co-IPed proteins obtained using lysis buffer containing 
either NP-40 (B) or CHAPS (C) were resolved by SDS-PAGE and stained using SYPROTM 
Ruby. Images are representative of at least 2 independent experiments. * denotes bands 
corresponding to HA-tagged Samsn1. ^ denotes bands corresponding to immunoglobulin 







4.2.2 Samsn1 does not bind to, but reduces the phosphorylation of, Hs1 
in 5TGM1 cells 
Given that Samsn1 has been shown to interact with endogenous Hs1 in primary mouse B 
cells249, the possibility that these proteins are binding partners in 5TGM1 cells was assessed 
through co-IP coupled with Western blot. Co-IPs were performed on 5TGM1-Samsn1-HA 
and 5TGM1-EV cell lysates using an anti-HA antibody and the isolated proteins were 
subjected to Western blot using anti-HA and anti-Hs1 antibodies. Despite Samsn1 being 
successfully IPed, Hs1 was not detected in the co-IPed proteins from the 5TGM1-Samsn1-
HA cell lysates, suggesting that Hs1 is not a binding partner of Samsn1 in 5TGM1 cells 
under the conditions tested (Figure 4.3A). In addition, the effect of Samsn1 on the activation 
of Hs1 was assessed by comparing Hs1 phosphorylation in 5TGM1-Samsn1-HA cells and 
5TGM1-EV control cells by Western blot. Under basal culture conditions, the amount of 
Hs1 phosphorylation on the activating tyrosine residue Y397 was found to be significantly 
reduced in Samsn1-expressing 5TGM1 cells compared to EV control 5TGM1 cells (P = 
0.006, paired t test; Figure 4.3B). This finding suggests that Samsn1 may inhibit the activity 
of the actin cytoskeleton regulatory protein Hs1 in 5TGM1 cells.  
 
4.2.3 Samsn1 does not affect the migration, or adhesion to endothelium, 
of 5TGM1 cells in vitro 
Given that Samsn1 may limit the activation of Hs1, it was hypothesised that actin 
cytoskeletal remodelling may be inhibited in Samsn1-expressing 5TGM1 cells. This was 
assessed by measuring the induction of polymerised filamentous actin (F-actin) formation in 
5TGM1-Samsn1 cells following treatment with CXCL12, which is a potent chemoattractant 
that drives homing of both normal and malignant PC to the BM330. However, neither the 
positive control 5TGM1-EV cells, nor the 5TGM1-Samsn1 cells, formed F-actin in response 
to CXCL12 (P > 0.05, two-way ANOVA with Sidak's multiple comparisons test; Figure 
4.4A). This is despite the fact that 5TGM1 cells express the receptor for CXCL12, CXCR4, 
and that CXCL12 has been shown to potently induce actin polymerisation in other MM PC 
lines331-333. Although the results of the actin polymerisation assay were inconclusive, the 
effect of Samsn1 on cellular processes that require cytoskeletal rearrangement, and are 
involved in the BM homing of MM PC, were also investigated334. The impact of Samsn1 
expression on the migration of 5TGM1 cells was assessed by a 24-hour transwell assay using 
primary murine BM stromal cell-conditioned medium as the chemoattractant. As shown in 







Figure 4.3: Samsn1 does not bind to, but decreases the phosphorylation of, Hs1 in 
5TGM1 cells. (A) 5TGM1-Samsn1-HA or 5TGM1-EV cells were lysed in buffer containing 
1% NP40 and co-IP was performed using anti-HA antibody-conjugated agarose. The 
proteins isolated by IP, as well as an equal amount of lysate from both cell lines pre-IP and 
post-IP, were resolved by SDS-PAGE and transferred to a membrane, which was probed 
with anti-Hs1 and anti-HA antibodies. A representative blot of three independent 
experiments is shown. (B) Western blots were performed on protein lysates from 5TGM1-
Samsn1-HA and 5TGM1-EV cells using an anti-pHs1 (Y397) and an anti-Hs1 antibody. A 
representative blot (left) and the quantitated pHs1 band intensity (right) are shown. The pHs1 
intensity was normalised to total Hs1 and was expressed relative to the EV control. The 







Figure 4.4: Samsn1 does not affect the F-actin polymerisation, migration or adhesion 
to endothelium of 5TGM1 cells in vitro. (A) 5TGM1-Samsn1 and 5TGM1-EV cells were 
stimulated with 200 ng/mL CXCL12 for the indicated times. The cells were immediately 
fixed and then stained for F-actin using Alexa FluorTM 680 phalloidin, which was measured 
by flow cytometry. The MFI was normalised to baseline levels and expressed relative to the 
EV control. (B) Migration of 5TGM1-Samsn1 and 5TGM1-EV cells toward primary mouse 
BM stromal cell-conditioned medium was assessed in a 24-hour transwell assay. Results are 
expressed relative to the EV control cells. (C) 5TGM1-Samsn1 or 5TGM-EV cells were 
seeded on a BM endothelial cell monolayer, and percent cell adhesion, relative to total cell 
input, was assessed by BLI after 15 minutes. Results are expressed relative to the EV control 
cells. Graphs depict the mean + SEM of three (A), or six (B&C) independent experiments. 






this stimulus after 24 hours (P = 0.8565, paired t test). Furthermore, the adhesion of 5TGM1 
cells to BM endothelial cells was shown to not be affected by Samsn1 expression (P = 
0.1267, paired t test; Figure 4.4C). 
 
4.2.4 Samsn1 expression does not have a significant impact on the 
transcriptome of 5TGM1 cells 
In order to further investigate the potential mechanisms by which Samsn1 inhibits 5TGM1 
tumour development in vivo, the effect of Samsn1 expression on the transcriptome of 
5TGM1 cells was assessed using RNA-seq. Four independent RNA samples from cultured 
5TGM1-Samsn1 and 5TGM1-EV cells in the exponential growth phase were analysed. In 
excess of 44 million reads were obtained for each sample and ~70% were uniquely mapped 
to the GRCh38/mm10 version of the mouse genome (Table 4.1). Excluding the expression 
of Samsn1 itself, principal components analysis revealed that the Samsn1-expressing and 
EV control 5TGM1 cell samples did not cluster separately, which suggests that Samsn1 had 
a minimal impact on the transcriptome of 5TGM1 cells (Figure 4.5A). Consistent with this, 
differential gene expression analysis revealed only 18 genes, including Samsn1, that had 
significantly altered expression (FDR < 0.1) in the Samsn1-expressing compared to control 
5TGM1 cells (Table 4.2 and Figure 4.5B). Excluding Samsn1, ten of the differentially 
expressed genes were found to be up-regulated, and seven were found to be down-regulated 
in the 5TGM1-Samsn1 cells compared to the 5TGM1-EV cells. Notably, only five of the up-
regulated and three of the down-regulated genes in the 5TGM1-Samsn1 cells had a fold-
change greater than 1.5. Of these genes, increased Tex101 (P = 0.0176, paired t test) and 
decreased Negr1 (P = 0.0109, paired t test) mRNA expression in the 5TGM1-Samsn1 cells 
was confirmed by RT-qPCR (Figure 4.5C). To identify the potential biological significance 
of the Samsn1-correlated genes, gene ontology (GO) analysis was performed on the up-
regulated or down-regulated genes using the DAVID Bioinformatics Database. However, no 
GO terms were found to be significantly enriched in the small number of genes that were 
up-regulated or down-regulated in the 5TGM1-Samsn1 cells compared to the 5TGM1-EV 















Table 4.1: Raw, trimmed and uniquely mapped reads for each RNA-seq sample from 


















Figure 4.5: Differentially expressed genes in Samsn1-overexpressing 5TGM1 cells 
identified by RNA-Seq. (A) Principal components analysis of RNA-seq expression data 
from four biological replicates of 5TGM1-Samsn1 (S1-4) cells and 5TGM1-EV (E1-4) cells 
was performed, excluding Samsn1, and the multi-dimensional scaling plot is shown. (B) 
Heat map showing two-way hierarchical clustering of the 18 differentially expressed genes 
(rows) between 5TGM1-Samsn1 and 5TGM1-EV cells (columns). The coloured scale bar 
represents the log2-transformed copies per million (CPM). (C) The expression levels of 
Negr1 (left) and Tex101 (right) were analysed in 5TGM1-Samsn1 cells compared to 
5TGM1-EV cells by RT-qPCR. Levels were normalised to the housekeeping gene Actb and 
expressed relative to the EV cells. Graphs depict the mean ± SEM of n = 4 biological 















Table 4.2: Differentially expressed genes (FDR < 0.1) in Samsn1-expressing compared 
to EV control 5TGM1 cells identified by RNA-seq. 




Samsn1 67742 16.15 4.26 1.02E-10 
Gm773 331416 2.14 0.92 4.34E-05 
Tex101 56746 1.71 4.24 1.64E-04 
Cpz 242939 1.70 -0.62 3.60E-02 
Bpifb2 66557 0.71 0.47 6.75E-02 
Tex13b 83555 0.69 2.14 9.84E-03 
Ssc5d 269855 0.52 1.91 7.44E-02 
Bbs7 71492 0.31 5.78 2.43E-04 
Card11 108723 0.19 6.11 7.97E-03 
Rac1 19353 0.12 7.37 7.97E-02 
Eif3b 27979 0.12 8.24 3.50E-02 
Chpf2 100910 -0.16 5.70 7.55E-02 
Cd93 17064 -0.18 10.33 1.77E-03 
Il1rap 16180 -0.26 3.86 6.80E-02 
Ets1 23871 -0.34 2.93 7.63E-02 
Negr1 320840 -0.66 2.49 6.75E-02 
Ighg2c N/A -0.77 0.74 4.99E-02 
Gm5297 N/A -3.06 1.85 4.99E-02 
 
Positive fold-change (FC) indicates that the gene is up-regulated, and a negative FC indicates that the gene is 
down-regulated, in 5TGM-Samsn1 cells vs 5TGM1-EV cells. CPM = copies per million, FDR = false 






4.2.5 Samsn1 inhibits the metastasis of 5TGM1 cells in vivo 
Given that the protein interaction and mRNA transcriptome analyses were unable to reveal 
potential mechanisms by which Samsn1 suppresses 5TGM1 tumour growth, the effect of 
Samsn1 on the tumourigenic behaviour of 5TGM1 cells was further investigated in vivo. To 
determine the effect of Samsn1 on the growth of 5TGM1 cells in the BM without the 
prerequisite of tumour cells homing from the circulation, 5TGM1-Samsn1 or 5TGM1-EV 
cells (1 x 105) were injected directly into the left tibia of KaLwRij mice. After 23 days, the 
primary tumour burden in the injected leg was not found to significantly differ between the 
mice inoculated with 5TGM1-Samsn1 cells and mice inoculated with 5TGM1-EV cells, as 
determined by BLI (P = 0.5907, Mann-Whitney U test; Figure 4.6A). In addition, the 
formation of large primary tumours by both 5TGM1-Samsn1 and 5TGM1-EV cells was 
confirmed by performing immunohistochemical staining of GFP+ cells in sections from 
injected tibiae (Figure 4.6B).  
 
Notably, in some intratibially (i.t.)-inoculated mice, the BLI showed that 5TGM1 cells had 
metastasised from the injected leg and formed secondary tumours at distal sites. The 
metastatic tumour burden was significantly lower in the 5TGM1-Samsn1 group of mice 
compared to 5TGM1-EV group of mice, as measured by BLI (P = 0.0093, Mann-Whitney 
U test; Figure 4.7A). In addition, the percentage of GFP+ 5TGM1 tumour cells in the BM of 
the femur and tibia from the non-injected, contralateral leg was significantly lower in the 
5TGM1-Samsn1-inoculated mice compared to the 5TGM1-EV-inoculated mice (P = 
0.0140, Mann-Whitney U test; Figure 4.7B). Considering both the BLI and flow cytometry 
data, the incidence of metastasis was significantly lower in mice inoculated with 5TGM1-
Samsn1 cells (n = 1/7, 14.3%) compared to mice inoculated with 5TGM1-EV cells (n = 7/8, 
87.5%; P = 0.0101, Fisher’s exact test; Figure 4.7C). Together, these data suggest that 
Samsn1 does not affect the growth of primary tumours following i.t. injection of 5TGM1 
cells into KaLwRij mice, but it significantly inhibits the subsequent metastasis of MM PC 
from these primary tumours. 
 
4.2.6 Samsn1 expression in 5TGM1 cells does not affect homing to, but 
inhibits expansion within, the BM in vivo 
Given that Samsn1 was found to inhibit the metastasis of 5TGM1 cells from primary 
tumours, it was hypothesised that Samsn1 suppresses the homing of MM PC to the BM. To 








Figure 4.6: Samsn1 does not affect the growth of primary tumours following i.t. 
injection of 5TGM1 cells in vivo. (A&B) 5TGM1-Samsn1 (Samsn1) or 5TGM1-EV (EV) 
cells      (1 x 105) were injected into the left tibia of KaLwRij mice and tumour burden was 
measured by BLI. (A) Ventral BLI scans of mice injected with 5TGM1-EV (above) or 
5TGM1-Samsn1 (below) cells (left) and the quantitated total flux of the injected leg (right) 
after 23 days are shown. Graph depicts the mean ± SEM of n=7-8 mice per cell line from 
two independent experiments. P > 0.05, Mann-Whitney U test. (B) Paraffin-embedded 
sections of the 5TGM1-injected tibiae were stained with H&E (left) or an anti-GFP antibody 
(right). Representative images of stained sections from a mouse injected with 5TGM1-EV 
(above) or 5TGM1-Samsn1 (below) cells (left panel) are shown. Images were taken at the 










Figure 4.7: Samsn1 inhibits the metastasis of 5TGM1 cells in vivo. (A-C) 5TGM1-
Samsn1 or 5TGM1-EV cells (1 x 105) were injected into the left tibia of KaLwRij mice and 
tumour burden was measured by BLI. (A) BLI scans of the contralateral side (injected leg 
covered) of the mice inoculated with EV (above) or Samsn1-expressing (below) 5TGM1 
cells (left) and the quantitated total flux (right) after 23 days are shown. (B) The number of 
GFP+ tumour cells in the BM from the non-injected, contralateral leg was assessed by flow 
cytometry after 23 days. (C) The number of mice injected i.t. with 5TGM1-EV or       
5TGM1-Samsn1 cells with overt metastasis, defined as visible BLI signal outside the 
injected leg and/or greater than 200 tumour cells per million in the BM of the contralateral 
leg by flow cytometry. Results were normalised to primary tumour burden and graphs depict 
the mean ± SEM of n = 7-8 mice per cell line from two independent experiments. *P < 0.05, 





KaLwRij mice and the number of GFP+ tumour cells present in the BM after 24 hours was 
assessed by flow cytometry. Notably, Samsn1 expression was found to not affect the number 
of 5TGM1 cells present in the long bones of the mice 24 hours post-tumour cell injection   
(P = 0.8182, Mann-Whitney U test; Figure 4.8). To determine the fate of the 5TGM1-
Samsn1 cells that successfully homed to the BM, the experiment was repeated, but the 
number of tumour cells in the long bones of the mice was assessed after 21 days. While the 
numbers of 5TGM1-EV cells in the BM expanded over time, the numbers of 5TGM1-
Samsn1 cells did not significantly differ between day 1 and 21 post-tumour cell injection   
(P < 0.0001, two-way ANOVA with Sidak’s multiple comparison test; Figure 4.8). These 
data suggest that while Samsn1 does not inhibit the homing of 5TGM1 cells to the BM, it 
does inhibit the outgrowth of disseminated MM PC within the BM microenvironment. 
 
4.3 Discussion 
It has previously been shown that SAMSN1 displays significantly lower expression in PCs 
from MM patients compared to healthy controls and that low SAMSN1 expression in the PCs 
of MM patients confers a poor prognosis260,261. In addition, Samsn1 was found to be deleted 
in the MM-prone KaLwRij mouse strain and its re-expression in the KaLwRij-derived 
5TGM1 MM PC line completely inhibited MM disease development in vivo260. These 
findings suggest that SAMSN1 may have a tumour suppressor role in the development 
and/or progression of MM. Although SAMSN1 has been implicated as a tumour suppressor 
in other cancers, the mechanism(s) by which it inhibits malignancy remains to be 
determined271-274. In this study, how SAMSN1 inhibits MM PC tumour development was 
investigated through unbiased molecular analyses coupled with in vitro and in vivo assays 
using Samsn1-expressing 5TGM1 cells. 
 
Given that PC are not circulatory, the fact that most MM patients have multiple tumours 
throughout their skeleton at diagnosis indicates that there is a continuous spread of tumour 
cells within the body335. This metastasis plays a crucial role in the development of 
symptomatic MM and disease progression, including the re-population of the BM with 
treatment-resistant clones during relapse335. In this study, the expression of Samsn1 in 
5TGM1 cells was found to significantly reduce the metastasis from primary i.t. tumours to 
distal BM sites in vivo. A vital step in the process of metastasis in MM is the active 
migration/homing of circulating tumour cells to new BM sites335. A previous study 

















Figure 4.8: Samsn1 does not affect the BM homing, but does inhibit the expansion, of 
5TGM1 cells in vivo. (A&B) KaLwRij mice were injected with 5 x 106 5TGM1-Samsn1 or 
5TGM1-EV cells i.v. and the number of GFP+ tumour cells in the long bones was determined 
by flow cytometry after 1 or 21 days. (A) Representative flow plots of GFP+ cells in the BM 
of mice inoculated with 5TGM1-EV (left) or 5TGM1-Samsn1 (right) cells after 1 day 
(above) or 21 days (below) are shown. (B) Graph shows the number of GFP+ tumour cells 
per million BM cells present in the long bones of mice injected with 5TGM1-EV or 5TGM1-
Samsn1 cells after 1 and 21 days. Graph depicts the mean ± SEM of n=5-6 mice per cell line 
at each time point from one (21 days) or two (1 day) independent experiments. ****P < 












for cell migration249. In addition, the closely related protein SASH1 has been shown to 
regulate actin cytoskeletal dynamics258 and inhibit the adhesion, migration and invasion of 
several epithelial cancer cell types277,280,281. The ability of Samsn1 to affect cytoskeletal 
dynamics was linked to its demonstrated interaction with Hs1249, which is activated by 
phosphorylation on key tyrosine residues and mediates actin polymerisation within, and the 
subsequent migration of, normal lymphocytes336-340. Notably, increased Hs1 
phosphorylation in malignant chronic lymphocytic leukemia B cells correlated with 
increased polymerised F-actin and migration of malignant cells in vitro341 and with enhanced 
BM homing in vivo342. Although a direct interaction between Hs1 and Samsn1 in 5TGM1 
cells was not detected, the levels of Hs1 phosphorylated on the activating Y397 residue were 
reduced in Samsn1-expressing cells. Hence, it was hypothesised that Samsn1 may suppress 
the activation of Hs1 within, and thus the migration of, 5TGM1 cells. However, the Samsn1-
expressing 5TGM1 cells showed neither decreased migration in vitro nor decreased BM 
homing in vivo. Together, these data suggest that the anti-metastatic effect of Samsn1 in vivo 
is unlikely to be attributable to a reduction in the number of MM PC that can migrate to the 
BM.   
 
Following homing of disseminated tumour cells to the BM, metastasis also involves 
colonisation, the expansion of solitary or small clusters of cancer cells into macroscopic 
tumours335. In this study, Samsn1 was found to suppress the colonisation of 5TGM1 cells 
when relatively small numbers were seeding the BM from the circulation, as occurred 
following i.v. injection or migration from a primary i.t. tumour. However, Samsn1 did not 
suppress the outgrowth of 5TGM1 cells when much larger numbers were introduced directly 
into the medullary cavity by i.t. injection. The interaction between 5TGM1 cells and the 
normal cells/factors within the BM microenvironment was greater when fewer tumour cells 
were present. Hence, these findings suggest that the ability of Samsn1 to inhibit the 
expansion of 5TGM1 cells within the BM is dependent on tumour-inhibitory signals derived 
from the microenvironment. This is consistent with our previous finding that Samsn1 
reduced the proliferation of 5TGM1 cells specifically when they were co-cultured with 
normal primary BM stromal cells260 
 
Interactions with the BM microenvironment are known to play an important role in 
regulating the growth, survival and drug resistance of MM PCs116. While interactions 





stage325, there is growing evidence that the normal BM microenvironment can also play an 
important role in restricting disease progression at the premalignant disease stage343. For 
example, exosomes derived from normal BM mesenchymal stromal cells were found to 
inhibit myeloma cell growth, whereas exosomes from MM stroma had a tumour-promoting 
effect344. In addition, a recent study demonstrated that PCs taken from MGUS patients with 
stable disease grow progressively in the BM of humanised mice, suggesting that MM disease 
progression is constrained by extrinsic signals from the BM microenvironment233.  
 
The ability of the BM microenvironment to influence the growth of MM PC has previously 
been demonstrated in the 5TGM1/KaLwRij murine model of MM. Recent studies from our 
group have shown that the majority of 5TGM1 cells that home to the BM localise to the 
osteoblast-lined endosteal surface and are maintained in a state of long-term dormancy, with 
only a few MM PCs undergoing clonal expansion and contributing to tumour burden345,346. 
However, the dormant state was found to be reversible upon re-injection of quiescent 
5TGM1 cells into naïve KaLwRij mice, suggesting that PC-extrinsic, not PC intrinsic, 
factors regulate the proliferative fate of MM PC in vivo345. Exposure to osteoblast-
conditioned medium was shown to reduce 5TGM1 cell proliferation and co-culture with the 
MC3T3 osteoblast-like cell line increased the rates of 5TGM1 cell dormancy in vitro345. In 
addition, the proliferation of primary patient MM PCs was previously found to be reduced 
when the tumour cells were co-cultured with primary osteoblasts in vitro347. These data 
suggest that osteoblastic lineage cells may play a key role in regulating the proliferation of 
MM PCs in the BM microenvironment through the production of as yet unidentified soluble 
factors. The fact that these studies were performed with Samsn1-/- 5TGM1 cells suggests that 
Samsn1 is not required per se for the establishment of MM PC dormancy. However, Samsn1 
may promote the quiescence of disseminated 5TGM1 cells by enhancing their response to 
osteoblast-derived anti-proliferative signals. Hence, future investigation of the effect of 
Samsn1 on the proliferation of 5TGM1 cells in the presence of osteoblasts is warranted.  
 
The BM microenvironment-derived signals that promote dormancy in MM PCs are poorly 
defined, but several factors that regulate haematopoietic stem cell dormancy have been found 
to induce quiescence in cancer cell types that metastasise to bone348. In prostate cancer and 
head and neck squamous cell carcinoma, osteoblast-derived transforming growth factor-β2 
(TGFβ2) was found to promote dormancy of disseminated tumour cells in the BM349,350. 





receptor III (TGFβRIII), which causes cell cycle arrest through the activation of p38 
mitogen-activated protein kinase and cyclin dependent kinase inhibitor p27349,350. In 
addition, the related ligand bone morphogenetic protein 7 (BMP7) was found to induce 
prostate cancer cell dormancy in the BM through a similar mechanism involving p38 
activation351. Notably, BMP7 has previously been demonstrated to inhibit the proliferation 
and promote the apoptosis of MM PCs352. Given that Samsn1 is a putative adaptor protein, 
it is hypothesised that Samsn1 may promote MM PC quiescence in the BM through 
positively regulating the intracellular signalling cascades that occur in response to 
microenvironment-derived anti-proliferative signals. Hence, examination of TGFβ2 and 
BMP7 as potential stimulators of MM PC dormancy, and the modulating effect of Samsn1 
on their activity, is warranted.  
 
Previous transcriptomic analysis of dormant versus proliferative 5TGM1 cells revealed that 
the expression of Axl, which encodes a receptor of the growth-arrest specific 6 (GAS6) 
ligand, was increased in dormant MM PCs345. Given that Axl has been shown to promote 
cellular dormancy of prostate cancer cells in the BM, it was hypothesised that it may also 
have a similar function in 5TGM1 cells353-356. Axl, or other known dormancy-associated 
genes, were not among the small number of only 17 genes, excluding Samsn1, that were 
found to be differentially expressed in Samsn1-expressing 5TGM1 cells in culture. The 
minimal effect of Samsn1 on the transcriptome of 5TGM1 cells suggests that it is more likely 
to exert its tumour suppressor effect, including potentially promoting MM PC dormancy, at 
a post-transcriptional level. However, if the tumour suppressor effect of Samsn1 is 
dependent on the interaction of 5TGM1 cells with the BM microenvironment, performing 
RNA-seq on 5TGM1-Samsn1 cells either co-cultured with BM stroma or pooled from the 
BM of KaLwRij mice may reveal additional gene expression changes that contribute to the 
anti-proliferative effect of Samsn1 in vivo.  
 
Further insight into the means by which Samsn1 expression may potentiate anti-colonisation 
signals from the BM microenvironment could be gained through identifying the interaction 
partners of this putative cytoplasmic adaptor protein in MM PCs. In the present study, 
despite the successful IP of HA-tagged Samsn1 from 5TGM1 cells, no proteins were found 
to co-IP specifically with Samsn1 under the conditions tested. Although several potential 
Samsn1-interacting proteins have been identified in other cellular contexts, other than Hs1, 





SAMSN1 appeared to bind very few endogenous proteins in a human B lymphoma cell line 
under basal conditions, but BCR stimulation induced interactions between SAMSN1 and 
several tyrosine-phosphorylated proteins241. This suggests that specific assay conditions 
and/or stimuli, such as co-culture with BM stroma, may be required to induce binding 
between Samsn1 and its key partners in 5TGM1 cells. It is also possible that Samsn1-
interacting proteins did not co-IP because their interactions in 5TGM1 cells are relatively 
weak and/or transient. In order to preserve these interactions, chemical cross-linking of 
proteins within 5TGM1 cells prior to co-IP could be utilised in future studies of the Samsn1 
interactome in MM PCs. In addition, given that there is evidence that phosphorylation of 
one protein (Hs1) is altered by Samsn1, a phosphoproteomic analysis of 5TGM1-Samsn1 
versus 5TGM1-EV cells using Stable Isotope Labelling by Amino acids in Cell culture 
(SILAC)-based mass spectrometry could reveal other proteins, and thus signalling pathways, 
that are modulated by Samsn1 in MM PCs. 
 
In summary, Samsn1 expression in 5TGM1 cells was shown to not affect the 
migration/homing of tumour cells to the BM in vitro and in mice. Notably, Samsn1 was 
found to specifically inhibit BM colonisation by small numbers of disseminated, not large 
numbers of directly injected, 5TGM1 cells in vivo. This suggests that Samsn1 may 
completely inhibit tumour growth in KaLwRij mice by promoting the effect of anti-
proliferative signals derived from the BM microenvironment on 5TGM1 cells. Further 
studies of the possible source and type of BM-derived anti-tumour factors that may be 
enhanced by Samsn1, and the PC-intrinsic molecular mechanism(s) by which this is 
achieved, are warranted. Such investigations have the potential to build on our increasing 
understanding of the important role played by the BM microenvironment in regulating the 
transition from MGUS to MM. This knowledge may aid in the rational design of therapies 
that modulate the interaction between clonal PCs and the BM microenvironment, which 
could not only enhance the effectiveness of the current treatments for MM patients but also 












5 INVESTIGATING THE POTENTIAL 
TUMOUR SUPPRESSOR ROLE OF 








Multiple myeloma (MM) is the second most common haematological malignancy in adults 
and is characterised by the clonal expansion of malignant plasma cells (PCs) within the bone 
marrow (BM)1. Despite recent improvements in the survival of MM patients due to the 
introduction of novel therapies, relapse is inevitable and MM remains an incurable 
disease357. MM is invariably preceded by an asymptomatic precursor disease, monoclonal 
gammopathy of undetermined significance (MGUS), which carries a 1% risk of progressing 
to symptomatic disease per year22. The aetiology of MM is complex, with genetic studies 
revealing an array of different DNA mutations, copy number alterations and epigenetic 
changes present in the PCs of patients146. Despite this variation in PC-intrinsic factors, all 
MM PCs are, at least initially, dependent on interactions with the BM microenvironment to 
support their growth and survival358. Several studies have found that the transition from 
MGUS to MM is not accompanied by the acquisition of additional mutations226,228,230,232 and 
clonal PCs from MGUS patients have the capacity to grow progressively in humanised 
mice233. These findings suggest that changes to PC-extrinsic factors in the BM 
microenvironment are likely to play an important role in driving the progression from MGUS 
to MM. Hence, treatments targeting microenvironmental alterations may be able to promote 
long-term MM disease control, and even prevent disease progression from the MGUS stage, 
irrespective of the genetic background of the PCs. However, in order to rationally design 
such therapies, an improved understanding of the dysregulated neoplastic PC-BM 
microenvironment interactions that promote MM disease progression is required.  
 
Given the known importance of the BM microenvironment in regulating the growth, survival 
and drug resistance of MM PCs325, murine models of MM are crucial for improving our 
understanding of disease pathogenesis and for pre-clinical testing of novel therapies. 
Xenograft models of MM are established through the injection of human myeloma cell lines 
(HMCLs) into immune compromised mice269. Previously non-obese diabetic and severe 
combined immune deficiency (NOD SCID) mice, which lack B and T cells and have reduced 
natural killer (NK) cell function, were used extensively for this purpose359. However, NOD 
SCID gamma (NSG) mice, which lack B, T and NK cell activity, have since been shown to 
enable enhanced HMCL engraftment360,361. There are various routes by which NSG mice 
can be inoculated with HMCLs, including sub-cutaneous or intraperitoneal injection. 
However, these methods of inoculation result in extramedullary tumour growth, which does 





microenvironment362. Alternatively, i.v. administration of HMCLs into NSG mice results in 
disseminated disease within the BM, but prior irradiation of the mice is required to promote 
successful MM PC engraftment359. In contrast, intratibial (i.t.) injection of HMCLs has been 
shown to result in efficient primary tumour engraftment and metastatic tumour formation in 
non-irradiated NSG mice363. Furthermore, there is the SCID-hu model in which HMCLs are 
grown in human fetal bone tissue implanted into irradiated immunodeficient mice269,364. 
While this model enables HMCLs to be grown in a human BM microenvironment, it does 
not recreate the composition of adult BM, and its use is limited by the availability and ethical 
concerns associated with the use of human fetal tissue269.  
 
The Samsn1 gene was found to be homozygously deleted in the C57BL/KaLwRij (KaLwRij) 
mouse strain260,261. Both KaLwRij and closely-related wildtype (WT) C57BL/6 mice are 
prone to developing an MGUS-like benign PC expansion, but only KaLwRij mice can 
develop an MM-like malignancy (0.5% in mice over two years old)264. Notably, re-
expression of Samsn1 in the KaLwRij-derived 5TGM1 MM PC line completely inhibited 
tumour development following i.v. inoculation into syngeneic KaLwRij mice260. These 
findings suggest that Samsn1 is a tumour suppressor in the context of murine MM. Our group 
previously showed that 5TGM1-Samsn1 cells have reduced proliferation compared to 
control 5TGM1 cells when co-cultured with BM stromal cells in vitro260. In addition, in the 
previous chapter, Samsn1 was found to suppress the outgrowth of disseminated 5TGM1 
cells in the BM of KaLwRij mice. Collectively, these observations suggest that Samsn1 acts 
as a tumour suppressor gene in the 5TGM1/KaLwRij model of murine MM by promoting 
extrinsic regulation of malignant PC growth by the BM stroma. However, the underlying 
molecular mechanism by which Samsn1 promotes PC-extrinsic inhibition of BM 
colonisation by 5TGM1 MM PC remains to be determined.  
 
In relation to human MM, SAMSN1 expression was found to be significantly reduced in PCs 
from MM patients compared to MGUS patients and normal controls, with ~25% of MM 
patients having SAMSN1 expression below the normal range260,261. In addition, reduced 
SAMSN1 expression was found to be significantly associated with increased PC burden and 
reduced overall survival of MM patients260. These data are consistent with SAMSN1 also 
potentially having a tumour suppressor role in the context of human MM. However, the only 
previous report of the functional effect of SAMSN1 on human MM PCs was the finding that 





vitro260. Hence, it remains unclear whether SAMSN1 also promotes tumour suppression in 
human MM PCs and whether this occurs through a mechanism that is dependent on the BM 
microenvironment. In this chapter, the aim was to investigate the potential tumour 
suppressor function of SAMSN1 in HMCLs using in vitro assays and an i.t./NSG mouse 
model of MM.  
 
5.2 Results 
5.2.1 Generation of HMCLs with stable knockdown of SAMSN1 using 
CRISPR-Cas9 
To determine if SAMSN1 has a tumour suppressor role in human MM PCs, the aim was to 
generate HMCLs with reduced SAMSN1 protein levels using CRISPR-Cas9 genome 
editing, which would replicate the down-regulation of SAMSN1 expression observed in the 
PCs from some MM patients260. The RPMI-8226 and JJN3 HMCLs were selected for 
SAMSN1 knockdown (KD) because they were found to have relatively high SAMSN1 
mRNA expression compared to other HMCLs by examination of a publicly available RNA-
seq dataset (http://www.keatslab.org/data-repository). These HMCLs were transduced with 
lentiviral vectors encoding Cas9 and one of two doxycycline-inducible guide RNAs 
(gRNAs) targeting exon 4 of SAMSN1 or an empty vector (EV) control (Figure 5.1A). Exon 
4 was selected because it is the first exon that is common to all SAMSN1 mRNA transcripts 
and is upstream of the exons that encode the key SAM and SH3 domains of the protein. 
Following doxycycline treatment of Cas9-expressing HMCLs transduced with either a 
gRNA-containing or empty vector, the resultant cell populations were analysed for the 
presence of indels in exon 4 of SAMSN1 through a heteroduplex mobility assay. 
Heteroduplex formation by SAMSN1 exon 4 PCR products was observed in the RPMI-8226 
and JJN3 cells expressing gRNA #1 or gRNA #2, but not the EV control, which indicated 
that indels were successfully generated in at least a proportion of SAMSN1 alleles in the 
SAMSN1-KD HMCLs (Figure 5.1B). To determine the effect of CRISPR-Cas9-mediatd 
DNA editing on the levels of SAMSN1 protein in the HMCLs, a Western blot was performed 
using lysates prepared from SAMSN1-KD and control RPMI-8226 and JJN3 cells. The 
expression of gRNA #1 was shown to reduce the levels of SAMSN1 protein by an average 
of 84% and 78% in the RPMI-8226 and JJN3 cells, respectively, compared to the EV 
controls (Figure 5.1C). Furthermore, the expression of gRNA #2 produced even greater 
knockdown of SAMSN1 protein levels, with a reduction of 92% observed for both HMCLs. 











Figure 5.1: Generation of HMCLs with SAMSN1 knockdown by CRISPR-Cas9 
genome editing. (A) Schematic for CRISPR-Cas9 targeting of SAMSN1 using doxycycline 
(dox)-inducible guide RNA (gRNA) lentiviral vectors. RPMI-8226 and JJN3 human 
myeloma cell lines (HMCLs) stably and constitutively expressing Cas9 were generated by 
lentiviral transduction with a mCherry-tagged expression vector. These cells were then 
transduced with a lentiviral, dox-inducible gRNA and GFP expression vector encoding one 
of two gRNAs (#1 and #2) targeting exon 4 of SAMSN1 or an empty vector (EV) control. 
The GFP+ cells were treated with dox for 72 hours to induce transient expression of the 
gRNAs, which direct Cas9-mediated indel formation in SAMSN1 exon 4. In turn, this causes 
knockdown (KD) of SAMSN1 (S) protein levels and thus the resultant HMCLs are denoted 
as SAMSN1-KD #1 or SAMSN1-KD #2, depending on the gRNA that was expressed. (B) 
DNA was extracted from the SAMSN1-KD #1, SAMSN1-KD #2 and EV RPMI-8226 and 
JJN3 cells and the SAMSN1 exon 4 region was amplified by PCR. The products were then 
analysed for the presence of indels using a heteroduplex mobility assay. Images of GelRed®-
stained polyacrylamide gels (6%) showing separation of homoduplex and heteroduplex PCR 
products for the RPMI-8226 (left) and JJN3 (right) HMCLs are shown. Small and large 
square brackets indicate homoduplex and heteroduplex bands, respectively. (C) 
Representative Western blots for SAMSN1 in whole cell lysates from CRISPR-Cas9-
targeted or control RPMI-8226 (left) and JJN3 (right) HMCLs from two independent 
experiments are shown. HSP90 was used as the loading control. The quantified densities of 
the SAMSN1 protein bands, which were normalised to HSP90 and expressed relative to the 











5.2.2 Reduced SAMSN1 does not affect the proliferation or migration of 
HMCLs in vitro 
To determine whether reduced levels of SAMSN1 affect the growth of HMCLs, the 
proliferation of RPMI-8226 and JJN3 cells with SAMSN1 KD compared to EV control cells 
was assessed using a WST-1 assay. Over 3 days, the basal proliferation of both the 
SAMSN1-KD RPMI-8226 and JJN3 cell lines was not significantly different to that of the 
EV control cell lines (P > 0.05, two-way ANOVA with Sidak’s multiple comparisons test; 
Figure 5.2A). The effect of SAMSN1 KD on the migration of HMCLs was also assessed by 
a transendothelial assay using 20% FCS or 100 ng/mL CXCL12 as the chemoattractant. The 
migration of the SAMSN1-KD #1 and SAMSN1-KD #2 RPMI-8226 and JJN3 cell lines did 
not significantly differ from the EV cell lines in response to either stimulus tested (P > 0.05, 
one-way ANOVA with Tukey’s multiple comparisons test; Figure 5.2B). Together, these 
data suggest that SAMSN1 KD does not affect the proliferation or migration of HMCLs in 
vitro.  
 
5.2.3 Reduced SAMSN1 does not affect the growth or metastasis of 
HMCLs in vivo 
To assess the effect of reduced SAMSN1 on the growth of HMCLs in vivo, SAMSN1 KD 
(SAMSN1-KD #2) or EV control RPMI-8226 and JJN3 cells were injected directly into the 
left tibia of immunodeficient NSG mice. As these HMCLs do not express luciferase, primary 
and metastatic tumour burden were not able to be assessed non-invasively by BLI. Instead, 
they were measured by flow cytometric detection of GFP+ tumour cells in the BM of the 
injected tibia and the contralateral femur and tibia, respectively, at the experimental 
endpoint. The endpoint was determined by the first signs of morbidity in the mice, which for 
the RPMI-8226 and JJN3 xenograft models was 5 and 3 weeks, respectively. There was no 
difference between the primary tumour burden within the injected tibiae of mice inoculated 
with SAMSN1-KD cells compared to the EV control cells for either the RPMI-8226 or JJN3 
HMCLs (P > 0.05, Mann Whitney U test; Figure 5.3A), although the number of animals per 
group was small and the variation was high in some groups. In addition, reduced SAMSN1 
expression did not affect the number of metastatic RPMI-8226 or JJN3 tumour cells in the 
BM of the non-injected leg of the mice (P > 0.05, Mann Whitney U test; Figure 5.3B).These 
findings suggest that SAMSN1 KD in HMCLs does not affect their ability to form primary 







Figure 5.2: Knockdown of SAMSN1 does not affect the proliferation or migration of 
HMCLs in vitro. (A) The proliferation of SAMSN1-knockdown (KD) and EV control 
RPMI-8226 (left) and JJN3 (right) cells was measured over 3 days by a WST-1 assay. 
Results were expressed as fold-change in absorbance (450nm), normalised to day 0. (B) 
Migration of SAMSN1-KD #1, SAMSN1-KD #2 and control RPMI-8226 (left) and JJN3 
(right) cells towards either 20% FCS (above) or 100 ng/mL CXCL12 (below) was assessed 
by a 20-hour transendothelial assay. Results are expressed relative to the EV control cells. 
Graphs depict the mean + SD of three or more independent experiments. P > 0.05, two-way 
ANOVA with Sidak’s multiple comparisons test (A) or one-way ANOVA with Tukey’s 










Figure 5.3: SAMSN1 knockdown does not affect the primary or metastatic tumour 
growth of HMCLs in vivo. (A&B) SAMSN1-KD #2 or EV control RPM1-8226 and JJN3 
HMCLs were injected (5 x 105 cells/inoculum) into the left tibia of NSG mice. Tumours 
were allowed to develop in mice inoculated with RPM1-8226 or JJN3 HMCLs over 5 or 3 
weeks, respectively. (A) The percentage of GFP+ SAMSN1-KD and EV RPM1-8226 (left) 
or JJN3 (right) cells in the BM of the injected tibia was determined by flow cytometry at the 
experimental endpoint. (B) The percentage of GFP+ SAMSN1-KD and EV RPM1-8226 
(left) or JJN3 (right) cells in the BM of the non-injected, contralateral femur and tibia was 
determined by flow cytometry at the experimental endpoint. Results were normalised to 
primary tumour burden. Graphs depict the mean ± SEM of n = 4-5 mice per cell line from 






5.2.4 Overexpression of SAMSN1 does not affect the proliferation of 
HMCLs in vitro 
In order to closely replicate our previous experiments using a Samsn1-overexpressing 
murine 5TGM1 MM PC line (Chapter 4), the aim was to generate SAMSN1-overexpressing 
HMCLs. The LP-1 and OPM2 HMCLs were selected for SAMSN1 overexpression studies, 
as examination of the aforementioned HMCL RNA-seq dataset revealed that they have 
relatively low SAMSN1 mRNA expression compared to other HMCLs. Using retroviral 
transduction, the LP-1 and OPM2 HMCLs were transduced with a SAMSN1 expression 
vector or an empty vector control. Overexpression of SAMSN1 was confirmed in the LP-
1/OPM2-SAMSN1 cells compared to the EV control cells by both RT-qPCR (P < 0.0001, 
two-way ANOVA with Tukey’s multiple comparisons test; Figure 5.4A) and Western blot 
(Figure 5.4B). The effect of SAMSN1 overexpression on the growth of LP-1 and OPM2 
HMCLs in vitro was determined using a WST-1 assay. Over 3 days, the overexpression of 
SAMSN1 was not found to affect the proliferation of LP-1 or OPM2 cells (P > 0.05, two-
way ANOVA with Tukey’s multiple comparisons test; Figure 5.4C). 
 
5.2.5 Overexpression of SAMSN1 does not affect the growth of HMCLs 
in vivo 
To determine whether SAMSN1 overexpression in HMCLs affects primary and/or 
metastatic tumour growth in vivo, SAMSN1-overexpressing or EV control LP-1 and OPM2 
cells were directly injected into the left tibia of NSG mice. The humane endpoint for the   
LP-1 and OPM2 cell i.t. xenografts was 8 and 3 weeks, respectively. For LP-1 cells, 
SAMSN1 overexpression did not significantly affect tumour burden either in the injected 
tibia (P = 0.0667, Mann Whitney U test; Figure 5.5A), or the non-injected leg (P = 0.5273, 
Mann Whitney U test; Figure 5.5B). However, the LP-1 cell line was only weakly metastatic, 
which is consistent with the previous report that LP-1 cells do not migrate in vitro333. In 
contrast, OPM2 cells were found to be highly metastatic, but neither the primary (P = 0.2319, 
Mann Whitney U test; Figure 5.5A) nor metastatic (P = 0.3969, Mann Whitney U test; Figure 
5.5B) tumour burden was found to differ between the mice injected with the OPM2-
SAMSN1 cells and those injected with the OPM2-EV control cells. Together, these data 
suggest that SAMSN1 overexpression in HMCLs does not affect the growth of primary i.t. 











Figure 5.4: SAMSN1 overexpression does not affect the proliferation of HMCLs in 
vitro. (A) The expression of SAMSN1 mRNA was assessed in LP-1 and OPM2 HMCLs 
transduced with a SAMSN1 expression vector or a control empty vector (EV) by RT-qPCR. 
Expression values were normalised to B2M mRNA levels and expressed relative to the       
LP-1-EV cells. (B) The levels of SAMSN1 protein were assessed in LP-1 and OPM2 
HMCLs transduced with a SAMSN1 expression vector or a control EV by Western blot. 
ACTB was used as the loading control. (C) The proliferation of SAMSN1-overexpressing 
versus EV LP-1 (left) and OPM2 (right) cells was measured over 3 days by a WST-1 assay. 
Results were expressed as fold-change in absorbance (450nm) normalised to day 0. Graphs 
depict the mean ± SD of triplicates (A) or biological replicates from three independent 











Figure 5.5: SAMSN1 overexpression in HMCLs does not affect primary or metastatic 
tumour burden in vivo. (A&B) SAMSN1-overexpressing (SAMSN1) or empty vector (EV) 
control LP-1 and OPM2 cells were injected (5 x 105 cells/inoculum) into the left tibia of 
NSG mice and disease was allowed to develop over 8 or 3 weeks, respectively. (A) The 
percentage of GFP+ SAMSN1 and EV LP-1 (left) or OPM2 (right) cells in the BM of the 
injected tibia was determined by flow cytometry at the experimental endpoint. (B) The 
percentage of GFP+ SAMSN1 and EV LP-1 (left) or OPM2 (right) cells in the BM of the 
non-injected, contralateral femur and tibia was determined by flow cytometry at the 
experimental endpoint. Results were normalised to primary tumour burden. Graphs depict 
the mean ± SEM of n = 4-8 mice per cell line from two independent experiments. P > 0.05, 






5.2.6 Samsn1 expression does not affect 5TGM1 tumour growth in NSG 
mice 
SAMSN1 overexpression in HMCLs did not significantly inhibit metastasis following i.t. 
injection of tumour cells in vivo, which contrasts with the significant suppression of 
metastasis caused by Samsn1 re-expression in the 5TGM1/KaLwRij i.t. model of MM 
(Chapter 4). It was hypothesised that these conflicting findings may be attributable to the 
use of immunodeficient NSG mice in the HMCL xenograft models. To test this, NSG mice 
were inoculated with Samsn1-expressing or EV control 5TGM1 cells by i.t. injection and 
primary and metastatic tumour burden were measured by BLI and flow cytometry after 23 
days. Similar to the results in KaLwRij mice, Samsn1 did not affect the growth of primary 
tumours in the injected tibia of NSG mice, as determined by BLI (P = 0.1649, Mann Whitney 
U test; Figure 5.6A&B) and flow cytometry (P = 0.2319, Mann Whitney U test; Figure 
5.6C). However, the metastatic tumour burden in the non-injected, contralateral hind leg was 
not reduced in NSG mice inoculated with 5TGM1-Samsn1 cells compared to those 
inoculated with 5TGM1-EV cells, as determined by flow cytometry (P = 0.4634, Mann 
Whitney U test; Figure 5.6D). In addition, Samsn1 did not inhibit the growth of 5TGM1 
cells following i.v. injection into NSG mice, as measured by BLI (P = 0.9108, Mann 
Whitney U test; Figure 5.7A) and SPEP (P = 0.3095, Mann Whitney U test; Figure 5.7B). 
Hence, the previously observed ability of Samsn1 to inhibit the outgrowth of disseminated 
5TGM1 cells in immunocompetent KaLwRij mice (Chapter 4) was lost in immunodeficient 
NSG mice, suggesting that the tumour suppressor effect of Samsn1 in MM PCs is dependent 
on the presence of a functional immune system.   
 
5.2.7 Samsn1 expression in 5TGM1 cells may enhance cytotoxic T 
lymphocyte activity  
It was hypothesised that Samsn1 suppresses the outgrowth of disseminated MM PC in the 
BM by promoting immune-mediated control of tumour growth. Both natural killer (NK) 
cells and T cells have been shown to have important roles in the immune control of cancer, 
including MM365. Hence, to investigate the effect of PC-intrinsic Samsn1 expression on the 
anti-tumour immune response in vivo, the NK, T and NKT cell populations in the peripheral 
blood (PB), BM and spleen of KaLwRij mice were analysed by flow cytometry following 
i.v. injection of 5TGM1-Samsn1 cells, 5TGM1-EV cells or PBS. Five days post-injection, 
no significant differences in the total percentage, or the percentage activated (CD69+), of 






Figure 5.6: Samsn1 expression in 5TGM1 cells does not affect tumour growth following 
i.t. injection into NSG mice. (A-D) Samsn1-expressing or EV control 5TGM1 cells (1 x 
105) were injected into the left tibia of NSG mice and disease was allowed to develop for 23 
days. (A) Tumour burden was measured by BLI on day 23 post-tumour cell inoculation and 
representative ventral scans of the mice are shown. (B) The total flux from the injected leg 
was quantitated from the ventral BLI scans. (C) The percentage of GFP+ Samsn1-
overexpressing/EV 5TGM1 cells in the BM of the injected tibia was determined by flow 
cytometry at the experimental endpoint. (D) The percentage of GFP+ Samsn1-
overexpressing/EV 5TGM1 cells in the BM of the non-injected hind leg was determined by 
flow cytometry at the experimental endpoint. Results were normalised to primary tumour 
burden. Graphs depict the mean ± SEM of n = 7 mice per cell line from two independent 










Figure 5.7: Samsn1 expression in 5TGM1 cells does not affect tumour growth following 
i.v. injection into NSG mice. (A&B) Samsn1-expressing or EV control 5TGM1 cells (5 x 
105) were injected i.v. into NSG mice and disease was allowed to develop for 4 weeks. (A) 
BLI of the mice injected with 5TGM1-Samsn1 or 5TGM1-EV cells was performed weekly 
from week 2. Representative ventral scans after 4 weeks (left) and the quantitated total flux 
from the ventral scans over time (right) are shown. (B) SPEP was performed on sera 
collected from the mice after 4 weeks. The SPEP gel (left, * = M-spike) and the M-spike 
intensity expressed relative to the EV control (right) are shown. Graphs depict the mean ± 
SEM of n = 6 mice per cell line from one experiment. P > 0.05, two-way ANOVA with 






mice inoculated with 5TGM1-Samsn1 cells compared to the mice inoculated with 5TGM1-
EV cells (Table 5.1). Moreover, injection of either 5TGM1 cell line did not alter the 
populations of these immune cells compared to the injection of PBS alone, which suggests 
that the anti-tumour immune response in KaLwRij mice may not involve the expansion of 
effector cells. 
 
Despite Samsn1 expression in 5TGM1 cells not influencing immune cell numbers in 
KaLwRij mice following inoculation, it was hypothesised that Samsn1 expression may 
enhance the activity of immune effector cells toward 5TGM1 tumour cells. Given that CD8+ 
cytotoxic T lymphocytes (CTLs) are known to be important mediators of anti-tumour 
immunity, the effect of Samsn1 on the targeting of 5TGM1 cells by CTLs was assessed in 
vitro. Cytotoxicity assays were performed in which purified splenic CD8+ T cells, which 
were isolated from KaLwRij mice inoculated with 5TGM1-Samsn1 or 5TGM1-EV cells, 
were used as effectors (Figure 5.8A&B). Due to a low yield of CTLs, these effectors were 
co-cultured with 5TGM1-Samsn1 or 5TGM1-EV cells at a ratio of 2:1 or 4:1 for 24 hours, 
followed by quantitation of tumour cell lysis by a lactate dehydrogenase release assay. A 
trend towards an increase in CTL-mediated cytotoxicity toward the Samsn1-expressing 
5TGM1 cells compared to the EV 5TGM1 cells was observed, which occurred in an effector 
to target ratio-dependent manner (Figure 5.8C). These data suggest that Samsn1 expression 
in 5TGM1 cells may promote CTL activity toward MM PCs in KaLwRij mice. 
 
5.2.8 Samsn1 does not affect the expression of MHC class I molecules on 
the surface of 5TGM1 cells 
One of the previously documented mechanisms by which tumour cells mediate escape from 
immune control is by down-regulating surface expression of major histocompatibility class 
I (MHC-I) molecules, which inhibits detection and destruction of tumour cells by CD8+ T 
cells366. Hence, it was hypothesised that Samsn1 may promote 5TGM1 tumour cell 
immunogenicity by up-regulating MHC-I expression. To assess this, the levels of MHC-I 
molecules on the surface of 5TGM1-Samsn1 compared to 5TGM1-EV control cells were 
measured by flow cytometry. The levels of both sub-classes of MHC-I molecules expressed 
by the KaLwRij strain, H-2Db and H-2Kb, on 5TGM1-Samsn1 cells were found to not be 
significantly different compared to the levels on 5TGM1-EV control cells (P > 0.05, paired 
t test; Figure 5.9). This suggests that Samsn1 expression does not enhance immune 









Table 5.1: Flow cytometry analysis of NK, T and NKT cells in KaLwRij mice 
inoculated with Samsn1-expressing 5TGM1 cells. KaLwRij mice were injected with 
5TGM1-Samsn1 cells, 5TGM1-EV cells or PBS only. Five days post-injection, cells from 
the PB, BM and spleen of the mice were stained with anti-CD3 and anti-DX5 antibodies and 
gated to show the percentages of NK (CD3-DX5+), T (CD3+DX5-) and NKT (CD3+DX5+) 
cells among total live leukocytes. The cells were also stained with an anti-CD69 antibody 
and the percentages of NK, T and NKT cells that were positive for this activation marker 
were assessed. Data are shown as the mean ± SD for n = 3 (PBS) or n = 5 (5TGM1-
Samsn1/EV) mice per group from two independent experiments. P > 0.05, Kruskal-Wallis 

















Figure 5.8: Samsn1 expression may sensitise 5TGM1 cells to KaLwRij-derived CD8+ T 
cell cytotoxicity in vitro. (A) Schematic illustrating the experimental design of the 
cytotoxicity assay. KaLwRij mice were twice i.v. injected with 1 x 106 irradiated 5TGM1-
Samsn1 or 5TGM1-EV cells. Five days after the last inoculation, splenic cells were isolated 
from the mice and CD8+ T cells were purified by MACS-mediated negative selection. 
Following 5 days of re-stimulation with cognate 5TGM1 cells in vitro, the CTLs were co-
cultured with irradiated 5TGM1-Samsn1 or 5TGM1-EV cells at effector to target ratios of 
2:1 and 4:1. After 24 hours, lactate dehydrogenase release was measured and used to 
calculate the percentage of cell-mediated cytotoxicity. (B) Representative flow cytometry 
plots showing the successful purification of splenic CD8+ T cells by MACS. (C) Graph 
depicting the percentage cytotoxicity of KaLwRij-derived CTLs toward 5TGM1-Samsn1 
and 5TGM1-EV cells at the indicated effector to target ratios (n = 3 mice per cell line, which 


















Figure 5.9: Samsn1 expression does not affect MHC-I expression on 5TGM1 cells. 
(A&B) 5TGM1-Samsn1 and 5TGM1-EV cells in culture were stained with anti-H-2Db, anti-
H-2Kb or an isotype control antibody and the mean fluorescence intensity (MFI) was 
determined by flow cytometry. Representative histograms (A) and graphs of the MFI (B), 
expressed relative to the EV control cell line, for H-2Db (left) and H-2Kb (right) on 5TGM1-
Samsn1 versus 5TGM1-EV cells are shown. Graphs depict the mean ± SD from three 





5.2.9 Samsn1 expression in 5TGM1 cells does not affect tumour growth 
in C57BL/6 mice 
Given the tumour suppressor effect of Samsn1 expression in 5TGM1 cells on tumour growth 
in immunocompetent KaLwRij mice260, it was hypothesised that Samsn1 would inhibit the 
growth of 5TGM1 cells in immunocompetent C57BL/6 wildtype (WT) mice. To test this, 
Samsn1-expressing or EV control 5TGM1 cells were injected i.v. into WT mice, which were 
then monitored for tumour development over 7 weeks. Contrary to the hypothesis, Samsn1 
expression in the 5TGM1 tumour cells was found to not affect tumour penetrance in WT 
mice, as determined by BLI or SPEP (P > 0.9999, Fisher’s exact test; Figure 5.10A). In 
addition, of those WT mice that developed tumour, tumour burden was shown to not differ 
between the mice injected with 5TGM1-Samsn1 cells and those injected with 5TGM1-EV 
control cells, as measured by BLI (P = 0.9722, two-way ANOVA with Sidak’s multiple 
comparisons test; Figure 5.10B) and SPEP (P > 0.8357, Mann Whitney U test; Figure 
5.10C). These data suggest that Samsn1 does not suppress MM tumour development in the 
presence of a competent immune system in WT mice. Hence, there may be unique features 
of the competent immune system in KalwRij mice that facilitate the suppression of 5TGM1-
Samsn1 tumour growth in this mouse strain. 
 
5.2.10 Samsn1 expression in 5TGM1 cells inhibits tumour growth in 
C57BL/Samsn1-/- mice 
Given that one of the most striking genetic differences between KaLwRij and WT mice is 
that KaLwRij mice have lost the Samsn1 gene260,261, it was hypothesised that this 
abnormality may contribute to the unique ability of the KaLwRij immune system to suppress 
5TGM1-Samsn1 cell growth in vivo. To test this, Samsn1-expressing or EV 5TGM1 cells 
were injected i.v. into the previously described immunocompetent C57BL/Samsn1-/- mice, 
which were generated by backcrossing the KaLwRij-derived Samsn1 genomic deletion onto 
a C57BL/6 background (Chapter 3). At 7 weeks post-tumour cell inoculation, 5 of the 20 
(25%) C57BL/Samsn1-/- mice injected with EV control 5TGM1 cells had developed tumour, 
whereas none of the 21 (0%) C57BL/Samsn1-/- mice that were injected with 5TGM1-Samsn1 
cells  had any evidence of disease development, as determined by BLI and SPEP (Figure 
5.11). This constituted a significant inhibition of tumour penetrance for 5TGM1-Samsn1 
cells compared to 5TGM1-EV control cells in the C57BL/Samsn1-/- mice (P = 0.0207, 














Figure 5.10: Samsn1 expression in 5TGM1 cells does not affect tumour growth in 
immunocompetent WT mice. (A-C) Samsn1-expressing or EV control 5TGM1 cells (5 x 
105) were injected i.v. into WT mice and tumour was allowed to develop for 7 weeks (n = 
22 mice per cell line). Tumour burden was measured by BLI at weeks 3, 5 and 7 post-tumour 
cell inoculation and by SPEP at week 7. (A) The numbers of WT mice inoculated with 
5TGM1-Samsn1 or 5TGM1-EV cells that were tumour-bearing by week 7, as determined 
by BLI and SPEP. (B) For tumour-bearing mice, representative BLI ventral scans at 7 weeks 
(left) and the quantitated total flux from the ventral scans over time (right) are shown. (C) 
Representative SPEP gel of serum samples from tumour-bearing and non-tumour-bearing 
WT mice (left, * = M-spike) inoculated with 5TGM1-EV or 5TGM1-Samsn1 cells are 
shown. For tumour-bearing mice, the quantitated M-spike intensities (right) are shown. 
Graphs depict the mean ± SEM of n = 6-7 tumour-bearing mice per cell line from two 
independent experiments (B&C). P > 0.05, Fisher’s exact test (A), two-way ANOVA with 



























Figure 5.11: Samsn1 expression in 5TGM1 cells inhibits MM tumour development in 
immunocompetent C57BL/Samsn1-/- mice. (A-C) Samsn1-expressing or EV 5TGM1 cells 
(5 x 105) were injected i.v. into C57BL/Samsn1-/- mice and tumour was allowed to develop 
for 7 weeks. Tumour burden was measured by BLI at weeks 3, 5 and 7 post-tumour cell 
inoculation and by SPEP at week 7. (A) Representative ventral BLI scans of mice inoculated 
with 5TGM1-EV (above) or 5TGM1-Samsn1 (below) cells at week 7 are shown. (B) A 
representative SPEP gel containing serum samples from the mice included in (A) is shown 
(* = M-spike). (C) The proportion of tumour-bearing mice inoculated with 5TGM1-Samsn1 
or 5TGM1-EV cells by week 7, as determined by BLI and SPEP. Graph depicts n= 20-21 











Samsn1 expression in vivo is dependent on the recipient mouse being both 
immunocompetent and Samsn1-/-. 
 
5.2.11 Samsn1-/- mice may generate a humoral immune response against 
5TGM1-derived Samsn1  
It was hypothesised that immune-mediated control of Samsn1-expressing 5TGM1 cells 
occurs exclusively in immunocompetent Samsn1-/- mice because their adaptive immune cells 
recognise Samsn1 as a foreign antigen. To test this, the production of anti-Samsn1 antibodies 
following exposure to 5TGM1-Samsn1 cells was assessed in vivo. KaLwRij, 
C57BL/Samsn1-/- and WT mice were twice inoculated with either Samsn1-expressing or EV 
control 5TGM1 cells and the presence of anti-Samsn1 antibodies in their serum was then 
determined by Western blot. Antibodies that bound to Samsn1 were not detected in the serum 
from any of the negative control WT mice inoculated with 5TGM1-Samsn1 cells or 5TGM1- 
EV cells (Figure 5.12A). For the C57BL/Samsn1-/- mice, anti-Samsn1 antibodies were 
detected in the serum from one of the five mice inoculated with 5TGM1-Samsn1 cells, 
whereas anti-Samsn1 antibodies were not detected in the serum from the four mice injected 
with 5TGM1-EV control cells (Figure 5.12B). However, no anti-Samsn1 antibodies were 
detected in the serum from any of the three KaLwRij mice inoculated with Samsn1-
expressing 5TGM1 cells or EV control 5TGM1 cells (Figure 5.12C). These findings suggest 
that Samsn1 expression in 5TGM1 cells may cause an antigen-specific humoral immune 
response specifically in Samsn1-/- mice. 
 
5.3 Discussion 
Reduced SAMSN1 expression has been detected in the PCs of MM patients and this was 
associated with higher tumour burden and poorer overall survival260. In addition, Samsn1 
was found to be deleted in the MM-prone KaLwRij mouse strain and restoration of its 
expression in the syngeneic 5TGM1 MM PC line inhibited tumour growth in vivo260. This 
suggested that SAMSN1 is a tumour suppressor gene in MM PC, but the biological effects 
of SAMSN1 in the context of human MM remained unknown. Hence, the aim of this chapter 
was to examine the functions of SAMSN1 in human MM PCs both in vitro and in vivo. In 
order to do this, HMCLs with CRISPR-Cas9-mediated knockdown of SAMSN1 levels and 
HMCLs with overexpression of SAMSN1 were generated. Altered SAMSN1 levels were 
not found to affect the proliferation or migration of HMCLs in vitro, which is consistent with 














Figure 5.12: Samsn1-/- mice may generate an anti-Samsn1 humoral immune response 
following inoculation of 5TGM1-Samsn1 cells. (A-C) C57BL/6 (WT), C57BL/Samsn1-/- 
and KaLwRij mice were twice inoculated, 2 weeks apart, with 5TGM1-Samsn1 (S) or 
5TGM1-EV (EV) cells and serum was collected five days after the second dose of tumour 
cells. The serum was incubated with resolved and membrane-bound proteins that were 
immunoprecipitated from 5TGM1-Samsn1-HA and 5TGM1-EV cell lysates using an anti-
HA antibody. The successful immunoprecipitation of Samsn1 from the 5TGM1-Samsn1 
cells was confirmed by Western blotting with an anti-HA antibody (A-C left). 
Representative blots probed with 5TGM1-Samsn1-inoculated serum (middle) or 5TGM1-
EV-inoculated serum (right) from C57BL/6 (A), C57BL/Samsn1-/- (B) and KaLwRij (C) 
mice are shown. In (B), the blot probed with serum from a 5TGM1-Samsn1-inoculated 
C57BL/Samsn1-/- mouse was the one out of five that showed evidence of anti-Samsn1 
antibodies. The blots for the C57BL/6 (A) and KaLwRiJ (C) mice are representative of n = 













(Chapter 4) of murine 5TGM1 cells in vitro. The growth of primary tumours following i.t. 
injection of HMCLs into NSG mice was not affected by SAMSN1 levels, as was the case in 
the 5TGM1/KaLwRij model (Chapter 4). However, SAMSN1 levels were not found to affect 
the metastasis of HMCLs in NSG mice, which contrasts with the significant reduction in 
metastasis caused by Samsn1 expression in the 5TGM1/KaLwRij model. These conflicting 
results suggest that either SAMSN1 does not have a tumour suppressor effect in human MM 
PCs or, it does, but this effect was not observable in this particular in vivo model.   
 
Given that the major difference between the HMCL and 5TGM1 in vivo models was the 
mouse strain used, it was hypothesised that the use of NSG mice may be inhibiting the 
tumour suppressor effect of SAMSN1 in HMCLs. Consistent with this, the ability of Samsn1 
to suppress the outgrowth of disseminated 5TGM1 cells in immunocompetent KaLwRij 
mice was found to be abolished in severely immunodeficient NSG mice. These data suggest 
that the tumour suppressor effect of Samsn1 expression on 5TGM1 cells in vivo is dependent 
on the presence of a functional immune system, not stromal cells (Chapter 4), within the BM 
microenvironment. The immune system is known to play an important role in suppressing 
the development of tumours, which is evidenced by the fact that immunodeficient mice are 
more susceptible to carcinogen-induced and spontaneous tumour formation367-371. The 
standard process of cancer immunosurveillance first involves an elimination phase in which 
effector cells of the innate (NK cells) and adaptive (CTLs) immune systems recognise and 
eradicate tumour cells366. Surviving cancer cells then typically enter the equilibrium phase, 
in which the adaptive immune system restrains their growth, resulting in a dormant state that 
can be maintained for extended periods of time372. Finally, malignant cells can eventually 
escape immune-mediated growth suppression through evolving reduced immunogenicity, 
which leads to the formation of clinically apparent tumours366. Hence, it was hypothesised 
that Samsn1 suppresses the outgrowth of 5TGM1 cells in the BM by promoting their 
immunogenicity and thus immune-mediated dormancy.  
 
MM disease progression is associated with increasing dysregulation and suppression of the 
immune system365. Depletion studies have shown that NK cells and CTLs have important 
roles in constraining the growth of MM PCs373,374, but their effector functions are 
increasingly inhibited with advancing disease375-378. This is at least partly due to an increase 
in the numbers of immunosuppressive cell types, including regulatory T cells379-382, tumour-





MGUS patient-derived tumour cells grow progressively in a humanised mouse model 
suggests that PC-extrinsic controls within the BM, such as immunosurveillance, restrain the 
progression from MGUS to MM233. Hence, the reduction in SAMSN1 expression in the PCs 
of MM patients compared to healthy controls260,261 is consistent with the possibility that the 
down-regulation of SAMSN1 promotes the escape of abnormal PCs from immune control 
and thus the development of symptomatic MM. The crucial role of the immune system in 
controlling MM disease progression is also made evident by the clinical success of 
immunomodulatory imide drugs (IMiDs), the effectiveness of which is at least partially 
attributable to increasing the cytotoxic activity of NK cells and CTLs70,388,389. Even the 
efficacy of autologous stem cell transplants has recently been shown to be partly attributable 
to the promotion of an anti-tumour T cell response390. Hence, gaining a better understanding 
of the potential role of SAMSN1 in regulating MM PC immunogenicity could aid in 
identifying new immunotherapeutic strategies that may enable long-term MM disease 
control. 
 
In a previous study in which IRF7 expression in murine breast cancer cells was found to 
promote immune-mediated control of metastasis to BM, an increase in the numbers of NK 
cells and T cells was found in the PB of mice inoculated with IRF7-expressing compared to 
control tumour cells five days post-injection391. Hence, it was hypothesised that if Samsn1 
promotes immune-mediated control of 5TGM1 cells in KaLwRij mice, a greater expansion 
of immune cells would be observed following the inoculation of 5TGM1-Samsn1 cells 
compared to 5TGM1-EV control cells in vivo. However, no differences in the size, or 
activation status, of NK cell and T cell populations were observed in KaLwRij mice injected 
with 5TGM1-Samsn1 cells, 5TGM1-EV cells or PBS after five days. This may have been 
because five days is not the optimal timepoint to observe an expansion of immune cell 
populations in the 5TGM1/KaLwRij model, or because increased immune cell function, not 
number, mediates the anti-tumour response in KaLwRij mice. In support of this, KaLwRij-
derived CTLs, which are known to be important effectors of tumour immunosurveillance365, 
were found to display increased cytotoxicity toward 5TGM1-Samsn1 cells compared to 
5TGM1-EV cells in vitro. This finding suggests that Samsn1 expression increases the 
immunogenicity of 5TGM1 cells to CTLs. Further investigation of the importance of CTL 
activity in maintaining 5TGM1-Samsn1 cells in immune-mediated equilibrium is warranted, 
for example, by determining the effect of antibody-mediated depletion of CTLs in KaLwRij 






CTLs detect tumour cells through TCR-mediated recognition of tumour-specific antigens, 
such as peptides from mutated or aberrantly expressed proteins, which are presented on the 
cell surface by MHC-I molecules366. Down-regulating surface expression of MHC-I 
molecules is a common mechanism by which tumour cells escape from immune-mediated 
growth suppression366. Although there have been conflicting reports as to whether this occurs 
in MM PCs392-394, it was hypothesised that Samsn1 expression may promote targeting of 
5TGM1 cells by CTLs by increasing surface expression of MHC-I molecules. However, the 
levels of MHC-I molecules were found to not differ between 5TGM1-Samsn1 and 5TGM1-
EV cells, suggesting that Samsn1 does not promote the immunogenicity of MM PCs in this 
way. Importantly, Samsn1 expression was found to completely inhibit 5TGM1 tumour 
development in immunocompetent C57BL/Samsn1-/- mice but not in immunocompetent WT 
C57BL/6 mice. These data suggest that the tumour suppressor effect of Samsn1 in vivo is 
dependent on the host being both immunocompetent and Samsn1-/-. In Samsn1-/- mice, 
developing B and T cells with antigen receptors that recognise Samsn1 peptides are not 
exposed to Samsn1 during the process of immune tolerance and thus will not undergo clonal 
deletion, as occurs in WT mice. Hence, it was hypothesised that the observed immune-
dependent tumour suppressor effect of Samsn1 on 5TGM1 cells in KaLwRij mice is 
mediated by Samsn1-specific adaptive immune cells.  
 
The ability to investigate the immunogenicity of Samsn1 in KaLwRij mice was constrained 
by the fact that there was no commercially available recombinant Samsn1 protein. In 
addition, antigenic peptides could not be synthesised because the immunodominant CTL 
epitope of Samsn1 in these mice was unknown. While CTLs are known to be the key 
mediators of immune responses to transgenes, studies have shown that a humoral immune 
response can also be generated395,396. Hence, the ability of Samsn1 to generate an antigen-
specific humoral immune response in Samsn1-/- mice inoculated with 5TGM1-Samsn1 cells 
was assessed by Western blot. Anti-Samsn1-specific antibodies were detected in the serum 
from a C57BL/Samsn1-/- mouse, but not any WT mice inoculated with 5TGM1-Samsn1 
cells. However, anti-Samsn1 antibodies were not detected in the serum from the other 
C57BL/Samsn1-/- mice and the KaLwRij mice inoculated with 5TGM1-Samsn1 cells. These 
data support the hypothesis that there is a Samsn1-specific immune response in Samsn1-/- 
mice exposed to 5TGM1-Samsn1 cells. However, they also suggest that the generation of a 





the major effectors of the immune response. This is consistent with previous reports of an 
effective CTL-mediated response to a xenogeneic protein being accompanied by a variable 
or absent antibody response in vivo395,397. If the immunodominant CTL epitope of Samsn1 
in KaLwRij mice can be determined, Samsn1-reactive CTLs in 5TGM-Samsn1-inoculated 
mice could be detected using an IFN-γ ELISPOT, as previously described397. 
 
In summary, the data suggest that the ability of Samsn1 to inhibit MM tumour growth in the 
5TGM1/KaLwRij murine model is most likely due to the presence of Samsn1-specific 
adaptive immune cells in KaLwRij mice. As SAMSN1-reactive lymphocytes would be 
eliminated during development in humans, the anti-MM effect of Samsn1 in the 5TGM1-
KaLwRij model no longer supports a potential tumour suppressor role for SAMSN1 in the 
context of human MM. The remaining evidence to suggest a potential role for SAMSN1 as a 
tumour suppressor in human MM includes the fact that Samsn1-/- KaLwRij mice are prone 
to developing a MM-like disease as they age263,264. However, KaLwRij mice have also been 
shown to harbour many other genetic abnormalities compared to WT mice260,261 and the 
relative contribution of Samsn1 loss to the development of MM in aged KaLwRij mice 
remains to be determined. In addition, the expression of SAMSN1 was found to be 
significantly reduced in the PCs from MM patients compared to healthy controls260,261, but 
this correlation does not demonstrate a causative link between SAMSN1 down-regulation 
and MM development. Furthermore, in this study, there was no evidence that SAMSN1 
affects the growth of human MM cells in vitro or in vivo. Collectively, the data no longer 
support a tumour suppressor role for SAMSN1 in the development of MM in patients. The 
findings here also highlight the need for caution in interpreting results obtained from 
immunocompetent tumour models in which the introduced malignant cells express a 



















MM is the second most common haematological malignancy and is characterised by the 
uncontrolled clonal expansion of neoplastic PCs within the BM1. All cases of MM are 
preceded by the premalignant PC proliferative disorder MGUS19,20, which has a 1% risk of 
progression to MM per year24,25. MM is a genetically heterogeneous disease, even at the 
MGUS stage, with considerable variation in the adverse genetic events present in clonal PCs 
both between and within patients145. Studies indicate that the transition from MGUS to MM 
is due to both the accumulation of co-operative PC-intrinsic lesions and tumour-promoting 
PC-extrinsic factors within the BM microenvironment343. Comparisons of paired and 
unpaired MGUS and MM samples suggest that the malignant transformation of PCs can 
occur by different pathogenic pathways, but these are incompletely understood229,232. This 
gap in knowledge inhibits accurate identification of MGUS patients who are at high risk of 
progression, which is crucial for their optimal clinical management. In addition, it means 
that there are molecules/pathways required for the development of MM, representing 
potential therapeutic targets, that are yet to be identified.  
 
Our group and others have identified the putative adaptor protein SAMSN1 as a novel 
tumour suppressor in MM, the down-regulation of which may promote the MGUS to MM 
transition260,261. This assertion was based on the finding that KaLwRij mice, which unlike 
C57BL/6 mice can progress from MGUS to MM, harbour a spontaneous homozygous 
deletion of the Samsn1 gene, suggesting that the loss of Samsn1 may promote MM 
development in this strain260,261. In support of this, the introduction of Samsn1 into the 
KaLwRij-derived MM PC 5TGM1 line was shown to abrogate tumour development in 
vivo260. In relation to human MM, SAMSN1 mRNA expression was found to be significantly 
reduced in the PCs of MM patients compared to healthy individuals, which was also 
consistent with SAMSN1 having a tumour suppressor role in patients with this disease260,261. 
The fact that Samsn1-/- KaLwRij mice only develop MM with late onset and incomplete 
penetrance (~1 in 200 mice over two years old)263,264 suggests that the loss of Samsn1 co-
operates with other lesions to promote disease progression from MGUS to MM in these 
mice, and also potentially in patients.   
 
The development of MM involves the non-random accumulation of genetic hits within 
PCs122. The fact that certain pairs of lesions significantly co-occur in the PCs of MM patients 
suggests that these genetic events co-operate to drive disease progression120,122,150. In 





associated with reduced GLIPR1 expression (Figure 3.1), suggesting a putative co-operative 
relationship between the down-regulation of these genes in promoting the development of 
MM. The expression of GLIPR1 was found to be decreased in the PCs from MM patients 
compared to healthy individuals, with nearly 75% of MM tumours harbouring mRNA levels 
below the normal range (Figure 3.2). This observation was consistent with studies which 
showed that GLIPR1 was down-regulated in other malignancies296-298,305-307. Notably, 
GLIPR1 was previously found to be deleted in ~9% of MM patients308, have reduced mRNA 
expression in HMCLs compared to normal B cells298 and inhibit the development of 
spontaneous late-onset plasmacytomas in mice298. Collectively, these findings suggested that 
GLIPR1, like SAMSN1, may have a tumour suppressor role in MM. While previous studies 
had demonstrated anti-tumour effects of GLIPR1 in several other malignancies296-298,305-307, 
the studies presented in Chapter 3 are the first to assess the functional effects of this gene in 
MM PCs. While Glipr1 expression was not found to affect the growth of 5TGM1 cells in 
vitro (Figure 3.3), it did result in a reduction in tumour growth in KaLwRij mice, although 
this did not reach statistical significance (Figure 3.4). While these findings suggest that 
Glipr1 is not a potent tumour suppressor on its own in MM, further investigation of the 
functional effects of GLIPR1 in HMCLs is warranted. 
 
To empirically determine if the loss of Samsn1 and the loss of Glipr1 co-operate to promote 
MM development, Samsn1-/-Glipr1-/- mice on an MGUS-prone C57BL/6 background were 
generated. This was achieved by using back-crossing or CRISPR-mediated gene editing to 
generate C57BL/Samsn1-/- mice and C57BL/Glipr1-/- mice, respectively, which were 
subsequently crossed (Figure 3.6 and Figure 3.7). The Glipr1-/-, Samsn1-/- and Samsn1-/-
Glipr1-/- mice were then monitored for the emergence of PC proliferative disorders in 
comparison to WT mice over a period of one year. Based on the frequency of M-spikes in 
serum and the percentages of PCs in the BM and spleen, the prevalence of clonal PC 
expansions did not differ between the Glipr1-/-, Samsn1-/- and Samsn1-/-Glipr1-/- mice 
compared to the WT mice (Figure 3.12 and Figure 3.13). These data suggest that the loss of 
Samsn1 and/or Glipr1 does not potently drive MM development in MGUS-prone C57BL/6 
mice. However, given the increased frequency of monoclonal gammopathy in C57BL/6 mice 
over one year of age239,262, a more modest effect of concomitant loss of Glipr1 and Samsn1 
on the development of PC disorders cannot be excluded without studying a larger cohort of 
mice over a longer timeframe. Future studies should also seek to identify other genetic hits 





MM. For example, the Multiple Myeloma Research Foundation (MMRF) CoMMpass 
dataset, which includes matched cytogenetic, mutational and gene expression profiles from 
a large cohort of MM patients, could be mined to detect other abnormalities that recurrently 
co-occur with down-regulated SAMSN1 expression.  
 
While the abrogation of tumour development by Samsn1 in the 5TGM1/KaLwRij model 
suggested it was a potent tumour suppressor in MM, the mechanism(s) by which Samsn1 
achieved this anti-tumour effect was unclear. Although Samsn1 was shown to have an anti-
proliferative effect in normal B cells following BCR stimulation241,245, Samsn1 expression 
in 5TGM1 cells was previously found to cause a modest reduction in proliferation only when 
the tumour cells were co-cultured with BMSCs in vitro260. This suggested that there may be 
a mechanism, other than the inhibition of MM PC proliferation, by which Samsn1 inhibits 
tumour growth in vivo. The previous finding that Samsn1 is involved in cytoskeletal 
remodelling249 and the discovery in Chapter 4 that the levels of activated Hs1, a regulator of 
actin dynamics, were reduced in Samsn1-expressing 5TGM1 cells (Figure 4.3), suggested 
that Samsn1 may limit the migration/homing of MM PCs. However, this was not supported 
by the findings that Samsn1 did not affect the in vitro migration (Figure 4.4) or the in vivo 
BM homing (Figure 4.8) of 5TGM1 cells. Notably, following the intratibial delivery of 
5TGM1 cells, Samsn1 was found to inhibit the growth of metastatic, but not primary, 
tumours in the BM of KaLwRij mice (Figure 4.7). The observation that Samsn1 only limited 
the outgrowth of 5TGM1 cells when relatively few had seeded the BM suggested that 
Samsn1 may promote BM microenvironment-mediated control of MM PC outgrowth343. 
Other PC-intrinsic changes have previously been shown to affect tumour growth through 
altering the interactions of tumour cells with the microenvironment233,343. For example, the 
upregulation of integrin B7 in MM PCs was shown to increase adhesion to BMSCs, thereby 
promoting tumour growth398. However, the identity of the source and type of anti-MM 
signals from the BM microenvironment that were enhanced by Samsn1 expression, and how 
Samsn1 mediated this at a molecular level, was yet to be determined.  
 
Other than showing that SAMSN1 increased the adhesion of the H929 HMCL to BMSCs260, 
the functional effects of SAMSN1 in HMCLs had not been previously reported. In Chapter 
5, it was revealed that neither the up-regulation of SAMSN1 by overexpression, nor the 
down-regulation of SAMSN1 by CRISPR-mediated genome editing, affected the growth of 





with the significant inhibition of disseminated 5TGM1 cell outgrowth in the BM of 
immunocompetent KaLwRij mice, which was shown in Chapter 4 (Figure 4.7). Crucially, it 
was revealed that the ability of Samsn1 to suppress the outgrowth of disseminated 5TGM1 
cells in the BM was absent in immunodeficient NSG mice (Figure 5.6), suggesting that 
functional immune cells are required for the tumour suppressor effect of Samsn1 in vivo. 
This led to the hypothesis that Samsn1 enhances the immunogenicity of MM PC, which was 
supported by the finding that CD8+ T cells from KaLwRij mice displayed greater 
cytotoxicity towards Samsn1-expressing 5TGM1 cells compared to control 5TGM1 cells 
(Figure 5.8). Crucially, given the known contribution of immune dysregulation to the 
pathogenesis of MM and the success of immunotherapies in treating MM365, the possibility 
that Samsn1 promoted an anti-MM immune response was of high clinical relevance. 
However, Samsn1 was subsequently found to inhibit 5TGM1 cell growth in 
immunocompetent C57BL/Samsn1-/-mice (Figure 5.11) but not in immunocompetent WT 
C57BL/6 mice (Figure 5.10). These findings suggest that Samsn1 only promotes an 
enhanced anti-5TGM1 immune response from Samsn1-/- hosts in which Samsn1-specific 
adaptive immune cells are not eliminated by immune tolerance (Figure 6.1). This postulate 
was supported by the detection of anti-Samsn1 antibodies in a Samsn1-/- mouse inoculated 
with 5TGM1-Samsn1 cells (Figure 5.12). Importantly, Samsn1-reactive adaptive immune 
cells will not be present in patients and, therefore, the previous finding that Samsn1 
suppresses tumour development in the 5TGM1/KaLwRij model no longer supports a 
probable tumour suppressor role for SAMSN1 in the context of human MM. 
 
Immunocompetent murine syngeneic transplantation tumour models are indispensable for 
the study of the complex interactions between cancer and immune cells and for testing novel 
immunotherapies. To enable the growth of the tumour to be tracked in vivo and ex vivo, it is 
common for the syngeneic tumour cells to be engineered to overexpress reporter proteins, 
such as GFP and luciferase. Studies have shown that the expression of these xenogeneic 
proteins can generate reporter-specific CTL responses in some immunocompetent tumour 
models, which limits tumorigenesis, especially metastasis397,399-402. The immunogenicity of 
the foreign protein is influenced by several factors, including the expression level of the 
protein, the cell type expressing the protein, and the genetic background of the host403,404. 
This is evidenced by the enhanced immune response to GFP displayed by Balb/c mice 
compared to C57BL/6 mice401,405,406. However, the expression of reporter proteins in 









Figure 6.1: Positive selection of Samsn1-specific CD8+ T cells in Samsn1-/- mice leads to 
immune suppression of Samsn1-expressing 5TGM1 tumour development in vivo. In 
Samsn1-/- mice (left), developing CD8+ T cells expressing a T cell receptor that recognises a 
Samsn1-derived peptide are not presented with this in the thymus and thus are positively 
selected. The expanded Samsn1-specific T cells then migrate to peripheral sites, including 
the BM, where they recognise the Samsn1 peptides presented in MHC I molecules on the 
surface of disseminated 5TGM1-Samsn1 cells, causing tumour cell apoptosis and inhibition 
of tumour formation. Conversely, in WT mice (right), self Samsn1 peptides are presented to 
developing Samsn1-reactive T cells in the thymus, leading to the negative selection/deletion 
of the clone by apoptosis. As a result, there are no T cells in the BM that recognise the 
Samsn1 peptides presented by 5TGM1-Samsn1 cells and, therefore, there is a more limited 
immune response to these cells in WT mice compared to Samsn1-/- mice, enabling MM PC 
outgrowth and tumour formation. APC = antigen presenting cell, TCR = T cell receptor, WT 






models407-410, including the 5TGM1/KaLwRij model in which the overexpression of GFP 
and luciferase does not prevent aggressive tumour development260,411,412. This suggests that 
if there is an immune response to 5TGM1-derived GFP and luciferase in KaLwRij mice, 
which has yet to be determined, it is not a major impediment to disease progression. Hence, 
it was unexpected that the expression of Samsn1, which is a foreign protein in Samsn1-/- 
KaLwRij mice, would elicit an immune response that was capable of completely abrogating 
tumour growth in vivo. The fact that Samsn1 is targeted by an effective immune response 
suggests that its dominant CTL epitope is highly immunogenic in KaLwRij mice. These data 
highlight the unpredictable nature of immune responses to xenogeneic proteins in 
immunocompetent in vivo tumour models. Hence, to correctly interpret the results from these 
models, the immunogenicity of each new foreign protein should always be empirically 
determined.  
 
The remaining lines of evidence suggesting that SAMSN1 may have a tumour suppressor 
role in human MM are largely circumstantial or inconclusive. Firstly, while the homozygous 
deletion of Samsn1 is a striking genomic abnormality in KaLwRij mice, many gene 
expression differences, single nucleotide variants and copy number alterations have also 
been discovered in the KaLwRij genome compared to the C57BL/6 genome260,261. Hence, it 
is unknown whether the KaLwRij strain’s ability to develop MM is attributable to their 
Samsn1-/- status or another genetic alteration(s). Secondly, the reduced expression of 
SAMSN1 in the PCs of MM patients compared to healthy controls260,261 describes a 
correlation, not a causative link, between SAMSN1 down-regulation and the development of 
MM. Hence, it is possible that SAMSN1 down-regulation may be a passenger, not a driver, 
event in the development of MM. Given that the reduced SAMSN1 expression in HMCLs 
was shown to be, at least partly, mediated by aberrant promoter hypermethylation260, 
SAMSN1 down-regulation may be a by-product, not a key target, of the known dysregulated 
epigenetics in MM PCs193-196.  
 
Thirdly, although below median SAMSN1 expression was found to be associated with 
reduced OS, this was based on a univariate survival analysis of one microarray dataset260. 
Hence, it is possible that the negative prognostic impact of low SAMSN1 expression is 
attributable to co-occurring independent predictors of inferior MM patient outcomes, as was 
found to be the case for del(13q)162. Finally, while another group has shown that Samsn1 





that Samsn1 caused a ~15% reduction in 5TGM1 cell proliferation only in the presence of 
BMSCs in vitro260. Hence, these conflicting results do not provide consensus support for 
Samsn1 having an anti-proliferative effect on 5TGM1 cells and thus acting as a tumour 
suppressor in MM. Notably, only one experiment examining the functional effect of 
SAMSN1 in another malignancy has been reported271. This study found that SAMSN1 
overexpression did not affect the growth of a lung cancer cell line in vitro271. Furthermore, 
the findings that SAMSN1 did not affect the growth of HMCLs in vitro or in vivo (Figure 
5.2-Figure 5.5) and that Samsn1 did not affect the growth of 5TGM1 cells in WT mice 
(Figure 5.10) collectively suggest that SAMSN1 is not a tumour suppressor in MM. Hence, 
the previously promising preliminary evidence suggesting that SAMSN1 was an important 
tumour suppressor in MM is now outweighed by empirical evidence indicating the contrary.  
 
In conclusion, the findings presented in this thesis show that Samsn1 expression in the 
5TGM1 murine MM PC line inhibits tumour growth in Samsn1-/- KaLwRij mice because it 
is targeted by Samsn1-reactive adaptive immune cells. Hence, these data do not support a 
tumour suppressor role for SAMSN1 in human MM, as SAMSN1-reactive lymphocytes 
would be deleted by immune tolerance in patients. In vitro proliferation/migration assays 
and in vivo tumour models in WT mice did not demonstrate tumour suppressor effects of 
Samsn1/SAMSN1 in mouse/human MM PCs. Together, these data suggest that the down-
regulation of SAMSN1 expression in MM PCs is not a key driver of malignant 
transformation. In addition, despite the finding that GLIPR1 expression is significantly 
reduced in MM patients, Glipr1 only displayed a non-significant tumour suppressor effect 
on 5TGM1 cells in vivo. Given that the results do not support an important tumour suppressor 
role for SAMSN1 or GLIPR1 in MM, it is likely that SAMSN1 and GLIPR1 down-regulation 
are passenger events that do not actively co-operate to drive the development of MM. Hence, 
further research is required to improve the current incomplete understanding of the PC-
intrinsic and microenvironmental factors that drive the development of MM. This will enable 
the rational design of new therapies and combination drug regimens that can prolong, and 
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